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Abstract 
 
Mycotoxins are highly toxic in nature and are widely found in food and feed at levels above the 
permissible limits. The work described focuses on mycotoxin detection using a wide array of 
immunoassays with high sensitivity.  
Polyclonal and two recombinant antibodies for specific detection of T-2 toxin, aflatoxin B2 
(AFB2) and zearalenone (ZEN) respectively, were generated. Single chain antibody fragment 
(scFv) libraries were generated from spleenomic RNA of mice immunized with AFB2 and ZEN 
conjugates. Polyclonal antibody (IgY) was isolated from eggs of T-2-KLH immunized chicken. 
Mono-specific IgY was isolated by affinity purification on T-2 toxin-immobilized amine-
activated sepharose beads. Anti-AFB2/ZEN scFvs and anti-T-2 IgY,  highly specific to the 
target (with very low cross reactivity to other mycotoxins), were used to develop competitive 
ELISAs and SPR-based inhibition assays which were applied to relevant food matrices and had  
assay sensitivities below the EU regulatory action levels.   
Novel separation and quantification techniques were developed using antibodies. A new 
method for the isolation of toxins was developed by covalent immobilization of highly specific 
antibody fragments onto silica particles, using an anti-AFB1 Fab fragment and anti-AFB2/ZEN 
scFvs. An ELISA assay, using covalently immobilized AFB1 surfaces and an anti-AFB1 Fab 
antibody fragment was optimised.  
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1.0 Introduction 
Mycotoxins are defined as low molecular weight, aromatic/aliphatic compounds produced by 
microfungi (Weidenborner, 2001) like Aspergillus, Fusarium and Penicillium. Mycotoxins are 
mainly found in tree nuts, peanuts and oil seeds, including corn and cottonseed. It is estimated 
that 25% of world food produce may be contaminated annually with mycotoxins (Hussein and 
Brasel, 2001). Despite wide-spread research that has been carried out for decades the mold 
infection is still a challenging issue (Munkvold, 2003).  
The global prevalence of these toxins has attracted the attention of regulatory authorities such 
as the European Commission and the WHO/FAO, resulting in the implementation of 
regulations for maximum permitted levels (MPL’s) in different food-stuffs, including cereals, 
baby foods and pasta (Table 1.1). The factors that govern these regulations include: 
 the availability of toxicological data and occurrence. 
 awareness of what foods are commonly contaminated. 
 knowledge of possible sampling techniques that may be used. 
 capacity of available analytical methods for detecting the toxins at the required levels. 
To achieve the required levels of food quality the necessary analytical tests for contaminants 
are necessary. The research described in this thesis focused on generating antibodies and test 
systems for mycotoxin determination.  
  
1.1 Mycotoxins,  foods safety and economic impact 
Mycotoxin contamination has a significant impact on the economy. The globalization of the 
food trade leads to the estimation of the economic losses based on two important factors. The 
first factor is the market and trade impact and the second is the health-related effects on both 
humans and livestock.  To-date, there are no substantial data as to the economic cost of 
mycotoxin contamination in the EU, except for Hungary, where major wheat contamination 
took place in 1998 with an overall loss of about €100 million. The annual losses due to 
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mycotoxin contamination in U.S.A. are approximately  $0.5 million - 1.5 billion from 
aflatoxins in peanuts, fumonisins in corn and deoxynivalenol in wheat, respectively (Robens 
and Cardwell, 2003). The major economic cost in developing countries is associated with 
effects on human health (Miller, 1998).  
Significant outbreaks of aflatoxin poisoning in Kenya were due to the consumption of maize 
contaminated with AFB1 (Lewis et al., 2005). The trichothecene outbreak in the Kashmir 
Valley, India, was due to consumption of mold-infected wheat (Ramesh et al., 1989). 
Therefore, in view of the devastating effects of mycotoxins and, also, to protect the end user 
(consumer) from contamination, the regulatory authorities are striving hard to make the 
necessary amendments to the existing permissible limits of mycotoxins to minimize exposure. 
Table 1.1: Maximum permissible levels of major mycotoxins in foods marketed in the EU (EU/ 
165/2010) 
 
Toxin EU  maximum permissible levels 
                 (µg/kg) 
 
Aflatoxins 
Groundnuts, oilnuts, hazelnuts, almonds and pistachio 
Dried fruits 
Cereals and cereal-based foods 
Maize & rice  
Chilli, pepper, nutmeg, ginger & turmeric 
 
                     
                       15 
                       10 
                       4 
                       10 
                       10 
Zearalenone 
Cereals  
Maize 
Pastries, biscuits and breakfast cereals 
Infant foods 
                   
                       10 
                       350 
                       50 
                       20 
T-2 & HT-2 toxins 
Cereals and cereal products 
                    
                     N/A 
N/A indicates maximum permissible limits are not established  
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1.2 Classification and chemical properties of mycotoxins 
Mycotoxins are toxic secondary metabolites and are classified based on the fungal genera 
producing them. The detailed chemical description and structural elucidation of the mycotoxins 
that are used in the present work are described in the following sections.   
 
1.2.1 Mycotoxins of Asperigillus species 
Asperigillus species are aerobic and, hence, are present in all ‘oxygen-rich’ environments. 
These species are the predominant producers of mycotoxins, consisting predominantly of 
aflatoxins. 
 
1.2.1.1 Aflatoxins 
Aflatoxins (M.Wt. ~ 320 Da) belong to a group of difuranocoumarins produced by Aspergillus 
flavus, A. nomius and A. parasiticus. Even though there are 20 different types of aflatoxins only 
AFB1, B2, G1, G2 are found in foodstuffs (http://www.micotoxinas.com.br/aflafacts.pdf). Other 
significant members such as AFM1 and AFM2 are hydroxyl metabolites of AFB1 & B2 and were 
isolated from bovine milk and less toxic than AFB1. The aflatoxins have a coumarin ring and a 
ketone carbonyl group. The ketone group is linked at the C3 or C4 position of the coumarin 
ring. The carbonyl group plays a key role in the modification of the toxin without affecting its 
active properties (Asao et al., 1965). The chemical structures of aflatoxins are shown in Figure 
1.1.  
Aflatoxins are crystalline compounds that can be isolated from contaminated matrices with 
highly polar solvents e.g. chloroform, methanol and dimethylsufoxide (DMSO). They are 
highly heat-stable and can withstand heating above 1000C. They possess excellent storage 
stability when kept in the dark. These molecules contains a carbonyl group in a ring structure 
that is cross conjugated with αβ unsaturated lactone functions (Pavao et al., 1995). This lactone 
ring makes them susceptible to alkaline hydrolysis, and processes involving ammonia or 
hypochlorite have been investigated as a means for their removal from food commodities. 
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Among the aflatoxins, AFB1 is the most toxic and their order of toxicity is B1>G1>B2>G2 
(http://www.icrisat.org/aflatoxin/aflatoxin.asp). These four types of aflatoxins are distinguished 
based on their fluorescence under UV and their separation patterns on TLC (Keller et al., 
2005).  The fluorescence emissions under UV, as stated by O'Neil et al. (2001), were blue for 
AFB1 & B2, green for AFG1, green-blue for AFG2 and blue-voilet for AFM1.   
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Figure 1.1:  Structures of the different types of aflatoxins (adopted from Huang et al., 2010). 
 
Aflatoxin contamination is mainly seen in food products like maize, peanuts, pecans, almonds, 
hazelnuts, brazil nuts, cheese, corn, pistachio nuts, almonds, spices and walnuts (Creppy, 
2002). Aflatoxins are detected occasionally in eggs, milk, cheese, yogurt and meat products, 
due to the consumption of aflatoxin-contaminated feed (Garrido et al., 2003) by hens or cattle. 
The food commodities with the highest risk of aflatoxin contamination are corn and peanuts 
due to the stability of aflatoxins in most associated food processing techniques. They are, 
however, unstable in processes such as those used in making tortillas that employ alkaline 
conditions or oxidizing steps. 
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1.2.2 Mycotoxins of Fusarium species 
Fusarium species (spp.) are potent producers of an array of toxins and play an important role as 
plant pathogens. The most important toxins of this group that can affect human and animal 
health are zearalenone, fumonisin, patulin, ochratoxin, moniliformin, enniatins and 
trichothecenes such as T-2 toxin & deoxynivalenol (Bennett and Klich, 2003; Eva, 2007). 
These are considered the most hazardous due to the contamination of cereals, wheat, oats, corn, 
fruit and vegetables (Richard, 2007). Trichothecenes (M.Wt. ~ 250-550 Da) are a large group 
of sesquiterpene epoxides produced by the genera Fusarium, Stachybotrys, Myrothecium, 
Trichodezma and Cephalosporium (Ciegler, 1978). Trichothecenes (12,13-epoxy-
trichothecenes) are subdivided into four groups, based on the substituted group at position 8 
and the presence/absence of macrocyclic ring (Table 1.2).  
Table 1.2: Structural variations and trichothecene classification 
Type          Structural difference     Example 
 
Type A 
 
Ketone group at C8 position 
 
T-2, HT-2, DAS 
Type B Carbonyl function at C8 position DON, NIV, FUS-X &  
acetylated DON 
Type C  Second epoxide group at C7, 8 or C9, 10 Crotocin 
Type D Macrocyclic ring system between C4 and C15  
with two ester linkages 
Satratoxin, Roridin &  
Verrucarin 
 
The toxins belonging to trichothecene group are non-volatile and they are highly soluble in 
acetone, chloroform, dimethylsulfoxide (DMSO), ethanol, methanol and propylene glycol 
(Cole and Cox, 1981). They are highly stable compounds during storage/processing of food, 
and they do not degrade at high temperatures but can be inactivated through the application of 
3-5% (w/v) sodium hypochlorite (Wannemacher et al., 1989). Massive outbreaks of 
trichothecene contamination were reported in the 19th century in Soviet Union, Japan and 
China. All of them resulted from the contamination of cereal-based products with T-2 toxin 
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along with other trichothecene members. The toxicological effects of the first outbreak in 
Soviet Union led to alimentary toxic aleukia and the other outbreak in China was associatd with 
gastrointestinal disorders.  
 
1.2.2.1 T-2 toxin 
T-2 toxin (M.Wt. ~ 466.5 Da), a trichothecene A member is produced by F. acuminatum, F. 
poae and F. sporotrichioides. It is commonly found in cereal crops like wheat, maize, barley, 
oats & rye and processed grains e.g. in malt, beer and bread. T-2 toxin a non-volatile 
compound, is insoluble in water and petroleum ether, but is highly soluble in other solvents 
such as acetone, ethylacetate, chloroform, dimethyl sulphoxide, propylene glycol, ethanol and 
methanol (Betina, 1984). It is highly resistant to temperatures employed during various food 
processing techniques and UV light. Heating above 2000C or treatment with base solutions 
such as sodium hypochlorite and sodium hydroxide solutions inactivates the toxin 
(Wannemacher and Wiener, 1997). The presence of a hydroxyl group at the C3 position is 
responsible for its biological activity (Figure 1.2). This toxin is metabolized to HT-2, which 
leads to the additive effects when both forms are present in food material simultaneously. The 
major structural difference between T-2 and HT-2 is based on the presence of an acetyl group 
in the C4 position.  
        
1.2.2.2 Zearalenone  
Zearalenone (M.Wt. ~ 318 Da) (Figure 1.2) is a resorcyclic acid lactone and naturally occurring 
estrogen produced by Fusarium graminearum. A double bond is present at the C12 position 
along with a ketone group. Zearalenone is a white crystalline solid that exhibits blue green 
fluorescence when excited at 360 nm and intense green flourescence when excited at 260 nm. It 
is soluble in benzene, acetonitrile, methanol, ethanol and acetone (Agag, 2004). ZEN is 
thermally stable and is found in maize, barley, oats, wheat, rice, sorghum and bread. The order 
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of their estrogen receptor (ER) binding affinity is α -ZOL > α -ZAL > β -ZAL > ZEN > β –
ZOL (Shier et al., 2001). The toxicity of the ZEN is reduced by ozone treatment, nutritionally 
inert sorbents and microorganisms (Zinedine et al., 2007). ZEN is classified as a type-III 
carcinogenic agent (IARC, 2002).  
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Figure 1.2:  Structures of the T-2 toxin and zearalenone (adopted from Bouaziz et al., 2009). 
 
1.3 Effects, mode of action and mycotoxicosis 
 
Mold infection is the cause of a wide range of human ailments and disabilities. During 
colonization, fungi will produce enzymes for the breakdown of protein, carbohydrates, nucleic 
acids and lipids, which are vital for fungal growth. The secondary metabolites produced by the 
molds during the process of colonization are called ‘mycotoxins’ and may induce toxicological 
effects in humans.  
Mycotoxins are present in all the parts of the fungi including hyphae, mycelia, spores and the 
substrate on which they grow. Their presence in the substrate results in serious symptoms upon 
consumption by humans/animals, and leads to ‘mycotoxicosis’. The associated symptoms may 
be acute or chronic, resulting in reduced growth and development, immunosuppression and 
tumor formation. Overexposure to mycotoxins causes symptoms such as fever, nausea, 
vomiting, diarrhoea, leukopeneia, lesions of skin and mucosa (Ellenhorn and Barceloux, 1988). 
The factors that increase the acute ‘mycotoxicosis’ in humans include limited availability of  
uncontaminated food, fungal development in crops and commodities induced by environmental 
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conditions, and lack of regulatory systems for mycotoxin monitoring and control. The 
toxicological effects of different classes of mycotoxins are described in Table 1.3. 
 
Table 1.3: Toxicological effects of some major mycotoxins 
 
Toxin  System affected Toxicological  symptoms 
 
Aflatoxins 
 
Circulatory system 
Immune system 
Nervous system 
Digestive system 
Gene expression 
 
Haemorrhage, anaemia 
Immunosupression 
Nervous syndrome 
Motility, diarrhoea 
Teratogenic, carcinogenic and hepatotoxic 
effects 
Trichothecenes Circulatory system 
Immune system 
Digestive system 
Nervous system 
Dermal system 
Haemorrhage  
Immunosupression 
Gastroenteritis, vomiting 
Restlesness and lack of reflexes 
Necrosis, oral and dermal lesions 
Zearalenone Digestive system 
Reproductive system 
 
Gene expression 
Diarrhoea 
Enlargement of mammary glands,  
uterus hypertrophy, testicular atrophy 
Teratogenic effects 
 
1.4 Mycotoxin risk management measures 
Mycotoxins are extremely difficult to remove or eradicate. To minimize the amount of 
mycotoxin food contamination two types of strategies were followed, including ‘in-field’ (pre-
harvest) and during storage (post-harvest) prevention strategies (Figure 1.3). The pre-harvest 
strategies involve gene level modification of plants or adoption of specific cultivation practices 
to minimize contamination. Post-harvest detoxification of contaminated grains will require 
physical, chemical or biological agents (Cole, 1989). The best approach should significantly 
prevent toxicity, be cost effective and should not create detrimental effects on animals.  
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Pre-harvest 
prevention 
strategies
• Application of anti-fungal agents or biopesticides
• Protection of crops from insects
• Reduction of moisture content
• Transgenic plant development
• Development of genetically modified plants resistant to insect damage
Post-harvest 
prevention 
strategies
• Discarding of damaged seeds
• Appropriate moisture level maintenance
• Supplying more CO2
• Application of anti-fungal agents
• Thermal inactivation of toxins through food processing techniques
• Application of mycotoxin-adsorbing agents
Mycotoxin prevention strategies
 
Figure 1.3:  Prevention strategies for elimination of mycotoxins. 
 
Major mycotoxins, such as aflatoxins, ochratoxin A, Fusarium toxins (trichothecenes like 
deoxynivalenol, nivalenol, T-2/HT-2 toxin, zearalenone and fumonisins), are potentially 
removable from feed by use of various adsorbing agents in the compound feed or by 
degradation with bio-transforming agents such as bacteria/fungi or enzymes. Some of the 
reported degrading agents were ammonia (Hoogenboom et al., 2001) and formaldehyde plus 
ammonia (Awadalla et al., 1991). The major disadvatanges of chemical detoxification is that 
such approaches are fungistatic but are not fungicidal and, in some cases, they may be bio-
hazardous. Most of the adsorbent materials have not, as yet, received EU regulatory approval. 
Certain biological agents, e.g. microorganisms, are capable of biotransforming particular 
mycotoxins into less toxic metabolites. For example, yeast and yeast cell walls can bind 
mycotoxins thus facilitating removal of ochratoxin A. In recent studies it was shown that the 
removal of the epoxide group of trichothecenes by bacterial species of Eubacterium (Binder et 
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al., 2001) leads to detoxification. Alkaline treatement of fumonisins leads to hydrolyses, thus 
making them less toxic (Palencia et al., 2003).  
The adoption of the HACCP (hazard analysis and critical control points) system, in parallel to 
the development of prevention techniques were found to be effective in mycotoxin control 
(FAO, 2001). This system is used to identify and control hazards within the production, 
handling, storage and processing of the individual food produce. However, in developing 
countries these processes are not always economically feasible. 
  
1.5 Mycotoxin detection methods 
The presence of mycotoxins in only trace quantities requires the development of highly 
sensitive and reproducible techniques for their quantification. The diversity in chemical 
structures and the variations in the physio-chemical properties of mycotoxins led to the 
development of various approaches for mycotoxin detection. The reliability of any assay is 
determined by characteristics such as precision, accuracy, detectability, sensitivity and 
specificity (Hans et al., 1986).  
 
1.5.1 Analytical techniques for mycotoxin detection 
Analytical techniques recognized by the AOAC frequently used for mycotoxin detection 
include TLC (Thin layer chromatography), HPLC (High performance liquid chromatography), 
GC (Gas chromatography) and LC-MS (Liquid chromatography-Mass spectrometry) (Turner et 
al., 2009). The basic steps involved in any chemical analytical technique are sampling, 
extraction, clean-up, separation, detection, quantification and confirmation. Each of the 
individual steps involved in the development of analytical techniques will now be discussed. 
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1.5.1.1 Sample preparation or extraction methods 
Due to the non-homogenous distribution of mycotoxins in a single crop or lot of product, it is 
necessary to use the proper sampling method to avoid sampling error. The choice of sampling 
method used is based on the structure of the mycotoxins to be determined (Stroka et al., 2004). 
Sample preparation plays a vital role in the success of the analytical technique because the 
accuracy of the analysis is based on the quality of the sample. Mycotoxin analysis frequently 
relies on extract clean-up that is based on polarity of the individual analytes in organic solvents. 
Problems with sample preparation have been addressed by the selection of an extraction 
method that is designed to take into account the type of food or feed matrix (Wilkes and 
Sutherland, 1998). Various extraction methods used include: (a) liquid-liquid extraction, which 
is suitable for small-scale experiments and is based on the dissolution property of the toxin in 
either the organic or the aqueous phase of the solution. (b) supercritical-fluid extraction 
involves the usage of CO2 for the extraction of the required compound but is not very feasible 
due to the high cost and also the need for sophisticated equipment 
(http://micotoxinas.com.br/boletim36.pdf) and (c) solid-phase extraction, where small columns 
are packed with silica gel, C-18 (Octadecylsilane), florisil and phenyl solid supports. This 
technique is used routinely for the isolation of toxins of interest from complex matrices. 
 
1.5.1.2 Separation methods  
After clean-up of samples, mycotoxins need to be separated from various impurities and 
interferences and then quantified by chromatographic techniques outlined below: 
 
1.5.1.2.1 Thin layer chromatography (TLC) 
 TLC is both quantitative and semi-quantitative, is cost-effective and is able to separate 
complex mixtures. Mycotoxins are readily separated by TLC with a range of organic solvent 
mixtures, as the mobile phase, and are easily observed under UV or with visualization reagents. 
Silica gel TLC plates are widely used for the separation of aflatoxins  (B1, B2, G1, G2) (Mehan 
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and Gowda, 1996). A number of improvements of conventional TLC such as two-dimensional 
and high-performance TLC have been applied to improve the separation of mixtures of 
mycotoxins. TLC was found to be cost-effective and suitable for the analysis of aflatoxins, 
zearalenone and ochratoxin, with detection limits of 1 ng/kg, 20-40 µg/kg and 0.3 µg/kg, 
respectively. Other mycotoxins have also been successfully analysed by TLC (Sokolović and 
Simpraga, 2006).  
 
1.5.1.2.2 Gas chromatography (GC) 
GC is a separation technique employed for the analysis of volatile compounds, in which the 
vaporized volatile compounds are separated and fractionated as a consequence of partition 
between a mobile gaseous phase and stationary phase held in the column. The volatilised 
sample will be carried through the column by an inert carrier gas such as helium or nitrogen. 
The components are separated based on their partition ratio. Concentration equilibration occurs 
repeatedly between the solid, stationary and the mobile phases. The level of adsorption or 
partition for each component causes differences in the retention time for each component 
within the column. Since mycotoxins are non-volatile in nature they are derivatized into their 
volatile trimethylysilyl forms through treatment with either trifluoroacetic acid or 
heptafluorobutyric acid anhydride, prior to analysis by GC.  
Various examples of the application of GC techniques for mycotoxin detection exist. The 
analysis and isolation of 13 different types of trichothecene members using GC was studied 
extensively using the derivatization of the hydroxyl group present on these molecules. The 
detection limits achieved with trichothecenes ranged from 50-200 µg/kg (Croteau et al., 1994). 
GC along with mass spectrometry was employed for the detection of zearalenone in cereals 
(Tanaka et al., 2000). Trichothecene detection in beer samples was evaluated using GC, with a 
flame ionization detector, and had a detection range of 8-25 µg/kg (Schothorst and Jekel, 
2003). Simultaneous detection of type A and B trichothecenes was developed by Eke et al. 
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(2004) using GC coupled with flame ionization in semolina, with a detection range of 300-470 
µg/kg. 
 
1.5.1.2.3 High performance liquid chromatography (HPLC) 
The principle for HPLC involves using high pressure to pass the sample through a pre-packed 
column with sorbant (stationary phase) and subsequent addition of a mobile phase consisting of 
solvents of different polarity. Due to the differences in the polarity of the individual 
components of the analyte they will partition to different degrees between the solid and mobile 
phases. The component with least interaction will be eluted first followed by the others. HPLC 
is commonly used for analysis of fumonisin, aflatoxins, zearalenone and ochratoxin A (Coker, 
2000). HPLC-MS/MS is employed for the detection of mycotoxins and their metabolites 
(Spanjer et al., 2008). In mycotoxin analysis by HPLC, UV and fluorescence are commonly 
used methods of detection, which rely on the presence of a chromophore in the toxin moiety. 
Derivatization is performed for compounds which are not fluorescent by nature. Due to the 
polar nature of mycotoxins they can be readily separated on reverse-phase HPLC leading to the 
emergence of a diverse array of methods (Bunaciu, 2010). The detection limits achieved with 
HPLC with a fluorescence detector are 0.025 ng/g for AFB1 and AFG1, 0.012 ng/g for AFB2 
and AFG2, 0.2 ng/g for OTA, 1.5 ng/g for ZEN, 6.2 ng/g for FB1, FB3 and HT-2 toxin, 9.4 ng/g 
for FB2 and T-2 toxin, and 18.7 ng/g for DON. In addition, the limits of quantification (LOQ) 
ranges from 0.04 ng/g for AFB2 and AFG2 and 62 ng/g for DON (Soleimany et al., 2011). 
Ochratoxin A (0.035-0.689 ng/g) and AFM1 (0.025 ng/g) were detected in infant formula milk 
using HPLC with fluorescence detection (Meucci et al., 2010).  
 
1.5.1.2.4 Capillary electrophoresis (CE) 
This is based on the separation of components depending on their mass to charge ratio in an 
electric field. CE is performed in smaller volumes of aqueous buffer and this method can 
eliminate the usage of large amounts of organic solvents that will be required for other 
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chromatographic techniques. Most of mycotoxins, such as aflatoxins, moniliformin, ochratoxin 
A, deoxynivalenol, fumonisins and zearalenone were separated successfully by CE (Galaverna 
et al., 2008). Capillary electrophoresis was used for the detection of MON in maize with a limit 
of detection of 0.1 µg/g (Maragos, 2004) and ZEN with a limit of detection of 0.0084 mg/L 
(Zeng et al., 2003). This technique was adopted for the detection of aflatoxin B1 by Maragos 
and Greer (1997). The CE method may suffer from problems with analytical impurities and 
smaller sample injection volumes for analysis, which might limit the usage of this technique for 
mycotoxin analysis (Bohs et al., 1995; Otieno and Mwongela, 2008). 
  
1.5.1.3 Separation and identification 
1.5.1.3.1 Chromatography with tandem MS (LC-MS/MS) 
In the LC-MS method, the physical separation capabilities of liquid chromatography are 
coupled with the mass analysis capabilities of mass spectrometry. This technique is now very 
widely used as it allows multi-toxin analysis (up to 31 types) in a single experiment. This 
technique was used for the simultaneous detection of multi-toxins including trichothecences, 
aflatoxins, fumonisins, ochratoxin A, zearalenone, beauverin and sterigmatocyst in sweet 
pepper with a detection range of 0.32 µg/kg-42.48 µg/kg (Monbaliu et al., 2009). Type A and 
B trichothecenes were also analyzed by LC-MS/MS in maize with a detection limit of 0.3-3.8 
µg/kg (Berthiller et al., 2005). This technique was adopted for the determination of 39 
mycotoxins in wheat and maize (Sulyok et al., 2006). Mycotoxins are negatively and positively 
charged chemically diverse molecules, and these can be analyzed easily on positive or negative 
modes of mass spectrometry. Increased high throughput detection and identification make this 
technique highly versatile. The major advantage of this method is the detection of mycotoxin 
metabolites, which cannot be analysed by chromatographic techniques and also the sensitivity 
of this technique falls within the permissible limit of contamination set by the regulatory 
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authorities. The high cost involved for the analysis using this method makes the adoption of 
this technique unsuitable for certain types of analysis e.g. low cost rapid qualitative tests. 
 
1.5.1.4 Limitations of current analytical techniques 
 The lack of ease of automation of TLC led to  development of other chromatographic    
            techniques. 
 The need for derivatization of the non-volatile mycotoxins for performing GC is a  
            major limiting factor for the application of this technique to detect mycotoxins. 
 Although chromatographic techniques are feasible they are expensive, time-consuming  
            and require trained personnel for handling the sophisticated equipment involved. 
 Almost all of these techniques require a sample ‘clean-up’ procedure, which might not  
            generate a representative sample lot for analysis. 
 Most of the mycotoxins undergo conversion to their metabolites, which are termed  
            masked mycotoxins either due to plant enzyme activity or the degradation of the toxin  
            during processing techniques. This may cause issues for analysis. 
 Formation of masked mycotoxins, like DON 3-glucoside (Berthiller et al., 2009), leads  
            to the false experimental results due to the inability of the technique to detect the   
           ‘hidden toxin’. 
 Due to the highly polar nature of these metabolites they are easily lost during extraction  
            and sample clean-up procedures. 
 There are no set commercial standards for some masked mycotoxins.  
To overcome the aforementioned limitations of the analytical techniques, the application of 
immunoassays was suggested as they are sensitive and the results are highly comparable with 
analytical techniques such as HPLC, GC and Mass spectrometry. 
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1.5.2 Novel mycotoxin binders for assays 
A wide array of mycotoxin binding ligands such as synthetic polymers (Appell et al., 2008; 
Maragos, 2009) and recombinant antibodies were developed in the recent past for incorporation 
into mycotoxin assays. Key roles played by antibodies include isolation of pure mycotoxins 
using immuno-affinity columns (IACs) and their incorporation into immunoassays based on the 
interaction of the antibody with the toxin. The limitations on the usage of antibodies are due to 
the fact that they are suseptable to denaturation and proteolytic degradation, the use of animals 
for immunization and also, the instability of the antibodies in organic solvents. This has driven 
researchers to use some alternatives that can overcome these limitations, e.g. polymers (e.g. 
molecular imprinted polymers) and modified natural materials (e.g. single chain antibody 
fragments). The following sections focus mainly on the generation of different types of 
recombinant antibodies.  
 
1.5.2.1 Antibodies 
Antibodies are globular proteins termed immunoglobulins. These are the key bio-recognition 
elements of the immune system. Structurally, full-length antibodies, such as immunoglobulin G 
(IgG) (Figure 1.4), possess amino and carboxyl-termini and are comprised of four polypeptide 
chains, namely, the variable heavy (VH), variable light (VL), constant heavy (CH) and constant 
light (CL) domains, which are interconnected via disulphide bonds. Natural antibodies are 
glycoproteins, possessing carbohydrate side chains attached to their polypeptide backbones at 
the antibody constant region. Interactions with antigenic determinants are promoted via 
Complementarity-Determining Regions (CDRs), which reside in the variable domains of the 
immunoglobulin and vary from antibody to antibody.  
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Figure 1.4: Structure of intact IgG molecule. IgG (molecular weight   ̴ 150 kDa) consists of four 
peptide chains, which include two variable heavy (VH) and light chains (VL) (Eremin et al., 2002) that 
are covalently linked together by disulfide bonds. The two arms of the IgG molecule are arranged to 
form a ‘Y’ shaped moiety with two antigen (binding) sites on either arm of the molecule.  
 
The other types of immunoglobulins (Figure 1.5) include IgM, IgE, IgD & IgA. IgM, which 
comprises 13% of the serum antibodies, is pentameric with 10 epitope binding sites and 
exhibits a half-life of 5 days. It is the first immunoglobulin produced in the immune response. 
IgA forms approximately 6% of the serum antibodies and has two sub-classes namely IgA1 & 2. 
It is dimeric with 4 epitope binding sites, with a half-life of 6 days. The Fc portion of this class 
of antibody contributes to the ability of mucous to trap microbes. IgD, which is monomeric, 
forms approximately 0.2% of total serum antibodies. It plays a vital role in the generation of 
self-reactive autoantibodies by the B-cells. IgE is monomeric, forms approximately 0.002% of 
the total serum antibodies, and plays a major role in mediating many allergic reactions.  
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Figure 1.5: Structure of different classes of antibodies. Antibodies may be monomeric (IgG, IgD and 
IgE), dimeric (IgA) or pentameric (IgM).   
 
1.5.2.2 Production of different types of antibodies 
Antibody preparations are classified into three types based on the production technique 
employed (Figure 1.6). These are polyclonal, monoclonal and recombinant forms. They may 
vary in their affinity, avidity, sensitivity and cross reactivity. For the production of antibodies 
against mycotoxins, first of all mycotoxins are covalently linked to carrier proteins like bovine 
serum albumin (BSA), keyhole limpet hemocyanin (KLH) or ovalbumin, since they are of low 
molecular weight and, therefore, cannot directly generate an immune response in the host used 
for immunization (i.e., hapten). It is a well established fact that the specificity and sensitivity of 
antibodies produced post-immunization are directly related to the quality of the immunogen. 
The availability of the functional groups like sulfhydryl, amine, carboxyl, etc., on mycotoxins 
plays a crucial role in efficient conjugation of the toxin to the protein carrier. The proper 
orientation of the hapten also plays a major role in the generation of antibodies that specifically 
recognize the antigen. Hapten density on the conjugate is also important and it influences the 
immune response directed toward the newly created antigenic determinant. After appropriate 
hapten-conjugate synthesis, the next step is to select a host for immunization. From the 
literature available on the generation of antibodies (Table 1.4) for mycotoxins, murine and 
leporine species are commonly choosen hosts. The route of immunization selected for 
conjugate administration may be intra-peritoneal, subcutaneous or intravenous. After boosting 
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the host several times with the antigen-conjugate and a suitable adjuvant such as Freund’s, the 
immune cells of the host will be trigerred for the generation of antibodies against the target. 
  
Table 1.4:  Literature based major anti-mycotoxin antibodies and their detection limits  
 
1.5.2.2.1 Polyclonal antibodies 
Polyclonal antibodies are a pool of immunoglobulin molecules secreted by the host immune 
system in response to an antigen. This pool of antibodies possess different immunoglobulins 
with different ‘epitope-recognizing’ capabilties (Scholler et al., 2010). Isolation of specific 
antibodies from the pool of immunoglobulins is an important step in polyclonal antibody 
production. Conventional ammonium sulfate precipitation (Ahmadzadeh et al., 2011) has 
certain limitations e.g.  yield and purity. This is often replaced by affinity purification with 
Toxin Reported antibodies  
& host 
Sensitivity Reference 
 
Deoxynivalenol 
 
 
Monoclonal [murine] 
 
Recombinant scFv  
[murine]  
 
18 ng/mL 
 
N/A 
 
(Maragos and McCornmick, 
 2000) 
 
(Choi et al., 2004) 
T-2 and HT-2 
Toxin 
Monoclonal [murine]  
Polyclonal [leporine] 
20 ng/mL 
0.12 ng/mL 
(Ueda and Akiwa, 2007) 
(Wang et al., 2010) 
Zearalenone Recombinant scFv  
[murine]  
 
Monoclonal [murine] 
Monclonal [murrine] 
14 ng/mL 
 
0.8 ng/mL  
0.3 ng/mL 
(Yuang et al., 1997)  
 
(Burmistrova et al., 2009)  
(Teshima et al., 1990) 
Fumonisins Polyclonal [murine]  
Polyclonal [leporine] 
Monoclonal [murine] 
Recombinant scFv 
[naïve library] 
100 ng/mL  
0.45 ng/mL 
1000-5000 ng/mL 
N/A 
 
(Azcona-Olivera et al., 1992)  
(Yu and Chu, 1996) 
(Fukuda et al., 1994) 
(Lauer et al., 2005) 
Aflatoxin B1 
 
Monoclonal [murine] 
Polyclonal [leporine] 
Recombinant Fab  
[murine]  
0.006 ng/mL 
15.8 pg/mL 
14.8 ng/mL 
(Devi et al., 1999)  
(Gathumbi et al., 2001) 
(Stapleton, 2007) 
Aflatoxin B2 Monoclonal [murine] 50 pg/mL (Kenneth et al., 1988) 
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protein A or G (Yan and Huang, 2000) (Figure 1.6(b)). With advances in chromatographic 
techniques, in conjunction with the conjugation chemistry, various other techniques such as 
purification on antigen-immobilized beads were introduced. While polyclonal antibodies are 
relatively easy to produce, a disadvantage is that a variety of different specificities exist with 
varying affinities for the desired analyte. In addition, it is not possible to re-create the identical 
binding properties once a given batch of antibody is completely used up. 
 
1.5.2.2.2 Monoclonal antibodies 
Monoclonal antibodies were first reported by George Kohler and Cesar Milstein in 1975 
(Kohler and Milstein, 1975; Akshaya et al., 2008). This technique uses B-cells that specifically 
produce the required antibodies to the target antigen. These antibodies have identical epitope 
binding specifications (Alisa, 1984). The production of monoclonal antibodies (Figure 1.6(c)) 
starts with immunization of the selected host with the specific antigen. When a suitable serum 
titre is obtained, the spleen is removed and antibody-producing B-cells are harvested (generally 
from the spleen). These cells are subsequently fused to myeloma cells. Selection of the 
hybridomas is carried out in selective medium followed by testing the specificity of the 
antibodies produced towards the antigen of interest (Tomita and Tsumoto, 2010).   
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Figure 1.6: Schematic representation of the production of recombinant, polyclonal and monoclonal 
antibodies. Immunization of the hosts is the initial step for the generation of any antibodies. For the 
production of recombinant antibodies (a) RNA will be isolated from the spleen or bone marrow 
followed by the synthesis of cDNA. The variable heavy and light chain genes will be amplified and the 
SOE product made and incorporated into the display vector. This is then electroporated into E. coli 
followed by the amplification of the genetic material through the usage of bacteriophage and 
subsequent screening of the antibody. Polyclonal antibody production (b) involves the isolation of the 
serum from the blood obtained from the immune host followed by affinity purification. Monoclonal 
antibody production (c) involves the isolation B-cells and their fusion with myeloma cells leading to the 
production of hybridoma. These are selectively enriched by screening on the antigen-immobilized 
surface ultimately leading to the production of the required specific antibodies. 
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1.5.2.2.3 Recombinant antibodies  
Recombinant antibody generation (Figure 1.6(a)) offers a valuable alternative to polyclonal and 
monoclonal antibodies. Recombinant antibody libraries can be classified based on two criteria. 
One criteria refers to the  library’s source of derivation i.e., whether the library is derived from 
a naïve or an immunized source with or without semi-synthetic or synthetic sequences (Brichita 
et al., 2005). The other criterion of classification is mainly based on the display system 
employed, which may be phage display (the most common method), bacterial display, yeast 
display, mammalian display or ribosomal display.   
 
1.5.2.2.3.1 Naïve or single-pot libraries  
Naïve or single-pot libraries are built through PCR amplification of IgM or IgG variable 
regions and subsequent cloning into vectors for screening. These libraries exhibit large 
antibody diversity of up to 1011 (Sblattero and Bradbury, 2000). Naïve libraries are non-
immune, aimed at a variety of targets through synthetic or semi-synthetic assembling of the 
genes (Vaughan et al., 1996). The first successful generation of an antibody against aflatoxin 
B1 using naïve libraries was reported by Moghaddam et al. (2001). Later on successful 
generation of anti-AFB1 scFv from a human naïve library was reported by Rangnoi et al. 
(2011). 
The advantages assosciated with the utilization of naïve libraries include: 
 High antibody diversity, thus increasing the chances of obtaining the antibody for the  
            desired target. 
 Avoids the need for immunization and reduces the usage of animals for the purpose of  
            library generation. 
 A very short time for implementation. 
 An increased opportunity of obtaining high affinity antibodies using these libraries. 
The limitations assosciated with these libraries include:  
 24 
 Major chances of formation of inclusion bodies leading to expression-related problems. 
 Multiple electroporation steps required for generation of diverse libraries. 
 Availability of limited information about the contents of naïve libraries. 
      To circumvent these limitation posed by the naïve libraries synthetic and semi-synthetic 
antibody libraries were developed.  
 
1.5.2.2.3.2 Synthetic & semi- synthetic antibody repoitre libraries 
In synthetic library generation, randomized sequences will be incorporated into CDR regions to 
bring about complete or partial degeneracy. The synthetic diversity bypasses the natural biases 
and redundancies (Winter and Milstein, 1991). The semi-synthetic library construction involves 
the incorporation of randomized sequences in one or more CDR regions through PCR 
reactions. The overall advantage of the utilization of these libraries over the naïve libraries is 
that the variability and overall diversity of the library can be controlled. 
 
1.5.2.2.3.3 Immune libraries 
Immune libraries are generated from hosts, where the host was injected with the target antigen. 
In general, the size of the immune library is quite low, which can be due to the development of 
selective antibodies recognizing the target (Abi-Ghanem et al., 2008). The quality of RNA 
originally isolated from lymphoid organs, coupled with the nature of the host-generated 
response, are key contributory factors in producing a diverse library.   
Immune library construction starts with the amplification of antibody-encoding genes from 
harvested lymphoid organs (e.g. spleen and bone marrow) using PCR.  This process is 
simplified by the availability of primers for the amplification of variable heavy and variable 
light genes from a selection of different host species (Barbas et al., 2001). Once cloned into a 
suitable expression vector, the construct is introduced into E. coli, typically by electroporation, 
and the resultant library is harvested (Conroy et al., 2009). The affinity of the antibodies can be 
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improved through affinity maturation using molecular biological approaches such as site-
directed mutagenesis, random mutagenesis or chain shuffling (Lou and Marks, 2010).  
Various types of antibody fragments may be produced, including the single chain variable 
fragment (scFv) and the fragment antigen binding (Fab) entity (Figure 1.7). The scFv fragment 
is composed of variable heavy and light chain domains of the immunoglobulin, which are 
covalently linked by an flexible linker with approximately 15 amino acids. The flexible nature 
of linker allows the proper folding of the antigen combining sites. The linker is rich in glycine 
(aids in the proper folding) and serine and threonine (enchances solubility). These scFv 
antibody fragments can be purified using protein L, which can bind to the variable region of the 
kappa light chain. The assembly of scFv libraries requires fewer PCR amplification cycles, and 
multimerisation of antibody fragments may be advantageous in improving avidity, which can 
be particularly useful when detecting structurally-related analogues. Furthermore, yields of 
scFv produced by induced cultures of Escherichia coli are often significantly higher than for 
those seen for Fab antibody fragments. Fab molecules, in contrast, have higher stability and do 
not multimerise (O'Kennedy et al., 2010). Papain digestion of the whole immunoglobulin 
molecule or monoclonal antibodies results in Fab and Fc fragments. The alternative way for the 
generation of Fab is recombinant library construction through utilizing primers and PCR 
reactions. The Fab fraction consists of a single antigen combining site with one variable 
domain of heavy and light chain each.  
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scFv (28 Kda) Fab (55 Kda) 
 
 
Figure 1.7: Recombinant antibody formats. The scFv and Fab antibody fragments are shown. The 
scFv consists of heavy (VH) and light (VL) chain that were connected through linker from the N-terminus 
of VH to the C- terminus of VL and vice-versa. scFv’s are relatively small and are easily expressed in E. 
coli. The Fab consists of constant and variable domains of the heavy and light chains. 
 
For the development of the aforementioned recombinant antibodies, phage display is frequently 
employed, due to its efficient antibody generation capability. This technique was first described 
by George P. Smith in 1985 (Smith, 1985). This has proven to be a powerful tool for 
recombinant antibody selection (Willats, 2002; Yau et al., 2003). The display of antibodies on 
the phage surface allows affinity selection by the antigen (Petrenko and Vodyanoy, 2003). The 
development of molecular methods for the expression and engineering of recombinant 
antibodies led to the development of a new era in the antibody generation (Maynard and 
Georgiou, 2000; Ahmad et al., 2012). The most prominant phage display technology used is 
based on the M13 display system.  
 
1.5.2.2.4 Structure of filamentous phage  
A bacteriophage is a virus that infects the bacterium by attaching to the surface. This is 
followed by the injection of the viral DNA into the host bacteria. The term bacteriophage is 
derived from two words i.e. bacteria and a Greek word ‘Phagin’ meaning ‘to eat’. These phage 
were discovered by Frederick Twort and Felix d’Herelle. The four most commonly used types 
of bacteriophages in molecular biology applications include the T-series of bacteriophages, 
temperate bacteriophages, small DNA bacteriophages (spherical phage and filamentous phage) 
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and RNA bacteriophages. Among these different types of phages, filamentous phage are widely 
used for phage display applications. A detailed description of the structure of a filamentous 
phage follows. 
All bacteriophage makes use of the host cell replication machinery to encode and replicate their 
genes. A filamentous phage is a rod shaped, single-stranded DNA (ssDNA) virus that mainly 
infects gram-negative bacteria (Figure 1.8). A typical phage particle is approximately 6.2 nm in 
diameter and 930 nm in length. This phage coat is composed of one major (pVIII comprising 
50 amino acids) and four minor hydrophobic (pIII, pVI, pVII & pIX) proteins. The F-pilus of 
the E. coli host attaches with the phage through the N-terminal of the pIII. The stages in the 
phage life-cycle include infection, replication of the viral genome, assembly of new viral 
particles and release of progeny particles into the host cells. The phage genome is transferred 
into the host’s cytoplasm and is converted into DNA, which serves as template for the 
expression of phage genes.    
Phage coat
Phagemid
Gene III
pIII protein 
Antibody gene
pVI protein 
pIX protein 
pVII protein 
 
 
Figure 1.8: Pictorial depiction of the M13 bacteriophage. The bacteriophage is typically cylindrical in 
shape with a phage coat composed of five different types of proteins. The pIII protein plays a vital role 
for antibody attachement to the phage. The major part of the phage coat is composed of pVIII proteins 
with minor proteins (pVI, pVII & pIX) on either ends of the cylindrical structure.  
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1.5.2.2.5 Antibody phage display 
The physical linkage of the encoding genotype to the phenotype in-vitro forms the basis for all  
display techniques (Leemhuis et al., 2005). The similarities in all the different display 
techniques include  (a) generation of genotypic diversity and (b) combining genotype to the 
phenotype (http://micotoxinas.com.br/boletim36.pdf) clonal selection (http://ec.europa.eu/food/ 
fs/sc/scf/ out74_ en.pdf) amplification of the selected clones. 
The in-vitro binding process used for selection of the desired antibody is called “panning” 
(Figure 1.9). Here, the antigen of interest is immobilized on a solid support like nitrocellulose 
(Hawlisch et al., 2001), magnetic beads (Moghaddam et al., 2003), plastic surfaces of 
polystyrene tubes (Hust et al., 2002) or 96 well microtitre plates (Kobayashi et al., 2005). The 
phage are then incubated with the antigen on the solid support. The weakly bound and unbound 
phage particles are removed through stringent washing. Specifically bound phage displaying 
antibodies will remain and may be eluted either through trypsinization or pH shift. They are 
then reamplified through infecting into E. coli cells. For the production of new antibody phage 
the phagemid-bearing E. coli will be supplemented with helper phage for quicker amplification 
of the required antibody gene.  
The various strategies that might be employed for increasing the number of high-affinity 
binders include: 
a. decreasing the antigen concentration during each round of panning (Strachan et al., 2002). 
b. use of free hapten for competitive elution, and 
c. adoption of substractive panning technique in which the phage will be pre-incubated with  
      the carrier protein to eliminate non-specific binding.  
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Figure 1.9:  Representation of the steps involved in the biopanning process for enrichment and 
selection of recombinant antibody fragments. The phage with the relevant target-specific antibody, are 
bound to the immobilized antigen. The unbound phage will be washed away leading to the selective 
enrichment and amplification of the required antibody gene. The enriched phage are then analysed to 
assess their capability to recognize the antigen moiety.  
 
The recombinant antibodies obtained after performing phage display will then be solubly 
expressed.  Despite the availability of a huge number of vectors for antibody expression the 
gram negative E. coli is frequently choosen (Karu et al., 1995). The presence of the Lac 
promoter in the expression vector allows high level expression upon the addition of IPTG (De 
Bellis and Schwartz, 1990). The various factors that might alter the yield include nutrient 
enrichment media used, temperature and IPTG induction time and quantity. The antibody 
expression will be followed by the determination of the reactivity of the antibody to the 
specified target through incorporating into a wide array of immunoassays that are specifically 
designed for the efficient detection of mycotoxins. The sections below give a detailed insight 
into some of the immunoassays that are developed to-date.  
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1.5.3 Immuno-techniques for mycotoxin detection 
Immunoassays are sensitive analytical techniques that utilize the unique properties of 
antibodies. The principle of immunoassay was first suggested by Rosalyn Yalow and Salmon 
Berson in 1959 (Wu, 2006). Selections of different quantitative immunoassay formats are 
available for toxin detection, and these include indirect, competitive and sandwich 
immunoassays (Figure 1.10). Exemplification of different types of immuoassays adopted so far 
for the detection of mycotoxins are depicted in Table 1.4. 
  
Table 1.5:  Examples of some of the reported immunoassays for mycotoxins 
  
Immunoassay Toxin Matrix & assay  
sensitivity 
 
Reference 
 
Fluorescence  
polarization  
 
Aflatoxins 
 
Deoxynivalenol  
Ochratoxin A 
Zearalenone 
 
Maize, sorghum, peanut,  
popcorn [28 ng/mL] 
 
Wheat & maize [12 ng/mL] 
Barley [3 ng/mL] 
Corn [137 µg/kg] 
 
(Nasir and Jolley, 2002) 
 
(Maragos and Plattner, 2002) 
(Won-Bo Shim et al., 2004) 
(Chun et al., 2009) 
Enzyme-linked  
immunoassays 
Aflatoxin M1 
 
Ochratoxin A 
Fumonisin B2 
Fumonisin B1 
Zearalenone  
Milk and milk products 
[3 ng/L] 
 
French wines [400 ng/L] 
Maize [6.09 µg/L] 
Cereals [7.6 ng/g] 
Cereals [1.13 µg/L] 
(Guan et al., 2011) 
 
(Radoi et al., 2009) 
(Song et al., 2009) 
(Barna-Vetro et al., 2000) 
(Thongrussamee et al., 2008) 
Lateral flow Aflatoxins 
Fumonisins 
T-2 toxin 
 
Maize [1 µg/kg] 
Maize [120 µg/L] 
Wheat & oats [100 µg/kg] 
(Anfossi et al., 2011) 
(Anfossi et al., 2010) 
(Molinelli et al., 2008) 
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Dipstick  T-2 toxin  
 
Aflatoxin B2 
 
Aflatoxin B1 
Wheat [0.25 ng/mL] 
 
Penauts, hazelnuts, pistachio &
& almonds [0.9 ng/mL] 
 
Rice, wheat, chillies &  
almonds [0.1 ng/mL] 
(De Saeger and Van  
Peteghem, 1996) 
 
(Tang et al., 2009) 
 
(Liao and Li, 2010) 
 
Biosensors Aflatoxin B1 
Ochratoxin A 
Corn [60 pg/mL] 
Cereals [4-100 ng/g] 
(Piermarini et al., 2007) 
(Ngundi et al., 2005) 
Immuno-affintiy 
Columns 
Nivalenol & 
Deoxynivalenol 
 
Wheat [0.2 mg/kg] (Kadota et al., 2010) 
 
1.5.3.1 Indirect immunoassay 
An indirect assay is performed using the conjugated or unconjugated antigen immobilized on 
solid surfaces (e.g. microtitre plates). In this type of assay the antigen-antibody complex 
formation is detected through the use of labels present on one of the reactants. The general 
labels include radioisotopes, enzymes, flurophores and luminescent substances. In this format, 
the primary antibody is added and binds to the immobilized antigen as depicted in Figure 1.10. 
The secondary labelled antibody is added with a suitable label for visualization. The major 
advantages and limitations with this types of assay format include: 
Advantages 
1. Commercial availability of wide range of labelled secondary antibodies makes the 
employment of this technique more versatile. 
2. Signal amplification can be achieved. 
3. Different visualization substrates can be used based on the labelling agent in the secondary 
antibody (e.g. alkaline phosphatase, horseradish peroxidase etc.). 
Limitations 
1. Potential cross reactivity of the primary antibody with the secondary antibody resulting in a 
non-specific signal. 
2. Problems with non-specific binding of antibodies to surfaces. 
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3. Need for effective blocking mechanisms to minimize non-specific binding. 
 
1.5.3.2 Competitive assay format 
Competitive assay formats are of two types, namely: direct and indirect. In the direct format, 
antibody is immobilized, whereas in indirect antigen is immobilized on the solid surface. 
Figure 1.10 shows the various steps involved in a competitive indirect assay format. Antigen 
immobilization is followed by the addition of antibody that was either pre or directly incubated 
with the antigen to be determined. Labelled secondary antibody is then added. Visualization is 
brought about by addition of substrate (e.g. in the case of enzyme labels). In this format the 
absorbance values decrease as the analyte concentration increases i.e. the amount of antigen 
and the signal are inversely related.    
 
1.5.3.3 Sandwich assay format 
In the sandwich assay format development, two distinct antibodies that could simultaneously 
bind to the analyte (antigen) will be utilized. One of the two antibodies will be labelled. The 
other antibody will be first immobilized on the solid surface followed by the addition of 
antigen. Later labelled antibody is added to form a sandwich. The amount of colour generated 
by the label is directly proportional to the quantity of analyte present. The sensitivity of this 
assay is governed by two major factors: the amount of captured antibody on solid surface and 
the avidity of the two antibodies towards the antigen. For a sandwich assay a given antigen 
must have atleast two epitopes that are available for binding antibodies. Ideally, this should be 
affected allowing the first antibody to capture the antigen whilst the second labelled antibody 
binds to the other epitope.  
Advantages  
1. These assays are highly sensitive. 
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Limitations 
1. Sandwich assay is particularly suitable for macromolecules. This assay is not suitable for 
lower molecular weight compounds, such as mycotoxins, due to the presence of only a single 
epitope. 
2. The large size of an antibody relative to that of the toxin inherently prevents a second 
antibody from binding due to steric hindrance (Frederick et al., 2009). 
 
Primary antibody 
addition
Secondary antibody 
addition
(A) INDIRECT IMMUNOASSAY
Antigen 
immobilization
Substrate addition Signal reading
Primary antibody 
inhibited with  antigen 
addition
Secondary antibody 
addition
(B) COMPETITIVE INDIRECT IMMUNOASSAY
Antigen 
immobilization
Substrate addition Signal reading
(C) SANDWICH IMMUNOASSAY
Antibody 
immobilization
Substrate addition Signal readingAntigen addition Secondary antibody
addition  
 
Figure 1.10: Pictorial representation of the different types of immunoassay formats. Figure (A) 
represents the indirect immunoassay, where the antigen is immobilized on the solid support, followed by 
the addition of varying dilutions of antibody. Figure (B) indicates the competitive indirect immunoassay 
format in which the antibody that was pre-incubated with antigen will be used instead of antibody 
alone. Figure (C) shows the sandwich immunoassay format, in which two different antibodies will be 
used. In all the above mentioned immunoassay formats the addition of primary antibody will be 
followed by the addition of suitable secondary antibody with a label, followed by the detection of the 
chromophore reaction with a visualizing agent.   
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1.5.4 Enzyme immunoassays 
Enzyme-based immunoassays, such as ELISA, were developed to overcome the difficulties 
associated with RIAs, and also to provide an analytical method with improved sensitivity.  
 
1.5.4.1 Stages in ELISA 
For the performance of ELISA, antigen is immobilized on the solid support. After antigen 
immobilization the antibody is added leading to the formation of antigen-antibody complex, 
which is detected using a secondary antibody. To reduce non-specific binding of the antibodies, 
washing steps are performed with mild detergents like PBS and PBST. The visualization is 
brought about through the addition of substrate, which is converted to a product whose 
absorbance is read using a plate reader.  
 
1.5.4.2 Factors affecting the ELISA assay performance 
The various physiochemical factors that might have influence on the performance of an ELISA 
include: pH shift, ionic strength, organic solvents, incubation time, type of blocking solution 
used, quality of the reagents used for the assay and the presence of detergents. Organic solvents 
like methanol, which are frequently used for dissolving haptens, show a significant impact on 
overall assay performance. The characteristics of the antibody, as represented by its sensitivity 
and cross reactivity, also play a major role in ELISA performance. The immobilization strategy 
employed for incorporating antigen onto the solid support is another important factor. 
 
1.5.4.3 Strategies to improve ELISA assay performance 
To improve the overall assay performace the following strategies can be followed: 
 Employing a well-designed and optimized antigen immobilization strategy to increase  
            the number of antigens available on the surface. 
 Selection of an appropriate antibody with high affinity towards the antigen. 
 Selection of optimal buffers for dilution and washing steps. 
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 Minimizing buffer pH shifts. 
 Reduction in the amount of organic solvents for dissolving the antigens in the assay. 
 Optimization of the incubation times of the primary and secondary antibodies. 
 Optimizing the dilutions of both primary and secondary antibodies. 
 
1.5.4.4 Hapten immobilization strategies onto the solid support  
The antigen is immobilized (either covalently or non-covalently) onto a solid support such as 
glass slides, a gold surface or polystyrene microtitre plates (Vidal et al., 2009). Non-covalent 
approaches, e.g. adsorption, for coating hapten-protein conjugates onto solid surfaces were 
frequently used (Shan et al., 2002). Drawbacks associated with non-covalent immobilization of 
haptens include the limited availability of haptens on the solid support surface for antibody 
binding (Wortberg et al., 1996). In addition, the synthesis of hapten-protein conjugates with 
reproducible hapten density may be problematic. Decreased sensitivity of immunoassays with 
hapten-protein conjugate-coated plates in the presence of organic solvents such as methanol 
(Sittampalam et al., 1996) and pH changes (Liu et al., 2009) were also reported. Covalent 
immobilization of antigens onto solid supports, may enhance stability and sensitivity of assays 
(Dixit et al., 2011), since the covalently attached antigen is less affected by factors such as pH, 
ionic strength, substrate, solvent and temperature (Willner and Katz, 2000).  
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1.5.5  Fluorescence-based immunoassays 
Fluorescence is the emission of energy from fluorophore upon absorbing radiation (Cui et.al., 
2012). Fluorophores are chemical entities that fluoresce e.g. rhodamine, FITC or fluorescein. 
Fluorescence-based assays are often significantly more sensitive than conventional 
spectrophotometric assays. The sensitivity of these assays is affected mainly by interfereces 
caused by impurities and instability of fluorophores.   
 
1.5.5.1 The MBio assay platform  
This platform (Figure 1.11) is based on the use of mutlimode planar wave guide technology. 
Briefly, laser light is directed into a waveguide substrate where total internal reflection takes 
place. The plastic wave guide is activated to make it amine- reactive. In this microarray assay 
format toxin conjugates or proteins are printed prior to assembly into the disposable cartridge. 
They are subsequently blocked with a protein-based blocking agent, spin-dried, and then 
coated with a sugar-based stabilizer for storage. The fluid is driven through the cartridge by 
capillary action and hydrostatic pressure. Low autofluorescent plastic is used in the 
construction of the cartridge.  The assay was performed by passing a fluorescently-labelled 
antibody over the antigen that was immobilized on the membrane of the MBio cartridges, 
followed by fluorescence intensity measurment. The assay results are processed using the 
MBio Diagnostics image processing software for measuring the fluorescence signal intensity.   
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Figure 1.11: Schematic representation of the MBio diagnostic platform. The major components of this 
system include the lower, upper chamber with a middle membrane (plastic waveguide), on which the 
antigens were imprinted. The upper chamber contains a fluid inlet. The sequential steps involved in the 
MBio assay setup after assembling the antigen immobilized plastic waveguide into the cartridge are (a) 
addition of primary antibody with a fluorescent label (b) incubation for 10-20 mins and reading the 
fluoresecence intensity using the MBio snapshot. The fluorescence intensities corresponding to different 
antigen-immobilized spots were recorded and image will be generated using the normalized values of 
the fluorescence reading attained (c).      
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1.5.6 Immunosensors (biosensors)  
A biosensor (Figure 1.12) is an analytical device that combines a biological ligand with a 
physical detector. It consists of three components, namely, a biological element (e.g. enzyme or 
antibody), a transducter for the conversion of the signal generated upon the interaction of 
analyte with the ligand into a measurable signal and a sensor output device that is capable of 
processing the signal and presenting it in an user-friendly format. Surface plasmon resonance 
(SPR) is an optical phenomenon, that occurs as a result of total internal reflection of light at a 
metal film-liquid interface. The major factors that may have significant impact on the quality of 
the biosensor-based assay are the binding capability and molecular weight of the analyte used. 
Due to their low molecular weight, a competitive assay is commonly used for mycotoxin 
detection in SPR-based systems.  
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Figure 1.12: Schematic representation of the detection employed in a Biacore SPR-based assay. 
Figure (a) indicates the specific change in the refractive index upon the passage of antibody over the 
analyte-immobilized surface. Figure (b) indicates a typical sensogram generated through measuring the 
shift in the reflected light and is presented as the change in measured response (RU) over time (mins).   
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1.5.7 Immunochromatographic assays             
Immunochromatographic assays utilize the principles of immunoassays combined with 
chromatographic techniques. They may be both qualitative and quantitative in nature. The 
advantages offered include ‘user-friendliness’, storage stability, rapid and ‘on-site’ 
determination and results that are highly comparable with the ELISA-based assays. The various 
practical considerations and steps involved in the immuno-affinity columns that was developed 
in the present work are described below. 
 
1.5.7.1 Immuno-affinity columns 
Immuno-affinity columns for use in mycotoxin isolation were designed for rapid, effective and 
‘one-step’ purification of mycotoxins from complex matrices with extremely low limits of 
detection (e.g. determination of toxins in baby food). The major steps in the preparation of 
immuno-affinity columns include: choosing the immunosorbant, selection of the appropriate 
covalent linkage strategy to be followed for antibody immobilization, sample loading, washing, 
elution of the analyte and regeneration of the column for further use. Different types of solid 
supports that can be used as immunosorbant materials include polysaccharides, silica-based 
supports and synthetic polymers.  
 
1.5.7.1.1 Key requirements for immuno-affinity column design  
 The porosity of the immunosorbant plays a major role in maintaining the stability of the 
matrix. Porosity and stability are inversely proportional i.e., as the porosity increases the 
stability of the immuno-affinity column (immunosorbant) may frequently decrease.  
 The immunosorbant should have functional groups on its surface that can be activated 
through the appropriate linker to allow the covalent immobilization of the antibody onto 
its surface.   
 The avidity and specificity of the antibody used for immobilization is vital. 
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 Judicious selection of the activation and coupling chemistries employed play a major 
role in the development and practical success of immuno-affinity columns. 
 
1.5.7.1.2 Steps involved in the operation of immuno-affinity columns 
 Loading the column: The capacity of the column is governed by three factors i.e, the 
nature of the sorbant, the coupling capacity of the sorbant and also the quality of the 
antibody. The quality of the antibody attained is dependent on the type of conjugate and 
conjugation chemistry employed for the generation of the immunogen originally used 
for the pupose of raising an immune reponse in the animal host used for immunization. 
Other factors that also play a significant role in the performance of the column include 
the antibody immobilization procedure employed, the availability of antigen binding 
sites and also the ‘flow-rate’ used. The higher the ‘flow-rate’ the lower will be the time 
available for antigen-antibody interaction, which could lead to decreased column 
performance. However, it is also possible to incubate the analyte matrix with the 
sorbant for longer periods. 
  Column washing: This step is performed to remove unbound and non-specifically 
bound substances from the column matrix. The lower the non-specific binding that 
occurs with the sorbant used the less stringent the washing required. 
 Elution of the analyte: Elution of the analyte may be achieved through: 
 Usage of organic solvents leads to reduction in the Ka value of the antibody.  
 Altering the ionic strength may also decrease the Ka. This type of strategy is 
very rarely used. 
 Application of a chaotropic agent is another way of achieving elution, but it 
is also infrequently used. 
 Regeneration of the column: To enable the column to be re-used a regeneration cycle is 
            mandatory. In general the column will be washed with either PBS or water. 
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 Storage of the column: After regenerating the column can be stored in PBS with sodium 
            azide (for preservation) at 40C.  
Immuno-affinity columns (IACs) can provide excellent recovery of the analyte, due to the 
highly specific nature of the antibodies. In the present work, scFvs specific to AFB2 and ZEN 
were developed and incorporated into IAC using conjugation chemistry. In addition, a Fab 
against AFB1 was similarly included.  
 
1.6 Thesis outline and aims 
The purpose of this research (Figure 1.13) was to develop antibody-based assays for the 
specific detection of four major mycotoxins i.e., AFB1, AFB2, ZEN and T-2 toxin and to 
determine their potential for toxin infected food samples analysis. AFB1 is highly toxic and 
hence there is a need to develop novel assays for its detection. AFB2 is highly resistant to 
alkaline conditions normally employed during food processing techniques leading to their 
presence in processed foods, coupled with its conversion (metabolic oxidation) to AFB1, led to 
the development of antibodies that could recognize AFB2. Zearalenone is another mycotoxin of 
interest because of its higher prevalence in cereals. Most of the antibodies developed to date 
were highly cross reactive with structural analogs of ZEN especially α-Zearalenol and β-
Zearalenol, which are the bye-products of biotranformation of ZEN. These components are not 
widely present in foods. Hence there is a need to develop antibodies that detect the parent 
moiety i.e. ZEN. Development of an antibody that could recognize structural analogs would be 
of interest for clinical sample analysis.  T-2 toxin is a major contaminant of many agricultural 
commodities and causes various disorders in humans and in liverstock. Thus, polyclonal 
antibodies were developed for purification and isolation of T-2 specific antibodies from egg 
yolks.     
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Even though cross reactive antibodies are desirable in many cases (e.g. to isolate total levels of 
mycotoxins from food), the logic behind the generation and selection of very highly specific 
antibodies (without any crossreactivity) was to develop highly targeted immunoassays.  
The production and characterization of scFv antibodies for AFB2 and ZEN were described in 
chapter 3 & 4, respectively. The scFvs were characterized by ELISAs (indirect and competitive 
ELISA), SDS-PAGE/western blotting and SPR-based inhibition assays for the detection of 
AFB1 and ZEN. Cross reactivity studies and the application of scFvs for the detection of AFB2 
in spiked almond extract and ZEN in sorghum reference materials was also performed.     
The application of a polyclonal anti-T-2 IgY for the development of Biacore SPR-based 
inhibition assay was presented in chapter 5. Polyclonal IgY was isolated from eggs from a 
hyperimmune chicken and subjected to affinity purification followed by the ELISA, FPLC and 
MALDI-TOF analysis. This IgY was then used in an SPR-based inhibition assay.  
Finally, in chapter 6, assay formats were developed for the isolation and detection of the 
aforementioned toxins using recombinant scFvs (for AFB2 & ZEN) or Fab (for AFB1) and 
polyclonal IgY (for T-2 toxin).  Immuno-affinity columns were developed for specific isolation 
of AFB1, B2 & ZEN. The intention of developing an MBio assay capable of simultaneous 
detection of AFB1, B2, ZEN and T-2 toxins, using fluorescence-based detection, was not 
successful due to the unavailability of the requested MBio cartridges. In addition, an ELISA-
based assay was developed for specific detection of AFB1, where the AFB1 was covalently 
immobilized on microtitre plates.  
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Figure 1.13: Layout of the thesis. This thesis has four major chapters excluding the introduction and 
materials and methods chapters. Recombinant antibodies were developed and incorporated into an 
immuno-affinity column format for the isolation of AFB2 and ZEN. An anti-T-2 toxin IgY was isolated 
with its subsequent incorporation into SPR-based inhibition. An immuno-affinity column was developed 
using anti-AFB1 Fab antibody. A microtitre plate-based assay using an AFB1 covalent immobilizaton 
approach was also developed. Thereafter MBio platform, which employs a fluorescence assay principle 
in conjunction with laser-activated waveguide technology was developed for the simultaneous detection 
of AFB1, B2, ZEN and T-2 toxins. 
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2. Materials and methods 
2.1 Materials 
The materials used for this study were described under the following headings: reagents, 
equipment, composition of culture media, bacterial strains, bacteriophages, buffers, commercial 
kits and antibodies. 
 
2.1.1 Reagents 
Reagent  Supplier 
 
Bacteriological agar, tryptone and yeast extract  
 
 
Cruinn Diagnostics Ltd.,  
Hume Centre, Parkwest Business Park, 
Nangor Road, Dublin 12, Ireland. 
T4 DNA ligase, helper phage and restriction enzymes 
(SfiI, SacI, Antarctic Phosphatase, XboI, XhoI) 
ISIS Ltd.,  
Unit 1 & 2, Ballywaltrim Business Centre,  
Boghall Road, Bray, Co. Wicklow, Ireland. 
PCR primers Eurofins MWG Operon,  
318 Worple Road, Raynes Park,  
London SW20 8QU, U.K. 
Page RulerTM Prestained protein ladder  Fermentas,  
Sheriff House,  
Sheriff Hutton Industrial Park,  
York Y060 6RZ, U.K. 
Superscript system Bio-sciences,  
3 Charlemont Terrace, Crofton Road,  
Dun Laoghaire, Dublin, Ireland. 
1 Kb plus DNA ladder Sigma Aldrich,  
Spruce street, St. Louis M063103, U.S.A. 
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2.1.2 Equipment 
Equipment Manufacturer 
 
Applied Biosystems Veriti 96 well Thermal Cycler  
(MODEL: 9902)                         
 
Life Technologies Corporation,  
5791 Van Allen Way,  
PO Box 6482, Carlsbad, 
California 92008, U.S.A. 
Nanodrop™ ND-1000      
 
NanoDrop Technologies, Inc.,  
3411, Silverside Rd 100BC,  
Wilmington DE19810-4803, U.S.A. 
Gene Pulser Xcell ™ electroporation system  
 
 
Bio-Rad Laboratories, Inc.,  
2000 Alfred Nobel Drive, Hercules,  
California 94547, U.S.A. 
ORBI-safe TS Netwise orbital shaking incubator  Sanyo Europe Ltd.,  
18 Colonial way, Walford WD24 4PT, U.K. 
Trans-Blot® Semi-Dry Transfer Cell   
 
 
Bio-Rad Laboratories, Inc.,  
2000 Alfred Nobel Drive, Hercules,  
California 94547, U.S.A. 
Roller mixer SRT1     
  
 
Sciencelab, Inc.,  
14025, Smith Rd. Houston,  
Texas 77396, U.S.A. 
Safire II plate reader     
 
Tecan Group Ltd.,   
Seestrasse 103,  
Mannedorf CH-8708, Switzerland. 
Vibra Cell™ sonicator    Sonics and Materials Inc.,  
53 Church Hill Road,  
Newtown CT 06470-1614, U.S.A. 
AKTA explorer FPLC 
 
GE Healthcare Life Sciences,  
Amersham Place, Little Chalfont,  
Buckinghamshire HP7 9NA, U.K. 
Shimadzu LC system HPLC 
 
Shimadzu Europa GmbH., 
Albert-Hahn-Str. 6-10, 
Duisburg 47269, Germany. 
ESI-Mass spectrometer 
 
Bruker Daltonics, Banner line, 
Coventry CV 4 9GH, U.K. 
Speedvac apparatus (Model: DNA 23050-A00) 
 
GeneVac Ltd, IP SWICH, England. 
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pH meter (Orion 3 star) Medical Supply Company Ltd.,  
Damastown, Mulhuddart, Dublin 15, Ireland. 
IKA® MTS 2/4 digital plate shaker Lennox,  
John F. Kennedy Drive, Naas Road,  
Dublin 12, Ireland. 
Water bath (Y6 model) Grant instruments (Cambridge) Ltd.,  
29 Station Road, Shepreth, Royston,  
Herts SG8 6PZ, U.K. 
Biacore ® 3000 machine GE Healthcare Biosciences  Ltd., 
Uppsala SE-751 84, Sweden. 
MBio array system Mbio Diagnostics Inc., 
5603 Arapahoe Avenue, Suite 1, 
Boulder, CO, 80303 U.S.A. 
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2.1.3 Bacterial culture media composition 
In this section, different types of media (and their composition) used for growing bacterial 
strains are given.  
Media                              Composition 
 
Superbroth medium  
 
  Tryptone 
  Yeast extract 
  MOPS 
                   
                  30 g/L 
                  20 g/L 
                         10 g/L 
Super optical catabolite medium  
(SOC medium) 
 
 
 
  Tryptone 
  Yeast extract 
  5 M NaCl 
  1 M KCl 
  1 M MgCl2 
  1 M MgSO4 
  1 M Glucose 
                  20 g/L 
                  5 g/L 
                  0.5 g/L 
                  2.5 mL 
                  10 mL 
                  10 mL 
                  20 mL 
2x Tryptone Yeast extract medium  
(2xTY) 
  Tryptone 
  Yeast extract 
   NaCl 
                  16 g/L 
                  10 g/L 
                  5 g/L 
Luria broth agar (LB agar)   Tryptone 
  Yeast extract 
   NaCl 
   Agar 
                 10 g/L 
                  5 g/L 
                  10 g/L 
                  15 g/L 
100X 505 media    Glycerol 
   Glucose 
     50% (v/v) 
      50% (w/v) 
 
Terrific broth (TB broth)   Tryptone 
  Yeast extract 
  Glycerol 
  KH2PO4 
  K2HPO4  
                   12 g/L 
                   24 g/L 
                   4 mL 
                   2.31 g/L 
                   12.5 g/L 
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2.1.4 Bacterial strains & bacteriophages 
Different types of bacterial strains used for expressing recombinant antibody fragments and 
bacteriophages, used for the effective enrichment of the required antibody fragments by phage 
display, are listed below: 
Bacterial strains 
 
E. coli TOP10 F ′ strain: {lacIq, Tn10(TetR)} mcrA ∆(mrr-hsd RMS-mcrBC) ϕ80lacZ ∆M15 
∆lacX74 recA1 araD139 ∆(ara-leu)7697 galU galK rpsL (StrR) endA1 nupG 
E. coli XL1-Blue strain: recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F′ proAB lac 
IqZ∆M15 Tn10 (TetR)] 
Bacteriophage (Helper phage) 
 
M13K07 
 
 
2.1.5 Antibiotic and synthetic analog of lactose (IPTG) stocks 
The antibiotic and synthetic analog of lactose (IPTG) stocks described were used for the 
supplementation of nutrient media and to induce expression of cloned gene.  
Antibiotic                    Stock 
 
Tetracycline 
         
       5 mg/mL of ethanol 
Carbenicillin       100 mg/mL of 150 mM PBS (pH 7.4) 
Kanamycin       50 mg/mL of 150 mM PBS (pH 7.4) 
0.5 M Isopropyl β-D-1-thiogalactopyranoside  
(IPTG) 
      1.19 g/10 mL of distilled water 
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2.1.6 Buffer composition 
The chemical compositions of the various buffers used in this study are listed below: 
Buffers                                                                   Composition 
 
1 L of Phosphate buffered saline (PBS)                  0.15 M NaCl                                       8 g 
(150 mM, pH 7.4)                                                           2.5 mM KCl                                        0.2 g 
                                                                           10 mM Na2HPO4                                                   1.44 g  
                                                                           18 mM KH2PO4                                  0.24 g  
                                                                        
The constituents were dissolved, the pH adjusted and the final volume made up to 1L. 
 
1 L of Phosphate buffered saline Tween (PBST)          1 L of  PBS (pH 7.4) 
(150 mM, pH 7.4)                                                          0.05% (v/v) Tween 20                                                                                   
 
2% (w/v) milk Marvel PBST                                        200 mg of milk Marvel 
                                                                                      10 mL PBST 
 
2% (w/v) milk Marvel PBS                                          200 mg of milk Marvel 
                                                                                      10 mL of 150 mM PBS (pH 7.4) 
 
4% (w/v) milk Marvel PBS                                          400 mg of milk Marvel 
                                                                                      10 mL of 150 mM PBS (pH 7.4) 
 
1 L of HEPES buffered saline (HBS, pH 7.4)              HEPES                                                 2.38 g 
                                                                                      NaCl                                                     8.77 g 
                                                                                      EDTA                                                   1.27 g 
                                                                                      Tween                                                   0.5 mL 
The constituents were dissolved, the pH adjusted and the final volume made up to 1L.                                                                                
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20 mL of MES NaCl (pH 7.4)                                            0.1 M MES                                     0.39 g 
                                                                                            0.9% (w/v) NaCl                             0.18 g 
The constituents were dissolved, the pH adjusted and the final volume made up to 20 mL.  
 
20 mL of 1 M Tris (pH 9.0)                                               Tris-base                                          2.42 g  
The constituents were dissolved, the pH adjusted and the final volume made up to 20 mL.  
 
100 mM of Glycine-HCl (pH 3.0)                                      Glycine                                            1.11 g 
The constituents were dissolved, the pH adjusted and the final volume made up to 100 mL.  
 
20 mL of 1 M NaCl                                                            NaCl                                                  1.17 g 
                                                                                            Water                                                 20 mL 
 
100 mL of 2 M NaOH                                                        NaOH                                                8 g 
                                                                                            Water                                                100 mL 
 
200 mL of 8 M Urea, 2% (w/v) sodium dodecyl               Urea                                                    96 g 
sulphate with 2% (v/v) mercaptoethanol                            2% (w/v) sodium dodecyl sulphate      4 g 
                                                                   2% (v/v) mercaptoethanol                 3.6 g 
                                                                                            Water                                                 200 mL 
 
500 mL of 20 mM Tris-HCl (pH 7.5),                               20 mM Tris-HCl                                0.6 g 
0.1% (v/v) Tween 20 and 500 mM NaCl                           0.1% (v/v) Tween 20                         200 µL 
                                                                                            500 mM NaCl                                    5.85 g                                                                   
The constituents were dissolved, the pH adjusted and the final volume made up to 500 mL.  
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2.1.7 SDS-PAGE and western blotting reagents 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) involves the 
principle of separation of proteins based on their molecular mass upon electrophoretic 
migration towards anode in a polyacrylamide matrix. The gel matrix is formed from 
polyacrylamide chains, which are cross linked with N,Nʹ-methylene bisacrylamide. The 
proteins are denatured under the presence of SDS leading to linearization. The protein will 
migrate through the gel towards the anode. The proteins are stained using Coomassie blue dye 
for visualization. The gel composition, buffer compositions, staining and destaining reagents 
for SDS-PAGE are given in the following list: 
 Separating gel  Amounts/6 mL gel 
 
1 M Tris-HCl (pH 8.8) 
 
1.5 ml 
30% (w/v) Acrylagel  2.5 ml 
2% (w/v) Bis-acrylagel 1.0 ml 
10% (w/v) Sodium dodecyl sulphate (SDS)  30 µL 
10% (w/v) Ammonium persulphate (APS) 30 µL 
TEMED (N,N,N',N'- tetramethylethylenediamine)                                6 µL 
Water   934 µL 
Stacking gel Amounts/2.5 mL gel 
 
1 M Tris HCl (pH 6.8) 
  
300 µL 
30% (w/v) Acrylagel  375 µL 
2% (w/v) Bis-acrylagel  150 µL 
10% (w/v) Sodium dodecyl sulphate (SDS) 24 µL 
10% (w/v) Ammonium persulphate (APS) 24 µL 
TEMED 2.5 µL 
Water                                                                                                                                1.74 µL 
Composition of SDS buffers   
10 X electrophoresis buffer  Amounts 
 
50 mM Tris  
 
30 g 
196 mM Glycine  144 g 
0.1% (w/v) SDS 10 g 
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Water                                1 L 
Loading buffer  Amounts 
 
0.5 M Tris   
 
     2.5 mL 
Glycerol                                2 mL 
2-mercaptoethanol      0.5 mL 
20% (w/v) SDS       2.5 mL 
Bromophenol blue      20 ppm 
Water      2.5 mL 
1 L Coomassie stain dye Amounts 
 
Coomassie blue R-250 
                             
                                   2 g 
Methanol   450 mL 
Acetic acid  100 mL 
Water  450 mL 
1 L Coomassie destain Amounts 
 
Acetic acid 
 
100 mL 
Methanol 250 mL 
Water 650 mL 
Western blot  
1L Transfer buffer Amounts 
 
Glycine 
 
14.4 g 
Tris base                               3.0 g 
Water 
 
                              800 mL 
 Methanol    200 mL 
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2.1.8 Commercial kits used for these studies 
Kits Supplier 
 
Superscript III reverse transcriptase kit  
( for cDNA synthesis from RNA)  
 
 
Invitrogen Corporation,  
5791 Van Allen Way, Carlsbad,  
CA 92008, U.S.A. 
Nucleospin Extract II     
(for DNA purification from PCR products)  
 
Fischer Scientific,  
Suite 3, Plaza 212,  
Blanchardstown Corporate Park 2, 
Ballycoolin, Dublin 15, Ireland. 
Nucleospin Plasmid    
(for plasmid purification)                                             
 
Fischer Scientific,  
Suite 3, Plaza 212,  
Blanchardstown, Corporate Park 2,  
Ballycoolin, Dublin 15, Ireland. 
 Eggcellent IgY purification kit  
(for IgY isolation from egg yolk)                                 
Fisher Scientific,  
Suite 3 Plaza 212, 
Blanchardstown Corporate Park 2,  
Ballycoolin, Dublin 15, Ireland. 
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2.1.9 Commercial antibodies  
Antibody Supplier 
 
HRP-labelled mouse anti-M13 monoclonal  
antibody  
 
GE Healthcare Bio-Sciences  
AB, Uppsala SE-751 84, Sweden. 
HRP-labelled rat anti-HA monoclonal  
Antibody 
Roche Diagnostics,  
Grenzacherstrasse 124, 
Basel 4070, Switzerland. 
AP-labelled goat anti-mouse IgG 
                  
Sigma Aldrich,  
Spruce Street, St. Louis M063103, U.S.A. 
HRP-labelled rabbit anti-chicken Ig  
 
Sigma Aldrich,  
Spruce Street, St. Louis M063103, U.S.A. 
 
 
2.2 Methods 
2.2.1 Synthesis of mycotoxin conjugates 
The mycotoxin conjugates mentioned below were synthesized and characterized by Dr. E. Om 
Prakash. The Matrix assisted Laser Desorption Ionization - Time of Flight (MALDI-TOF) 
analysis and fluorescence estimation data were presented in appendix (Appendix III & IV).  
 
2.2.1.1 AFB2-BSA and KLH 
2.2.1.1.1 Preparation of Aflatoxin B2–carboxymethoxylamine hemihydrochloride (AFB2-
CMO):  
Carboxylmethoxylamine hydrochloride (15 mg) was added to a stirred solution of aflatoxin B2 
(2 mg) in 600 µL of ethanol with 1 N NaOH (70 µL). After 10 mins stirring at room 
temperature, the solution was refluxed for 4 hrs at 800C. The solvent was evaporated on a speed 
vac. The residue was dissolved in 300 µL of water and the pH was adjusted to 2.0. The aqueous 
mixture was extracted with ethylacetate and spotted onto a 20 x 20 cm (L X W) 250 µm thick 
silica gel (particle size 17 µm, pore size 60 Å) coated TLC plate with fluorescent indicator (254 
nm). Preparative TLC plate was developed under UV light in chloroform:methanol (9:1) plus 
1% (v/v) acetic acid. The AFB2-CMO derivative was removed from the TLC plates through 
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scratching the upper silica layer and re-dissolved in chloroform. The mixture was centrifuged 
for 5 mins to remove silica gel residues before proceeding to next step. 
 
2.2.1.1.2 Preparation of NHS ester of AFB2-CMO  
Freshly prepared DCC (50 µL from 40 mg/mL) and NHS (40 µL from 40 mg/mL) in dioxane 
were prepared and added to above AFB2-CMO in dioxane (500 µL) solution. The reaction 
mixture was stirred overnight at room temperature. Fine needles of the dicyclohexylurea bye-
product were then observed and the mixture was centrifuged (2,109 xg) for 5 mins to remove 
them. The formation of the NHS ester was confirmed by TLC in chloroform and methanol (7:3) 
solvent system. 
  
2.2.1.1.3 Preparation of AFB2-protein conjugates 
Stock solutions of KLH (8 mg) and BSA (6 mg) were prepared by dissolving in coupling buffer 
(800 µL of 0.1 M NaHCO3, pH 9.5). AFB2-CMO-NHS ester solution (300 µL) was then added 
dropwise to an ice-cold solution of each respective protein and kept at room temperature for 
another 2 hrs with continuous magnetic stirring. The reaction mixture was dialyzed (buffer 
exchanged) with 150 mM PBS (pH 7.4) using a Vivaspin column (M.Wt. ‘cut-off’: 5 kDa). 
After buffer exchange, the mixture was collected and resuspended in PBS to make up 1 mg/mL 
final concentration of AFB2-BSA/KLH conjugate. This conjugate was confirmed by indirect 
ELISA using monoclonal anti-AFB2 antibody obtained commercially from Abcam. 
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Figure 2.1: Schematic representation of AFB2 conjugate synthesis. 
 
2.2.1.2 ZEN-BSA and KLH  
2.2.1.2.1 Preparation of Zearalenone-carboxymethoxylamine hemihydrochloride (ZEN-
CMO) 
Zearalenone (5 g) was dissolved in 300 µL of anhydrous pyridine. Then, 10 mg of 
carboxymethoxylamine hydrochloride were added. The mixture was stirred for 24 hrs at room 
temperature under argon. The solvent was evaporated on a speed vac apparatus. The residue 
was dissolved in 500 µL of water and extracted with toluene (500 µL X 5) spotted onto silica 
gel TLC plate with fluorescent indicator (254 nm). Preparative TLC plate (20 X 20 cm) was 
developed with the solvent system toluene:ethylacetate:formic acid (5: 4: 1 (v/v)) under UV 
light to visualize the spots. The ZEN-CMO derivative was then removed from the TLC plates 
by scratching the silica surface and re-dissolved in chloroform and centrifuged for 5 mins to 
remove silica gel residues. 
 
2.2.1.2.2 Preparation of NHS ester of ZEN-CMO  
Freshly prepared DCC (50 µL from 40 mg/mL of dioxane) and NHS (40 µL from 40 mg/mL of 
dioxane) solutions were prepared and added to 5 mg of ZEN-CMO in 500 µL of dioxane. The 
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reaction mixture was stirred overnight at room temperature. Fine needles of the 
dicyclohexylurea by-product were then observed and the mixture was centrifuged (2,109 xg) 
for 5 mins to remove them. The formation of NHS ester was confirmed by TLC in chloroform 
and methanol (7:3).  
 
2.2.1.2.3 Preparation of ZEN-protein conjugates 
Stock solutions of KLH (8 mg) and BSA (6 mg) were prepared by dissolving in coupling buffer 
(800 µL of 0.1 M NaHCO3, pH 9.5). ZEN-CMO-NHS ester solution (300 µL) was then added 
to an ice-cold solution of each respective protein and kept at room temperature for another 2 hrs 
with continuous stirring. After the reaction, the mixture was dialyzed (buffer exchanged) with 
150 mM PBS (pH 7.4) using a Vivaspin column (M.Wt. ‘cut-off’: 5 kDa). The buffer exchange 
was followed by the confirmation of the conjugate formation through indirect ELISA assay 
using anti-ZEN serum. 
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Figure 2.2: Schematic representation of ZEN conjugate synthesis. 
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2.2.1.3 T-2-BSA and KLH 
T-2 (5 mg) was dissolved in dimethyl sulfoxide (100 µL), and 2.5 mg of carbonyldiimidazole 
were added. The mixture was stirred for 15 mins at room temperature in the dark. The mixture 
was split into half and added drop-wise to an ice-cold solution of either BSA (15 mg) or KLH 
(15 mg) dissolved in 1 mL of 0.1 M Na2CO3 (pH 9.6) solution, in individual vials. The reaction 
mixture was stirred at 40C overnight followed by stirring at room temperature for 1 hr. The 
mixture was then dialyzed (buffer exchanged) with 150 mM PBS (pH 7.4) using a Vivaspin 
column (M.Wt. ‘cut-off’: 5 kDa). This was followed by the performance of indirect ELISA 
assay for confirmation of conjugate formation. 
T-2 toxin
CDI
T-2 toxin CDI
NH-KLH/BSA     
 
 
Figure 2.3:  T-2 toxin conjugate synthesis by CDI method. 
 
2.2.1.4 Mycotoxin conjugate confirmation 
2.2.1.4.1 MALDI-TOF analysis of hapten conjugates 
The mass analysis of hapten conjugates (Appendix IV) was done with a MALDI-TOF mass 
spectrometer (Bruker Autoflex MALDI-TOF Mass Spectrometer). The matrix (sinapinic acid 
solution) was prepared at a concentration of 15 mg/mL in acetonitrile. All the above mentioned 
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hapten protein conjugates were dialyzed (buffer exchanged) with distilled water using a 
Vivaspin column (M.Wt. ‘cut.off’: 5 kDa) to a final conjugate concentration of 2.0 mg/mL. The 
hapten-protein conjugate sample and matrix solution were mixed in equal amounts (1 µL each) 
with 0.1% (v/v) formic acid and added onto a silicon MALDI-TOF chip. The samples were 
allowed to dry in a vaccum desiccator and were then used for mass analysis. The data were 
acquired in the linear mode at 20 kV and analyzed using the Compass software suite. 
 
2.2.1.4.2 Fluorescence assay 
The AFB2 and ZEN conjugates were confirmed by fluorescence intensity measurements 
(Appendix III). Fluorescence of 150 mM PBS (pH 7.4) and BSA/KLH were also read at the 
same wavelengths, which were treated as background values. A higher fluorescence reading 
was recorded when either AFB2 or ZEN conjugates were used, when compared to the 
background values, which clearly indicates the presence of fluorescent compounds (AFB2 and 
ZEN).  
 
2.2.1.4.3 2, 4, 6-Trinitrobenzene sulfonic acid (TNBS) assay 
The hapten densities of both BSA and KLH conjugates were determined through estimating the 
number of amino groups present on the protein before and after hapten conjugation by TNBS 
assay. The percentage amino groups consumed was estimated by the difference in absorbance 
of control (BSA/KLH) and conjugate read at 335 nm.  This result will give the approximate 
number of amino groups used for conjugation (where BSA has 60 and KLH has 1430 available 
number of amino groups). A higher density of haptens on KLH when compared to BSA was 
noticed (Appendix III), which is due to the availability of more lysine NH2 groups that are 
capable of reacting with carboxylic groups of hapten. 
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2.2.2 Immunization and immune response determination in Balb/c mice boosted with 
mycotoxin conjugates 
2.2.2.1 Immunization schedule 
This work was carried out under the license number B100/4202. Utmost care was taken to 
minimize the pain and suffering to any animals used. For the isolation of highly specific 
antibodies, a widely diverse library coupled with an efficient selection procedure is required. 
The initial step for the construction of an immune library is the proper immunization schedule 
with an antigen capable of eliciting immune response in the animal models. A high titer value 
indicates the presence of abundant amount of RNA that was enriched with the antigen binding 
immunoglobulin genes. Sets of three female Balb/c mice, aged 5-8 weeks, were immunized for 
the first time with 200 µL/mouse of 100 µg/mL of BSA or KLH conjugates of AFB2 and ZEN, 
individually, which were synthesized following the procedure that was stated in section 2.2.1, 
along with Freund’s complete adjuvant in the ratio of 1:1. The conjugate-adjuvant emulsion 
was made through vortexing the eppendorf tube with both the conjugate and adjuvant for one 
hour. Further immunizations (boosters) were carried out with the same amount (200 µL/mouse 
of 100 µg/mL of conjugate) of immunogen along with Fruend’s incomplete adjuvant in the 
ratio of 1:1. Pre-immunization bleeds were collected through tail bleeding and the serum titre 
was checked after administering the immunogen for the third time. The immunization schedule 
is depicted in the Table 2.1. 
Table 2.1: Immunization schedule of female Balb/c mice 
Immunogen        Quantity/mouse   Injection interval 
 
AFB2-KLH/BSA 
             
            20 µg/200 µL 
 
             3 weeks 
ZEN-KLH/BSA             20 µg/200 µL               3 weeks 
 
 
 
 62 
2.2.2.2 Immune response determination of mice to mycotoxin conjugates (Indirect 
ELISA) 
A 96-well Nunc Maxisorb™ microtitre plate was coated overnight with 100 µL of 5 µg/mL of 
individual mycotoxin conjugates (4 rows) as determined by checkerboard ELISA, BSA (2 
rows) and KLH (2 rows). The plate was then blocked with 4% (w/v) milk Marvel in 150 mM 
PBS (pH 7.4) for 2 hrs at 370C. Serial dilutions (1:100 to 1:512,000) of both pre-immunization 
and post-immunization sera were made in 2% (w/v) milk Marvel PBST and 100 µL of each 
were added in duplicate to the individual wells of the microtitre plate. Following one hour 
incubation, the plate was washed three times with both PBST & PBS. Then, 100 µL of anti-
mouse IgG AP-labelled goat secondary antibody (1:1,000 dilution) were added and incubated 
for an hour at 370C. The plates were again washed thrice with PBST & PBS after decanting the 
solution. Following the addition of 100 µL of pNPP substrate, the plates were incubated for 30 
mins at 370C. The absorbances were then read on a Tecan Saffire plate reader at 405 nm.  
 
2.2.3  Generation of murine scFv library for AFB2 
2.2.3.1 Serum titre determination 
Four out of the 8 rows for a 96 well Nunc microtitre plate were coated overnight at 40C, with 5 
µg/mL of AFB2-BSA conjugate. Two rows were coated with 5 µg/mL BSA in 150 mM PBS 
(pH 7.4) and the remaining two rows with 5 µg/mL KLH in 150 mM PBS (pH 7.4). An indirect 
ELISA procedure described in section 2.2.2.2 was performed. 
 
2.2.3.2 Isolation of RNA from the spleen 
The mouse with the highest immune response (titre value 1:512,000) was sacrificed for the 
isolation of RNA. In this process, the laminar hood was cleaned with denatured alcohol (IMS) 
and sprayed with RNA Zap to kill any RNases that might destroy the RNA present in the 
spleen. The mouse was euthanized with tetraflourane, followed by neck dislocation. The spleen 
was then carefully and quickly transferred into a 50 mL ‘RNase-free’ tube with TRIZOL 
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reagent, which aids in maintaining the structural intergrity of the RNA.  Efficient 
homogenization is critical in reducing the effects of nucleases present in the spleen, hence, 
homogenization was carried out using a handheld device. The homogenized spleen was kept 
static for 15 mins at room temperature in a laminar hood to aid in the settlement of the solid 
fraction to the bottom of the tube. The mixture was then centrifuged for 10 mins at 2,109 xg at 
40C in an Eppendorf centrifuge (model: 5810R). This process aids in the separation of solid 
particles leaving behind the solution that possess the genetic material i.e., RNA in the 
supernatant. Then, 2 mL of chloroform was added, mixed gently and incubated for 15 mins at 
room temperature. Through the addition of chloroform, the proteins were denatured and 
became soluble in the organic phase while the nucleic acids remained in the aqueous layer. The 
mixture was then centrifuged at 17,500 xg for 20 mins at 40C in an Eppendorf centrifuge 
(model: 5810R) using the rotor model No. F-34-6-38, which led to the formation of three layers 
i.e., lower organic, middle fatty and the upper aqueous layers. Due to the presence of nucleic 
acids in the top aqueous layer, it was collected into a separate tube and 5 mL of isopropanol 
was added, then mixed and kept at room temperature for 10 mins. The use of isopropanol with 
NH4 cations removed the alcohol-soluble salts and also caused to the aggregation of the RNA 
for the formation of a fine pellet upon centrifugation of the solution at 40C for 25 mins at 
17,500 xg. After centrifugation, the supernatant was removed carefully without disturbing the 
pellet. Then 10 mL of 75% (v/v) ice cold ethanol was added to the pellet for dehydrating the 
RNA and, thus, leading to its subsequent precipitation. The  eppendorf tube with the pellet and 
75% (v/v) ice-cold ethanol in 25% (v/v) molecular grade water, was centrifuged for 20 mins at 
40C at 17,500 xg in an Eppendorf centrifuge (model: 5810R) using the rotor model No. F-34-6-
38. The supernatant was discarded leaving behind the pellet, which was air dried and re-
suspended in 250 µL of molecular grade water. The amount of RNA thus obtained was 
quantified on the Nanodrop™ and the final amount of RNA attained was calculated using the 
formula nano drop reading (ng/µL) X total volume.   
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2.2.3.3 Reverse transcription of cDNA from RNA 
The process of synthesis of cDNA from the RNA template by means of the enzyme reverse 
transcriptase is termed reverse transcription. For the performance of reverse transcription, all 
the reagents except the enzymes, were thawed on ice. The PCR reaction was carried out by 
placing the master mixture 1 (composition described in the table below), into 8 PCR tubes each 
containing a final volume of 25 µL. Denaturation of secondary structure of RNA was 
performed by placing mixture 1 at 650C for 5 mins. Then 25 µL of the master mixture 2 
(composition given in table mentioned below) were added to the master mixture 1 with 
denatured RNA. The reaction mixture was incubated at 500C for 50 mins, during which the first 
cDNA strand was synthesized. The reaction was terminated by heating the mixture at 850C for 
5 mins. During these two steps of PCR reaction annealing of the Oligo-(dt) to the RNA 
template with a poly (A) tail at the 3′ end was performed. Finally, 5 µL of RNase™ H was 
added to individual tubes and incubated for 20 mins at 370C. This step ensured the removal of 
residual RNA, which might effect the final quality of the cDNA. The composition of the two 
types of mixtures and the PCR conditions are outlined below: 
Mixture 1 Mixture 2 
 
RNA                                  15 µL (5 µg/rxn) 
 
10X RT Buffer                     40 µL (2X) 
Oligo-(dt)20                      20 µL (0.5 µg/rxn) MgCl2                                   80 µL (2.5 mM) 
dNTPs                               20 µL (1 mM) DTT                                      40 µL (20 mM)  
RNaseOUT                           20 µL (1 U/µL) Water (DEPC)                  145 µL (N/A) 
 
 
Superscript III RT                 20 µL (200 U/µL) 
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PCR conditions 
The PCR reaction was carried out on Applied Biosystems 96 verticell machine. 
Stages PCR temperature Time  
1     650C 5 mins 
Added 25 µL of mixture 2 after keeping on ice for 1 min  (PAUSE) 
2     500C 50 mins 
3     850C 5 mins 
Added 5 µL of RNase H  (PAUSE) 
4     370C 20 mins 
5     40C ∞ 
 
2.2.3.4 Amplification of variable heavy and light chains 
Following the reverse transcription of RNA to cDNA the Vλ, Vk and VH genes were amplified 
separately on a PCR machine. In this process the conditions were first optimized using a range 
of MgCl2 concentrations (1, 1.5, 2 & 3 mM). The optimization was followed by scale-up of the 
product through performing 20X reactions. Ethanol precipitation of the amplified heavy and 
light chain genes was carried out through the addition of 100% (v/v) ice cold ethanol (2X 
volume of either Vλ/ Vk/VH), 1/10
th volume of 3 M sodium acetate and 2 µL of glycogen. The 
low dielectric point of ethanol when compared to water makes the usage of ethanol more 
feasible for precipitating DNA. Three molar sodium acetate aids in neutralizing the charges on 
the sugar phosphate backbone, thus making it far less hydrophilic. Glycogen was used as a 
carrier for better recovery of the DNA present in lower concentrations, upon overnight 
incubation. The ethanol-precipitated PCR products were then resolved on 1% (w/v) agarose 
gel. The DNA present in the gel was purified using Nucleospin Extract II kit.  
The primers used for the amplification of heavy and light chains along with the PCR mixture 
composition and the PCR conditions were: 
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Murine scFv primers 
Vʎ primers 
Forward primers 
5ʹ GGG CCC AGG CGG CCG AGC TCG ATG CTG TTG TGA CTG TTG TGA CTC AGG AAT 
 C 3ʹ    
Reverse primers (Long linker) 
5ʹ GGA AGA TCT AGA GGA ACC ACC CCC ACC ACC GCC CGA GCC ACC GCC ACC  
AGA GGA GCC TAG GAC AGT CAG TTT GG 3ʹ 
VH primers 
Forward primers  
5ʹ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG AAG GTC ATC GAG TC 3ʹ 
5ʹ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG AAC TTG GAA GTG TC 3ʹ 
5ʹ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTC CAA CTV CAG CAR CC 3ʹ 
5ʹ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTT ACT CTR AAA GWG TST G 3ʹ 
5ʹ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG AAR STT GAG GAG TC 3ʹ 
5ʹ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTR AAG CTT CTC GAG TC 3ʹ 
5ʹ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG CAR CTT GTT GAG TC 3ʹ 
5ʹ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG AAG CTG ATG GAR TC 3ʹ 
5ʹ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG CAM CTG GTG GAG TC 3ʹ 
5ʹ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG CAG SKG GTG GAG TC 3ʹ 
5ʹ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG AWG YTG GTG GAG TC 3ʹ 
5ʹ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG AAS STG GTG GAA TC 3ʹ 
5ʹ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTC CAC GTG AAG CAG TC 3ʹ 
5ʹ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTY CAR CTG CAG CAG TC 3ʹ 
5ʹ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTY CAG CTB CAG CAR TC 3ʹ 
5ʹ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTC CAR CTG CAA CAR TC 3ʹ 
5ʹ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG CAG CTG AAG SAS TC 3ʹ 
5ʹ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTB CAG CTB CAG CAG TC 3ʹ 
5ʹ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTR MAG CTT CAG GAG TC 3ʹ 
5ʹ GGA AGA TCT AGA GGA ACC ACC TTT CAG CTC CAG CTT GGT CCC 3ʹ 
Reverse primers 
5ʹ CCT GGC CGG CCT GGC CAC TAG TGA CAT TTG GGA AGG ACT GAC TCT C 3ʹ 
5ʹ CCT GGC CGG CCT GGC CAC TAG TGA CAG ATG GGG CTG TTG TTG T 3ʹ 
5ʹ CTG GCC GGC CTG GCC ACT AGT GAC AGA TGG GGS TGT YGT TTT GGC 3ʹ 
VK primers  
Forward primers 
5ʹ GGG CCC AGG CGG CCG AGC TCG AYA TTT TGC TGA CTC AGT C 3ʹ 
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5ʹ GGG CCC AGG CGG CCG AGC TCG AYA TTG TGA TGA CAC AAC C 3ʹ 
5ʹ GGG CCC AGG CGG CCG AGC TCG AYA TTG TGA TGA CCC AGW T 3ʹ 
5ʹ GGG CCC AGG CGG CCG AGC TCG AYA TTG TGA TAA CYC AGG A 3ʹ 
5ʹ GGG CCC AGG CGG CCG AGC TCG AYA TTG TGA TGA CBC AGK C 3ʹ 
5ʹ GGG CCC AGG CGG CCG AGC TCG AYR TTK TGA TGA CCC ARA C 3ʹ 
5ʹ GGG CCC AGG CGG CCG AGC TCG AYA TTS TRA TGA CCC ART C 3ʹ 
5ʹ GGG CCC AGG CGG CCG AGC TCG AYA TTG WGC TSA CCC AAT C 3ʹ 
5ʹ GGG CCC AGG CGG CCG AGC TCG AYA TTG TTC TCA WCC AGT C 3ʹ 
5ʹ GGG CCC AGG CGG CCG AGC TCG AYA TYC AGA TGA CAC AGA C 3ʹ 
5ʹ GGG CCC AGG CGG CCG AGC TCG AYA TTC AGA TGA YDC AGT C 3ʹ 
5ʹ GGG CCC AGG CGG CCG AGC TCG AYA TTM AGA TRA MCC AGT C 3ʹ 
5ʹ GGG CCC AGG CGG CCG AGC TCG AYA TTG TRA TGA CMC AGT C 3ʹ 
5ʹ GGG CCC AGG CGG CCG AGC TCG AYA TTG TGY TRA CAC AGT C 3ʹ 
5ʹ GGG CCC AGG CGG CCG AGC TCG AYA TTG TGM TMA CTC AGT C 3ʹ 
5ʹ GGG CCC AGG CGG CCG AGC TCG AYA TTG TTC TCW CCC AGT C 3ʹ 
5ʹ GGG CCC AGG CGG CCG AGC TCG AYA TCC AGC TGA CTC AGC C 3ʹ 
Reverse primers (Long linker) 
5ʹ GGA AGA TCT AGA GGA ACC ACC CCC ACC ACC GCC CGA GCC ACC GCC ACC AGA  
GGA TTT KAT TTC CAG YTT GGT CCC 3ʹ 
5ʹ GGA AGA TCT AGA GGA ACC ACC CCC ACC ACC GCC CGA GCC ACC GCC ACC AGA  
GGA TTT TAT TTC CAA CTT TGT CCC 3ʹ 
5ʹ GGA AGA TCT AGA GGA ACC ACC CCC ACC ACC GCC CGA GCC ACC GCC ACC AGA  
GGA TTT CAG CTC CAG CTT GGT CCC 3ʹ 
 
PCR mixture composition  Amount in 50 µL final volume 
 
cDNA 
 
0.5 µL 
Sense primers 0.5 µL 
Reverse primers 0.5 µL 
5X PCR buffer 10 µL 
2.5 dNTP 1 µL 
MgCl2 2, 3, 4 or 6 µL 
Molecular grade water 35.24, 34.25, 33.25 or 31.25 µL 
Tag polymerase 0.25 µL 
 
 
 68 
PCR condition  
Stages 
 
     Temperature                                    Time 
Initialization               950C                    5 mins 
Denaturation  
Annealing 
Elongation 
             940C 
             560C 
             720C 
                   15 sec 
                   30 sec          30 cycles  
                   90 sec 
Final elongation               720C                    10 mins 
                 40C                     ∞ 
 
2.2.3.5 Nucleospin Extract II purification of variable heavy and light chains  
The amplified heavy and light chain products were run on 1% (w/v) agarose gel at 100 V in 
Bio-Rad gel chamber using 1X TAE as the running buffer. The bands corresponding to the 
386-440 bp, for the VH chain and 375-402 bp, for the VL chain were cut out and placed in 
weighed 2 mL eppendorf tubes. The weight of the gel was determined and twice the volume of 
the binding buffer with the chaotropic agent (for easy dissolution of the DNA present in the 
gel) was added and incubated at 500C for 10 mins in a water bath. After the gel was dissolved 
completely, the solution was transferred onto silica columns provided with the Nucleospin 
Extract II system to enable the binding of the DNA to the silica particles present in the column. 
The column with the dissolved gel was centrifuged at 11,498 xg for 1 min at 40C in Hermle 
Z233 MK-2 centrifuge. The solution in the lower collection tube was discarded. This was 
followed by ‘clean-up’ of the column with NT3 wash buffer, which is an ethanol-based 
solution that will aid in the removal of unnecessary salts and macromolecules from the column. 
The washing step was performed through the addition of 700 µL of wash buffer and the column 
was centrifuged for 1 min at 11,498 xg at 40C followed by a another spin (without any solution 
in the column) of the column for 2 mins at 11,498 xg to remove any traces of wash buffer. For 
the efficient elution of DNA, the elution buffer, composed of 5 mM of Tris/HCl (pH 8.5), was 
pre-heated to 700C and was added to the column and incubated at room temperature for 1 min. 
This was followed by centrifugation for 1 min at 11,498 xg at 40C. The final quantification of 
pure DNA was determined on a NanodropTM at 260 nm.    
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2.2.3.6 Splice by overlap extension (SOE)   
The purified VH and VL antibody fragments were connected via glycine-serine linker using an 
SOE-PCR. The following primers were utilized for the performance of splice by overlap 
extension using a Platinum® Taq DNA Polymerase High Fidelity  for efficient proof reading of 
the proper base pairs.  
SOE primers 
Forward primers 
5ʹ GAG GAG GAG GAG GAG GAG GCG GGG CCC AGG CGG CCG AGC TC 3ʹ 
Reverse primers 
5ʹ GAG GAG GAG GAG GAG GAG CCT GGC CGG CCT GGC CAC TAG TG 3ʹ 
 
The PCR reaction was carried out on an Applied Biosystems PCR machine under the following 
conditions: 
PCR condition  
Stages 
 
                  Temperature                                      Time 
1 940C                        2 mins 
2 
3 
4              
940C 
560C 
720C 
                       30 sec 
                       30 sec        30 cycles  
                       120 sec 
5 720C                        10 mins 
 6 40C                       ∞ 
 
2.2.3.7 SfiI restriction digestion of the SOE product 
The purified SOE fragment was used for SfiI restriction digestion at the sites 5ʹ 
GGCCNNNNNGGCC 3ʹ and 3ʹ CCGGNNNNNCCGG 5ʹ. The reaction mixture was composed 
of 10 µg of purified overlap PCR product, 360 units of SfiI (36 units per µg of DNA) and 20 
µL of 10X reaction buffer. The digestion was carried out at 500C for 5 hrs on an heating block. 
Later, the digested SOE product was ethanol-precipitated overnight. Purification of the digested 
insert (~700 bp) was carried by running on a 1% (w/v) agarose gel and through subsequent 
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purification of the DNA using a Nucleospin Extract II system. The composition of the SfiI 
digestion mixture is described in the following table: 
Components SOE (k) SOE (ʎ) 
 
SOE 
 
240 µL 
 
 240 µL 
SfiI   10 µL   12 µL 
100X BSA    3  µL     3 µL 
NEB II buffer   30 µL    30 µL 
Molecular grade water   17 µL    15 µL 
TOTAL  300 µL  300 µL 
 
2.2.3.8 Restriction digestion of pComb 3XSS 
The plasmid with human influenza hemagglutinin (HA) tag was first confirmed through 
restriction digestion with SfiI and SacI restriction enzymes. For this a small-scale reaction was 
carried out with SfiI (500C for 4 hrs) and SacI (370C for 4 hrs) along with the vector (pComb 
3XSS). This was followed by running the samples on a 0.5% (w/v) agarose gel. The 
recognition sites for SacI were 5ʹ GAGCTC 3ʹ and 3ʹ CTCGAG 5ʹ.  The vector was linearized 
when SacI digestion was performed. Restriction digestion with SfiI leads to the segregation of 
Stuffer fragments present between the two SfiI recognizing sites. The vector used for ligation 
was restriction digested only with SfiI enzyme. 
Large-scale digestion of the vector used was performed using SfiI enzyme. The reaction 
mixture for the SfiI restriction digestion of pComb 3XSS consisted of 20 µg of vector DNA, 
120 units of SfiI (6 units per µg of plasmid DNA) and 20 µL of 10X reaction buffer. The SfiI 
digestion of the vector was carried out for 4 hrs at 500C. Then, the mixture was treated with 
XhoI and XbaI for 1 hr at 370C for the further breakdown of the Stuffer fragments. Later 
Antarctic phosphatase was added and incubated at 370C for 15 mins for the prevention of self-
ligation of the vector through removing the phosphate group from the 5ʹ end. The enzyme was 
then deactivated by placing at 650C for 5 mins. The digested vector was ethanol-precipitated 
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overnight. Purification of digested vector, which is ~3,400 bp, was performed by running the 
ethanol-precipitated mix over an 0.5% (w/v) agarose gel, followed by the purification of the 
spliced DNA embedded gel using Nucleospin Extract II system. 
The composition of the restriction digestion mixture is as follows: 
Components    Amount/100 µL final volume 
 
Vector (pComb 3XSS) 
 
                20 µL 
NEB II buffer                 10 µL 
100 X BSA                    1 µL 
SfiI                   9 µL 
Molecular grade water                 60 µL 
  
2.2.3.9 Ligation of SOE product into pComb 3XSS 
The digested vector was then ligated into the SfiI cut SOE using T4 DNA ligase. The vector 
and SOE were in the ratio of 3:1 and the reaction mixture was kept static at room temperature 
(180C) for 18 hrs and the enzyme was deactivated through heating the mixture at 900C for 10 
mins over a heating block. The components of the ligation mix are shown in the table below: 
Components SOE (k)  SOE (ʎ)  
 
5 X ligase buffer 
   
  20.0 µL 
  
 20.0 µL 
Digested SOE   46.97 µL   7.15 µL 
Digested pComb 3XSS   11.55 µL  11.55 µL 
T4 DNA Ligase   0.5 µL   0.5 µL 
Molecular grade water   20.98 µL   160.80 µL 
Final Volume    200 µL    200 µL 
 
The ligation mixture was then subjected to ethanol precipitation using 1/10th volume of 3 M 
sodium acetate (pH 5.2), twice the volume of 100% (v/v) ice cold ethanol and 2 µL of 
glycogen. The ethanol-precipitated ligation mixture was left overnight at -200C and it was then 
centrifuged at 18,625 xg for 30 mins at 40C in Hermle Z233 MK-2 centrifuge.  The supernatant 
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was discarded leaving behind the pellet. The pellet was washed with 70% (v/v) ice cold 
ethanol. The washing procedure was done in such a way that the pellet remained undissolved in 
the ethanol solution. This washing step was followed by the centrifugation of the solution at 
18,625 xg for 20 mins at 40C in Hermle Z233 MK-2 model centrifuge. Again, the supernatant 
was discarded and the pellet was air dried and dissolved in 15 µL of molecular grade water. 
This DNA mixture was then transformed into the XL-1 Blue electrocompetent cells using a 
Gene Pulser electroporation unit. 
 
2.2.3.10 Transformation of the ligation mixture into XL-1 Blue electrocompetent cells  
Initially the commercially obtained XL-1 Blue electrocompetent cells (Agilent Technologies) 
were thawed for 10 mins on ice. The parameters for the electroporation were set on the 
machine to 25 µF, 1.25 kV and gene pulse controller at 200 Ω. Following thawing of the 
competent cells, 5 µL of the ligation mixture were added to the cells, mixed, tapped twice, and 
left on ice for 1 min. Then the mixture was transferred into an 0.2 cm electroporation cuvette 
and placed in the shockpad. The mixture was pulsed and immediately 1 mL of fresh pre-
warmed SOC medium was added. The culture was transferred into a 50 mL tube followed by 
thorough cleaning of the cuvette with another 1 ml of the SOC medium. The cells were rescued 
at 370C with shaking at 220 rpm for 1 hr. Culture (20 µL) was diluted in fresh SB medium to 
make dilutions from 101 to 1010.  A 100 µL volume from each of these dilutions was plated out, 
using the spread plate technique, on the individual LB agar plates with 100 µg/mL of 
carbenicillin and 1% (v/v) glucose. The agar plates were incubated in upright position 
overnight and on the following day the colonies were counted and the library size was 
determined using the formula.  
            Library size =   No. of colonies X culture volume X total ligation volume    
                                               Plating volume X ligation volume 
To the rest of the culture 10 mL of pre-warmed SB medium with 6 µL of 100 mg/mL of 
cabenicillin and 30 µL of 5 mg/mL tetracycline were added and incubated for another hour at 
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370C. Then another 9 µL of 100 mg/mL carbenicillin was added and shaken for one more hour 
at 370C. M13K07 (900 µL) was added along with 570 µL of pre-warmed SB medium 
supplemented with carbenicillin and tetracycline. The culture was grown for 2 hrs at 370C. 
Kanamycin (840 µL of 50 mg/mL stock) was added and the culture was grown overnight at 
370C. This will inititate the biopanning process for the selective screening of the scFv-
expressing clones. 
 
2.2.3.11 Selective enrichment of anti-AFB2 clones through biopanning 
The aforementioned (section 2.2.3.10) culture, that was infected with M13K07 helper phage (2 
X 1011 pfu/mL), was selectively screened on immunotubes coated with AFB2-BSA conjugate. 
For this, the overnight grown culture was transferred into 250 mL Sorval tubes and centrifuged 
at 5,858 xg for 20 mins in Sorvall RC5B plus centrifuge. The pellet was discarded and the 
phage particles, expressing the scFv gene present in the supernatant, were precipitated on ice 
for 30 mins with 4% (w/v) polyethylene glycol (PEG) and 3% (w/v) sodium chloride (NaCl). 
After half an hour the supernatant was centrifuged without breaks in Sorvall RC5B plus 
centrifuge at 13,182 xg for 20 mins. The precipitated phage particles were re-suspended in 2 
mL of 1 mg/mL of BSA in 150 mM PBS (pH 7.4),  following discarding of the supernatant and 
subsequent drying of the phage, by placing the Sorval tube with phage in an inverted position 
for 10 mins. In the meanwhile, the immunotube that was coated with AFB2-BSA conjugate 
overnight at 40C was blocked for 2 hrs at room temperature on a roller with 1 mL of 4% (w/v) 
milk Marvel 150 mM PBS (pH 7.4). After blocking, the immunotube was washed three times 
with PBST & PBS and then 1 mL of phage, that had been resuspended in 1 mg/mL of BSA in 
150 mM PBS (pH 7.4) was added. The phage were incubated in the milk Marvel blocked 
immunotube for 2 hrs at room temperature with continuous rolling. The unbound phage were 
removed through washing three times with PBST & PBS. The bound phage were eluted 
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through trypsinization. For this 10 mg/mL of trypsin dissolved in 150 mM PBS (pH 7.4) was 
added to the immunotube and incubated for 30 mins at 370C.  
Eluted phage were added to 2 mL of XL-1 Blue E. coli culture, which had reached the mid- 
exponential growth phase (OD 0.4 @ 600 nm) and left static at room temperature for 15 mins. 
Then, 6 mL of pre-warmed SB medium, with 12 µL of 5 mg/mL tetracycline and 1.6 µL of 100 
mg/mL of carbenicillin were added. After incubating the culture for 1 hr at 370C, another 2.4 
µL of 100 mg/mL of carbenicillin was added and allowed to incubate at 370C for another hour. 
Then, 600 µL of M13K07 helper phage were added. The culture was then transferred into a 
conical flask with 200 mL of pre-warmed SB medium with 368 µL of tetracycline (5 mg/mL) 
and 92 µL of 100 mg/mL of carbenicillin. Following 2 hrs of culture growth at 370C, 280 µL of 
50 mg/mL of kanamycin were added and the culture allowed to grow overnight. The changes 
that were made during different rounds of panning are outlined below: 
Rounds of  
panning  
      Amount of  
AFB2-BSA coated 
Number of washes Culture volumes 
 
Round 1 
       
         250 µg 
   
   3X PBST & PBS 
 
   200 mL 
Round 2          100 µg    3X PBST & PBS    100 mL 
Round 3            50 µg    6X PBST & PBS    100 mL 
Round 4            25 µg    9X PBST & PBS    100 mL 
Round 5              5 µg    12X PBST & PBS    100 mL 
 
 
2.2.3.12 Polyclonal phage ELISA  
A 96-well microtitre plate was incubated with 100 µL/well of 5 µg/mL of AFB2-BSA in 150 
mM PBS (pH 7.4) overnight at 40C. The solution was decanted and the plate was washed once 
with 150 mM PBS (pH 7.4). The plate was then blocked for an hour with 200 µL of 4% (w/v) 
milk Marvel PBS. Immediately after blocking, the plate was washed three times with PBST & 
PBS and 100 µL of phage inputs from the five rounds of panning along with the pre-pan 
(diluted 1:2 in 2% (w/v) milk Marvel PBST) were added to three different wells (triplicates) of 
the microtitre plate. The plate was then incubated for 1 hr at 370C followed by three times 
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washes with PBST & PBS. Next, 100 µL/well of 1:1,000 dilution of anti-M13 HRP-labelled rat 
secondary antibody was added, followed by incubation for 1 hr at 370C. The plate was washed 
thrice with PBST & PBS and the antigen-antibody complex was detected through the addition 
of 100 µL of TMB substrate. After 20 mins at room temperature the substrate color 
development was stopped though the addition of 50 µL of 1 M HCl. The absorbance was read 
on a Tecan Saffire plate reader at 450 nm. 
 
2.2.3.13 Soluble expression of scFv in Top 10Fʹ cells 
Soluble expression of the clones was initiated through infecting the phage from the fifth round 
of panning into E. coli Top 10Fʹ cells (Stratagene, U.S.A.) at mid-logarithmic phase (OD600nm= 
0.6). For this SB medium (5 mL) with 10 µL of 5 mg/mL tetracycline was inoculated with 5 µL 
of Top 10Fʹ cells and grown overnight at 370C. The overnight culture of Top 10Fʹ was then 
sub-cultured and was grown until the OD600nm reached 0.6. Then 20 µL of phage from the fifth 
round of panning were added to the Top 10Fʹ cells and incubated at room temperature for 15 
mins while static. Serial dilutions from 101 to 108 were made using SB medium and the culture 
was plated out on LB agar plates with 100 µg/mL of carbenicillin and 1% (v/v) glucose. The 
agar plates were incubated overnight at 370C to allow growth of colonies.     
 
2.2.3.14 Monoclonal ELISA of the solubly expressed anti-AFB2-expressing scFvs 
Individual colonies (384 in total) were picked from the agar plate that was incubated overnight 
(2.2.3.13) and inoculated into 96 wells of a sterile Nunc plate containing 200 µL of SB medium 
with 100 µg/mL of carbenicillin and 505 medium.  After overnight incubation at 370C, 20% 
(v/v) glycerol was added to the culture and it was stored at -800C. Prior to adidition of glycerol, 
20 µL of culture were taken and added to another 96 well Nunc plate with 200 µL of SB 
medium. The culture was allowed to grow at 370C while shaking at 220 rpm until the OD600nm 
reached 0.6 and 1 mM of IPTG was added and incubated overnight at 300C while shaking at 
220 rpm. Separate 96 well plates were coated overnight with 5 µg/mL of AFB2-BSA at 4
0C.  
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The following morning the conjugate-coated microtitre plates were blocked for 1 hr with 200 
µL/well of 4% (w/v) milk Marvel 150 mM PBS (pH 7.4). Meanwhile, the culture plates were 
freeze-thawed thrice for the lysis and release of the proteins into the periplasmic layer. After 
freeze-thawing, the plates were centrifuged in an Eppendorf centrifuge (model: 5810R) at 2,754 
xg for 20 mins and 100 µL of the supernatant (recombinant scFv’s with HA tag) were added to 
the individual wells of the already blocked microtitre plates and incubated for 1 hr at 370C. The 
incubation step was followed by the washing of the plates three times with PBST & PBS. Then 
100 µL/well of 1:1,000 dilution of anti-HA HRP-labelled rat secondary antibody in 2% (w/v) 
Milk Marvel PBST was added and incubated for 1 hr at 370C. The plates were washed thrice 
with PBST & PBS and 100 µL/well of TMB substrate added. The plates were left at room 
temperature for 20 mins for the color reaction to take place. The chromophore reaction was 
then stopped with addition of 50 µL of 1 M HCl and the absorbance was read at 450 nm on a 
Tecan Saffire plate reader.     
 
2.2.3.15 Titration and competitive inhibition ELISA of randomly selected positive AFB2 
binding clones 
Out of 384 clones (section 2.2.3.14), 10 positive clones whose absorbance was high 
(absorbance above 3 @ O.D. 450 nm), were selected and titre determined by indirect ELISA. 
The 10 clones were grown up overnight in 2 mL SB medium with 1 µL of 100 mg/mL of 
carbenicillin. The following morning these were sub-cultured into another 10 mL of SB 
medium with 5 µL of 100 mg/mL of carbenicillin. They were allowed to grow until the 
OD600nm reached 0.6 and 20 µL of 0.5 M IPTG was added in order to promote the expression of 
the desired antibody. After IPTG induction they were grown at 300C overnight. Next day the 10 
mL cultures were subjected to freeze-thawing followed by centrifugation in an Eppendorf 
centrifuge model No. 5810R at 2,754 xg for 20 mins at 40C.  
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Meanwhile, the microtitre plates that were coated overnight with 100 µL/well of 5 µg/mL of 
AFB2-BSA were blocked for an hour using 200 µL/well of 4% (w/v) milk Marvel 150 mM 
PBS (pH 7.4). After blocking, the plates were washed thrice with PBST & PBS and 100 
µL/well of serially diluted (1:10 to 1:5,120) scFv lysates were added to the individual wells of 
the microtitre plates (in duplicate). The rest of the ELISA procedure was the same as that 
described in section 2.2.3.12. A graph was plotted to determine the titre value for individual 
scFvs. From the titration curve the dilution of antibody to be used for competitive ELISA was 
determined.  
The competitive inhibition ELISA was performed through inhibiting 1:4 dilution of the 
supernatant in 2% (w/v) Milk Marvel PBST with 20 µg/mL of free AFB2 in methanol and 
blocked for one hour at 370C with 200 µL of 4% (w/v) milk Marvel 150 mM PBS (pH 7.4). 
Doubling dilutions of AFB2 were made from a concentration of 20 µg/mL down to 0.039 
µg/mL. Equal amounts of lysate, and antigen of varying concentrations (0.039-20 µg/mL), 
were incubated for 30 mins at 370C. The blocked plates were washed thrice with PBST & PBS 
followed by addition of 100 µL/well of inhibited antigen-antibody mixture. Following 
incubation for 1 hr at 370C, the plates were washed thrice with PBST & PBS and then 100 µL 
of 1:1,000 dilution of secondary antibody (anti-HA HRP-labelled rat mAb) were added to the 
individual wells. The plate was incubated for another hour at 370C. The washing step, as 
described earlier, was repeated and 100 µL/well of TMB substrate was added and incubated for 
20 mins at room temperature for the color development. The reaction was stopped with 50 
µL/well of 1 M HCl. The absorbances were read on a Tecan Saffire plate reader at 450 nm. An 
inhibition curve was plotted after calculation of the A/A0 value (A= absorbance of the antigen 
antibody complex & A0= absorbance value of 1:4 dilution of antibody).  
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2.2.3.16 Cross reactivity based ranking of anti-AFB2 scFvs  
Cross reactivity studies were performed by competitive ELISA (section 2.2.3.15) using varying 
concentrations (0.039-20 µg/mL) of AFB1, G1, G2 and M1. Calibration curves were generated 
from the data and cross reactivity percentage was calculated through considering IC50 value of 
AFB2 as 100% and measured using the formula  
                                                 IC50 of scFvs in presence of aflatoxins  X 100 
Percentage cross reactivity =   IC50 of scFvs in presence of AFB2 
 
 
2.2.3.17 Large-scale expression, IMAC purification and analysis of scFvs-E9 and H12 
SB medium (10 mL) with 5 µL of 100 mg/mL of carbenicillin was inoculated with 20 µL of 
scFvs stocks and grown overnight at 370C. The following morning 1 mL of culture was 
inoculated into 500 mL SB culture with 250 µL of 100 mg/mL of carbenicillin and grown at 
370C with shaking (220 rpm) until the OD600nm reached approximately 0.6, after which 500 µL 
of 1 M IPTG were added and the culture grown overnight at 300C. The overnight culture was 
then transferred into 250 mL sorval tubes (Nalgene) and centrifuged at 2,754 xg for 30 mins at 
40C. The bacterial pellets were resuspended in 20 mL of lysis buffer (50 mM Na2H2PO4, 300 
mM NaCl and 10 mM imidazole, pH 8.0) after discarding the supernatants. This suspension 
was sonicated for 5 mins with 10 sec pulses at amplitude 60 using Sonicator. The cell debris 
was removed by centrifugation of the sonicated mixtures at 18,514 xg for 30 mins at 40C. The 
lysate supernatants were collected into a fresh tube. Then 2 mL of Nickel-Nt resin were packed 
in two columns, which were equilibrated with 10 mL of loading buffer (50 mM Na2H2PO4, 300 
mM NaCl and 10 mM imidazole, pH 8.0). The lysates were added to the equilibrated columns, 
followed by washing the columns with 5 mL of washing buffer (50 mM Na2H2PO4, 300 mM 
NaCl and 30 mM imidazole, pH 8.0). The bound scFvs were eluted using 6 mL of buffer (50 
mM Na2H2PO4, 300 mM NaCl and 250 mM imidazole, pH 8.0). The eluates were dialyzed 
against (buffer exchanged with) 1X PBS using 5,000 M. Wt. ‘cut-off’ Vivaspin columns 
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(Sartorious Stedium, Germany). The scFv concentrations were then quantified on a 
Nanodrop™ spectrophotometer. 
 
2.2.3.17.1 Competitive inhibition ELISA for scFvs-E9 and -H12 
Competitive inhibition ELISA procedure described in section 2.2.3.15 was performed using the 
scFvs-E9 and -H12. Due to the higher sensitivity of scFv-E9 further analyses were carried out 
using this scFv.  
 
2.2.3.17.2 SDS-PAGE and western blotting of scFv-E9 
The anti-AFB2 scFv-E9 after immuno-affinity purification (IMAC) was run on SDS-PAGE gel, 
whose composition was described in section 2.1.7. The scFv-E9 was dissolved in loading dye 
in the ratio of 1:3. The gel was run at 100 V for 1 hr 30 mins and stained 1 hr on roller shaker at 
room temperature using Coomassie blue and subsequently destained for 1 hr at room 
temperature using destaining solution. Another gel was run as described above and the protein 
was transferred onto the nitrocellulose membrane and blocked with 4% (w/v) milk Marvel PBS 
for 1 hr at room temperature. The blocked nitrocellulose membrane was probed with 1/5,000 
dilution of anti-HA-HRP labelled secondary antibody, after which the blot was developed using 
TMB solution.  
 
2.2.3.18 CM5 chip immobilization and competitive inhibition assay development 
The immobilization of AFB2 onto the CM5 chip surface was done on bench. The volumes of 
solutions used were 30 µL unless otherwise stated. Briefly, a CM5 chip was primed with HBS-
EP buffer. The surface was activated with 1:1 mixture 0.4 M EDC and 0.1 M NHS in water for 
30 mins, after which the buffer was removed using a tissue paper. An amine (Jeffamine, in 50 
mM carbonate buffer (pH 8.5)) was applied to the surface for 1 hr followed by the blockage or 
deactivation of unreacted sites with 1 M ethanolamine, pH 8.5 for 30 mins. The reactive AFB2-
CMO-NHS synthesized following the procedure described in section 2.2.1.1. was allowed to 
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react with amine activated chip overnight at room temperature, followed by washing and 
storage at 40C for future use.  
 
2.2.3.19 Binding and kinetic analysis of the scFv-E9  
Kinetic analysis of the scFv-E9 (without any cross reactivity and highest displacement) was 
carried out after subjecting to purification on IMAC. Initially varying concentrations of scFv 
were analyzed by SPR to attain response units of 200 to 300 RU. The scFv-E9 was injected at 
concentrations of 43.7-350 nM, randomly onto the AFB2 immobilized CM5 chip for 2 mins 
(flow rate of 10 µL/min), and dissociation was monitored for 10 mins. Regeneration of the 
surface was carried out, after 10 mins of dissociation with 30 mM NaOH for 30 sec twice (flow 
rate 30 µL/min). The data were evaluated on BIAevaluation software. The equilibrium 
dissociation constant (KD) was calculated through fitting the data in 1:1 Langmuir binding 
model.  
 
2.2.3.20 Post extraction spiking of almond samples   
Almond sample was extracted using 80% (v/v) methanol (Whitaker et al., 2006), followed by 
centrifugation for 30 mins at  2108 xg. The supernatant was filtered using Whatsman grade 1 
filter paper. Five millilitres of almond extract were evaporated to dryness in a rotary evaporator 
and resuspended in 5 mL of HBS buffer. To each mL of almond sample in HBS buffer varying 
concentration of AFB2 (0.15-2.5 µg/mL) were added and recovery was measured through 
fluorescence estimation. 
 
2.2.3.21 SPR-based inhibition assay condition and validation 
Anti-AFB2 scFv-E9 (1/100 dilution) in HBS buffer was added to decreasing concentrations of 
AFB2 (0.9-1,000 ng/mL) in the ratio of 1:1. This mixture was incubated for 30 mins at 37
0C. 
The samples were then randomly passed over the AFB2 immobilized sensor chip in triplicate. 
Likewise, spiked almonds samples were also mixed with antibody (1:1 spiked sample/antibody) 
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and injected (flow rate 15 µL) onto the surface of the sensor chip, with a contact time of 90 sec. 
The surface was regenerated with 30 mM NaOH for 30 sec twice (flow rate 30 µL/min). The 
limit of detection (LOD) of the assay was determined from the mean of limit of blank (n=20) 
plus 3 times standard deviation of blank samples. The precision of the assay was measured 
through performing inter-day (within runs) and intra-day (between runs) of the assay and 
represented as % CV (coefficient variance).   
 
2.2.4 Generation of anti-Zearalenone murine scFv antibodies 
Zearalenone (M.Wt. 318.36 g mol-1) was first conjugated to carrier proteins (BSA and KLH) 
following the procedure given in section 2.2.1.2. The ZEN-KLH conjugate was used as an 
immunogen in the presence of Freund’s adjuvant to generate immune responses in mice. The 
immune response was determined by indirect ELISA. 
  
2.2.4.1  Serum titre determination 
Four out of the 8 rows for a 96 well Nunc microtitre plate were coated overnight at 40C, with 5 
µg/mL of ZEN-BSA conjugate. Two rows were coated with 5 µg/mL BSA in PBS and the 
remaining two rows with 5 µg/mL KLH in 150 mM PBS (pH 7.4). An indirect ELISA (section 
2.2.2.2) was performed. 
 
2.2.4.2 RNA isolation and cDNA synthesis from mice spleen enriched with anti-ZEN 
immunoglobulins 
The procedure described in section 2.2.3.2 was followed for the isolation of RNA. Synthesis of 
the first strand of DNA i.e., cDNA through the reverse transcription was carried out empoying 
the procedure outlined in section 2.2.3.3.  
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2.2.4.3 Recombinant anti-ZEN scFv library 
2.2.4.3.1 Amplification of antibody variable heavy and light chains using pComb 3X series 
primers 
A long linker library in which the VL is linked to VH with an 18 amino acid linker was 
generated using the set of primers described in section 2.2.3.4 following the procedure outlined 
by Barbas et al. (2001). The PCR conditions for the amplification of Vʎ, Vk and VH were 
optimized using a MgCl2 gradient. Using the appropriate amount of MgCl2 the variable heavy 
and light chain genes were amplified and resolved on a 1% (w/v) agarose gel with Sybersafe. 
The required bands were cut out and purified using Nucleospin Extract II, following the 
procedure outlined in section 2.2.3.5. 
  
2.2.4.3.2 Splice by overlap extension (SOE) PCR  
The ~750 bp amplicon SOE product was synthesized after performing a set of optimizations 
using a MgSO4 gradient. The following PCR mixture was used for overlapping of the heavy 
and light chain genes.  
PCR mixture composition   Amount in 50 µL final  volume Conc. in 50 µL volume 
 
VH 
              
             0.8 µL 
 
100 ng/rxn 
Vk              2 µL 100 ng/rxn 
dNTP              1 µL 0.2 mM 
Hi fi buffer              5 µL 1X 
SOE forward primer              0.5 µL 60 pM 
SOE reverse primer              0.5 µL 60 pM 
MgSO4              1, 1.5, 2 or 4 µL 1, 1.5, 2, 4 mM 
Molecular grade water              39, 38.5, 38 or 36 µL N/A 
Platinum tag              0.2 µL 5 U/ µL 
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The PCR reaction was carried out on Applied Biosystems machine using the following 
conditions: 
PCR condition  
Stages 
 
Temperature                                        Time 
 1 940C 5 mins 
 2 
 3 
 4 
                   
940C 
560C 
720C 
 
30 sec 
30 sec          30 cycles  
120 sec 
 5 720C 10 mins 
  6 40C ∞ 
 
2.2.4.3.3 SfiI restriction digestion and ligation of the purified SOE and pComb 3XSS 
vector  
Both the SOE product and vector were restriction digested with SfiI. This aids in the 
unidirectional cloning of the scFv (SOE) into the vector. The digestion of both SOE and vector 
was carried out at 500C for 5 hrs on a heating block. The digested SOE product was ethanol-
precipitated at -200C. The vector was treated with XhoI and XbaI to further digest the Stuffer 
fragment. Finally, the vector was treated with antarctic phosphatase in order to prevent re-
ligation of vector prior to the performance of the ligation of SOE with the vector. The 
completely digested vector was then ethanol-precipitated. The composition of the reaction 
mixtures are given below: 
Components SOE(k) SOE(ʎ)  Components   Amount in  
100 µL volume 
 
SOE 
 
240 µL 
 
240 µL 
  
Vector 
        
        20 µL 
SfiI 10 µL 12 µL  NEB II buffer         10 µL 
100X BSA 3 µL 3 µL  100X BSA         1 µL 
NEB II buffer 30 µL 30 µL  SfiI         9 µL 
Molecular grade water 17 µL 15 µL  Molecular grade water         60 µL 
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The ethanol-precipitated mixtures of both the SOE and the vector were resolved on 0.5% (w/v) 
agarose gel and purified following the procedure described in section 2.2.3.5. The restricted 
digested SOE was then ligated into pComb 3XSS vector overnight using T4 DNA ligase. The 
composition of the ligation mixture is outlined below: 
Components SOE (k)      SOE (ʎ)  Conc. in 200 µL volume 
 
5 X ligase buffer 
 
20 µL 
      
     20 µL 
           
            2X 
Digested SOE 46.97 µL      7.15 µL            1.4 µg/rxn 
Digested pComb 3XSS 11.55 µL      11.55 µL            2.4 µg/rxn 
T4 DNA Ligase 0.5 µL      0.5 µL             800 U/µL 
Molecular grade water 120.98 µL      160.80 µL             N/A 
TOTAL 200 µL      200 µL             N/A 
 
After ligating the SOE with the vector the ligase enzyme was deactivated through heat 
treatment at 600C for 15 mins. The ligation mixture was then subjected to ethanol precipitation 
overnight at -200C using 1/10th volume of 3 M sodium acetate, twice the volume of 100% (v/v) 
ice-cold ethanol and 2 µL of glycogen. The ethanol precipitation was followed by the 
centrifugation of the mixture in Hermle Z233 MK-2 centrifuge at 18,625 xg for 30 mins 
followed by the washing of the pellet with 70% (v/v) ethanol. The pellet was air dried and then 
dissolved in 16 µL of molecular grade water. 
 
2.2.4.3.4 Transformation of scFv gene into E. coli by electroporation 
Commercially available XL-1 Blue electrocompetent cells (Agilent technologies) were used for 
transforming the ligated scFv vector construct using the Gene Pulser Xcell electroporation 
system (Bio-Rad Laboratories, U.S.A.) unit. The electrocompetent cells (100 µL) were thawed 
on ice for 5 mins. The ligation mixture (4 µL) was added to each of four thawed vials of the 
electrocompetent cells. This was then transferred into an ice-cold 0.2 cm electroporation 
cuvette (Bio-Rad Laboratories, U.S.A.). The cuvette was tapped for the cells to settle down and 
was pulsed using 25 µF, 1.25 kV and the Pulse Controller at 200 Ω after placing the cuvette in 
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the shock pad. Then, the cuvette was washed twice with 1 mL of pre-warmed SOC. The re-
suspended cells were transferred into a 50 mL sterile universal container containing 2 mL of 
SOC medium, and incubated for 1 hr at 370C while shaking at 220 rpm, to rescue the library. A 
set of dilutions 101 to 1010 was made using the rescued library to determine the library size. 
They were plated out on LB agar supplemented with 100 µg/mL of carbenicillin and 1% (v/v) 
glucose to determine the library size. In parallel, XL-1 Blue cells (negative control) alone were 
plated out. The plates were incubated overnight at 370C. The rescued library was used for 
performing biopanning. 
 
2.2.4.4  Selective enrichment and screening of scFv-expressing clones 
To 2 mL of the rescued library (section 2.2.4.3.4) 10 mL of pre-warmed SB broth enriched with 
3 µL of 100 mg/mL carbenicillin and 30 µL of 5 mg/mL tetracycline were added. This culture 
was incubated for one hour at 370C, while shaking at 220 rpm. Further supplementation of the 
medium with 4.5 µL of 100 mg/mL of carbenicillin was followed by incubation for 1 hr at 
370C. M13KO7 helper phage (900 µL) was added and the final culture volume was made up to 
600 mL through addition of 588 mL of SB medium supplemented with 450 µL of 100 mg/mL 
carbenicillin and 1800 µL of 5 mg/mL tetracycline. The culture was grown for 2 hrs at 370C 
followed by supplementation with 840 µL of 50 mg/mL of kanamycin and then grown 
overnight at 370C.  
 
2.2.4.4.1 Phage precipitation        
The overnight ‘grown-up’ culture was transferred into 250 mL Sorval tubes (Nalgene) and 
centrifuged at 2,603 xg for 20 mins in Sorval RC5B plus centrifuge. The bacterial cell pellet 
was discarded and the phage in the supernatant was precipitated through the addition of 4% 
(w/v) polyethylene glycol (PEG) and 3% (w/v) sodium chloride (NaCl) on ice bath for 30 mins. 
The precipitated phage were pelleted by centrifugation for 20 mins at 13,182 xg in Sorval 
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RC5B plus centrifuge. The phage pellet was air dried and re-suspended in 2 mL of a 1 mg/mL 
solution of BSA in 150 mM PBS (pH 7.4). 
 
2.2.4.4.2 Biopanning for selective enrichment of scFv-expressing clones  
Six rounds of panning were performed on immunotubes that were coated overnight at 40C with 
ZEN-BSA conjugate. The immunotubes were blocked with 1 mL of 4% (w/v) milk Marvel in 
150 mM PBS (pH 7.4) for 2 hrs followed by washing thrice with PBST & PBS. The 
precipitated phage in BSA (section 2.2.4.4.1) were added to the immunotube and incubated for 
1 hr at room temperature followed by washing to remove the unbound phage. Bound phage 
particles were removed from the immunotube through the addition and susbsequent incubation 
with 10 mg/mL of trypsin for 30 mins at 370C. The trypsinized phage mixture was now added 
to the 2 mL of XL-1 Blue culture whose OD600nm is 0.4 and was left static at room temperature 
for 15 mins. To this, 2 mL of XL1-Blue phage culture, 8 mL of SB medium, supplemented 
with 12 µL of 5 mg/mL of tetracycline, and 1.6 µL of 100 mg/mL of carbenicillin were added 
and incubation for 1 hr at 370C followed. Then the culture was again supplemented with 
another 2.4 µL of 100 mg/mL of carbenicillin. The culture was grown for 1 hr and M13K07 
phage (4 X 1011 pfu) was added along with 200 mL of SB medium. After 2 hrs of incubation at 
370C, 280 µL of 50 mg/mL of kanamycin was added and the culture was allowed to grow 
overnight at 370C.  The determination of the output and input titre from each of the round was 
done through plating out a set of dilutions from the inputs and outputs every day. The 
variations in the conditions during each round of panning are shown in the table below: 
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Rounds of  
panning  
ZEN-BSA coating 
concentration 
Number of washes   Culture volumes 
 
Round 1 
      
        250 µg 
  
   3X PBST & PBS 
     
     200 mL 
Round 2         100 µg    3X PBST & PBS      100 mL 
Round 3         50 µg    6X PBST & PBS      100 mL 
Round 4         25 µg    9X PBST & PBS      100 mL 
Round 5         5 µg   12X PBST & PBS      100 mL 
Round 6                                2.5 µg   12X PBST & PBS      100 mL 
 
2.2.4.5  Polyclonal phage ELISA and colony pick PCR for ZEN  
The microtitre plate was coated with 5 µg/mL of ZEN-BSA conjugate, BSA and 4% (w/v) milk 
Marvel. The ELISA procedure used was as in section 2.2.3.12. 
To ensure that the scFv insert was present in the colonies, six colonies were picked from the 
output plates from round 5 of the panning. A colony pick PCR reaction was carried out using 
the primers for the amplification of the appropriate insert (SOE) present in the individually 
picked colonies. The composition of the reaction mixture is given below: 
Composition  Amount in 50 µL reaction  Amount in control reaction 
 
Water  
          
          35.75 µL 
           
            35.75 µL 
Forward primers           0.5 µL             0.5 µL 
Reverse primers           0.5 µL             0.5 µL 
5 X PCR buffer           10 µL             10 µL 
dNTP           1 µL             1 µL 
Colony            1             N/A 
MgCl2           2 µL             2 µL 
Tag polymerase           0.25 µL             0.25 µL 
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The PCR reaction was carried out on an Applied Biosystems PCR machine using the following 
PCR condition:    
PCR condition  
Stages 
 
 
                   Temperature                             Time 
   1 940C                   3 mins 
    2 
    3 
    4 
                    
940C 
560C 
720C 
 
                  30 sec 
                  30 sec          30 cycles  
                  120 sec 
5 720C                   10 mins 
    6 40C                    ∞ 
  
2.2.4.6 Soluble expression of clones expressing scFv that binds to ZEN 
The phage (10 µL) from rounds 5 & 6 was infected into Top 10Fʹ cells whose OD600nm reached 
the mid-exponential phase (0.6) in individual vials. The mixture was left static at room 
temperature for 15 mins. A set of doubling dilutions were made and 100 µL of the culture from 
each dilution were plated out on separate LB agar plates with 100 µg/mL carbenicillin and 
supplemented with 1% (v/v) glucose. The plates were incubated overnight at 370C. To 
individual wells of a sterile 96 well microtitre plate 200 µL of SB medium with 100 µg/mL of 
carbenicillin and 505 medium (0.5% (v/v) glycerol & 0.05% (w/v) glucose) were added. 
Individual colonies from the agar plates were inoculated into the 96 wells of the microtitre plate 
with SB medium. The culture was allowed to grow overnight at 370C. A aliquot 20 µL of 
culture was sub-cultured into a fresh microtitre plate with SB medium. To the rest of the 
overnight grown culture (master plate) 20% (v/v) glycerol was added and stored at -800C. The 
sub-cultured plate was incubated at 370C until the OD600nm reached 0.6. Twenty µL of 1 M of 
IPTG was then added to the individual wells in order to promote the process of protein 
expression. After IPTG addition the culture was grown at 300C overnight, while shaking at 220 
rpm.  
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2.2.4.7 Monoclonal ELISA for anti-ZEN antibody secreting clones 
The culture plates that were induced with IPTG (section 2.2.4.6) were freeze-thawed three 
times followed by centrifugation at 2,754 xg for 20 mins (Eppendorf centrifuge, 5810R, A4-62 
rotor). The ELISA was performed on a microtitre plate coated with 5 µg/mL of ZEN-BSA 
conjugate overnight at 40C. The conjugate-coated ELISA plates were blocked with 200 µL/well 
of milk Marvel PBS at 370C for one hour. The blocked plates were washed thrice with both 
PBS and PBST. Then 100 µL of supernatant from the freeze-thawed culture plates were added 
to the individual wells of the microtitre plates. A detailed description of the ELISA procedure 
was given in section 2.2.3.14.    
 
2.2.4.8  Master plate construction and scale-up of the positive clones binding to ZEN 
Twenty positive binders were selected based on the signal obtained in the monoclonal ELISA 
performed using the solubly expressed clones. These 20 positive clones were grown in an 
microtitre plate, with 200 µL of SB medium with 100 µg/mL of carbenicillin, overnight at 370C 
with shaking at 220 rpm. Clones were then sub-cultured in a fresh 200 µL, 1 mL and 10 mL of 
SB medium with 100 µg/mL of carbenicillin. The sub-cultures were allowed to grow at 370C 
till they reached the mid-exponential phase (OD600nm= 0.6). One mM of IPTG was then added 
to the culture and it was allowed to grow overnight at 300C while shaking at 220 rpm. On the 
following morning the cultures were freeze-thawed thrice followed by centrifugation at 2,754 
xg for 20 mins (Eppendorf centrifuge, model 5810R, A4-62 rotor). ELISA was performed on 
the supernatant to determine the level of expression and specificity of the expressed antibodies 
towards ZEN. 
 
2.2.4.9  Titration and inhibition assay of the ZEN-positive clones   
The supernatant obtained from the 10 mL culture was used for the determination of the titre 
value of the expressed positive clones. The microtitre plate was coated overnight at 40C with 5 
µg/mL ZEN-BSA conjugate. The ZEN-BSA-coated microtitre plate was blocked with 200 
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µL/well of milk Marvel PBS for 1 hr at 370C followed by washing thrice with PBS and PBST.  
Varying dilutions of cell lysate from 1:2 to 1:256 were made by doubling dilutions. One 
hundred µL of these dilutions were added to the individual wells of a milk Marvel-blocked 
plate. The titration was performed following the procedure described in section 2.2.3.14.  
A competitive inhibition assay was then performed to determine the reactivity of the clones 
towards ZEN. A 50 µL of 1:2 dilution of the antibody was used to inhibit 50 µL of 0.039-20 
µg/mL of ZEN toxin. The protocol followed for performance of the inhibition assay is 
described in section 2.2.3.15.  
 
2.2.4.10 Large-scale expression, purification and analysis of scFv-P2A2 
For the expression of scFv-P2A2 a single colony was incubated overnight at 370C with shaking 
(220 rpm) in 5 mL of Terrific Broth and 50 µg/mL of carbenicillin. The following morning 1 
mL of this culture was used to inoculate 500 mL of fresh Terrific Broth supplemented with 50 
µg/mL of carbenicillin and grown at 370C with shaking (200 rpm) until the OD600nm= 0.6. Then 
1 mM of IPTG was added and incubated overnight at 300C with shaking (220 rpm). The 
cultures were spun down at 2,108 xg for 30 mins at 40C and the pellet was resuspended in lysis 
buffer (50 mM Na2H2PO4, 300 mM NaCl and 10 mM imidazole, pH 8.0) and subjected to 
sonication. The sonication mixture was subjected to centrifugation at 2,108 xg for 30 mins 
followed by the addition of the supernatant to already packed Nickel Nt resin (2 mL) 
equilibrated with 10 mL of loading buffer (50 mM Na2H2PO4, 300 mM NaCl and 10 mM 
imidazole, pH 8.0). After completely passing the supernatant through the column, it was 
washed with 20 mL of washing buffer (50 mM Na2H2PO4, 300 mM NaCl and 30 mM 
imidazole, pH 8.0), followed by elution of bound protein using 6 mL of elution buffer (50 mM 
Na2H2PO4, 300 mM NaCl and 250 mM imidazole, pH 8.0). The eluted protein was dialyzed 
(buffer exchanged) with PBS in a Vivaspin column (M. Wt. ‘cut-off’: 5 kDa). The amount of 
protein was estimated on Nanodrop™ spectrophotometer.    
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2.2.4.10.1 Competitive inhibition assay  
Competitive inhibition ELISA procedure described in section 2.2.3.15 was performed with an 
exception of the usage of 1/800 dilution of scFv in the presence of 0.004-5 µg/mL of ZEN.  
 
2.2.4.10.2 Cross reactivity of the scFv-P2A2 
Cross reactivity studies were performed using β & α- Zearalenol at concentration 0.004-5 
µg/mL following the competitive inhibition assay described in section 2.2.3.15. 
 
2.2.4.10.3 SDS-PAGE and western blotting of scFv-P2A2 
The gel compositions were described in section 2.1.7. The gel was run at 100 V for 1 hr 30 
mins. It was then stained for 1 hr on roller shaker at room temperature using Coomassie blue 
and subsequently destained for 1 hr at room temperature using destaining solution.  
 
2.2.4.11 Immobilization of ZEN onto CM5 sensor chip 
Immobilization of ZEN on the surface of CM5 sensor chip was done following the EDC-NHS 
method  (Jonsson et al., 1991) with a few additional steps (e.g., addition of an amine). The 
ZEN-CMO-NHS synthesis procedure described above (section 2.2.1.2) was used for the 
generation of ZEN derivative to be immobilized on the CM5 sensor chip. The immobilization 
of ZEN was carried out under static condition and the volume of reagents used in each of the 
steps was 30 µL unless otherwise stated. Initially the sensor chip was primed with HBS-EP 
buffer. Then 1:1 mixture of 0.4 M EDC/0.1 M NHS was applied to the surface for 30 mins. An 
amine (Jeffamine in 50 mM carbamate buffer (pH 8.5)) was added and allowed to incubate for 
1 hr at room temperature. Like in other CM5 immobilization procedures, 1 M ethanolamine 
was used to block the unreacted sites for 30 mins. The ZEN-derivative (section 2.2.1.2.2) was 
allowed to react with the amine activated surface overnight at room temperature in dark. The 
sensor chip was washed with water and stored at 40C for future use. 
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2.2.4.12 Binding and kinetic analysis of scFv-P2A2 utilizing ZEN immobilized CM5 chip    
For the determination of affinity constants of scFv-P2A2 varying concentration (1.25-10 mM) 
of it were passed over the ZEN-immobilized sensor chip with a flow rate of 10 µL/min for 3 
mins followed by the dissociation phase of 10 mins using kinetic analysis tool in Biacore™ 
3000.   
 
2.2.4.13 Extraction of ZEN from sorghum  
Sorghum was extracted using modified procedure developed by Bennett et al. (1984). To 50 g 
of sorghum 250 mL of methanol and water mixture (1:1) were added and stirred continuously 
for 10 mins followed by centrifugation at 2108 xg for 5 mins at 40C. The supernatant was taken 
into another tube followed by the addition of another 250 mL of methanol and water mixture 
(1:1). This suspension was again centrifuged for 5 mins at 2108 xg. The two supernatants were 
pooled together, filtered and evaporated to dryness through rotary evaporation. The residue was 
re-suspended in 50 mL acetonitrile. The recovery efficiency of extraction procedure was 
evaluated through fluorescence estimation.    
 
2.2.4.14 SPR-based inhibition assay and its validation 
To assess the binding ability of P2A2 scFv to ZEN in solution, an inhibition assay was 
performed by passing the mixture containing equal volumes of scFv-P2A2 (1/100 dilution) and 
varying concentration of ZEN (0.0039-1 µg/mL). The flow rate was kept at 10 µL/min with a 
total contact time of 60 sec. Regeneration of chip surface was performed twice using 20 mM 
NaOH in between the successive steps. A standard curve was constructed using the sorghum 
samples. The accuracy of measurement was evaluated through inter-day (n=3) and intra-day 
(n=5) analyses. The final working concentration of ZEN was 0.0039-1 µg/mL. The limit of 
blank (LOB) was determined by passing equal volumes of 1/100 dilution of antibody and 
sorghum extract that was free from ZEN contamination (n=20).   
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2.2.5 Isolation and purification of IgY raised against T-2 toxin  
2.2.5.1 Immunization of chicken 
A leghorn chicken was immunized with 1 mL of 200 µg/mL of T-2-KLH-Fruend’s complete 
adjuvant for the initial boost followed by three subsequent boosts with Fruend’s incomplete 
adjuvant in the ratio of 1:1, with a time interval of 3 weeks between each boost. After the third 
boost the chicken was bled and the serum isolated. A bleed was taken from the same chicken 
prior to immunization. The antibody response of the chicken for T-2 toxin was determined by 
an indirect ELISA. 
 
2.2.5.2 Determination of serum antibody titre (indirect ELISA) to T-2 toxin 
A microtitre plate was coated overnight with 5 µg/mL of either T-2-BSA conjugate in PBS (4 
rows), BSA in PBS (2 rows) or KLH in PBS (2 rows). The titre was determined (as in section 
2.2.2.2.) with the exceptions that the anti-chicken HRP-labelled rabbit secondary antibody  was 
used instead of anti-mouse AP-labelled goat secondary antibody, TMB in place of pNPP as 
substrate and the absorbance measured at 450 nm on Tecan Saffire plate reader.  
 
2.2.5.3 Isolation of IgY from egg yolks 
Eggs were collected from the immunized chicken after the third and fourth boost and stored at 
40C. The isolation of IgY was performed using the ‘Eggcellent’ chicken IgY purification kit. 
This kit consists of delipidating agent and IgY precipitation reagent. The egg shell was broken 
and the egg white along with the yolk were placed in an yolk separator provided with the IgY 
purification kit.  The egg white was drained completely into a waste beaker. The yolk left in the 
yolk separator, was washed with distilled water. The washing of the yolk was followed by 
rolling the yolk on a piece of tissue to ensure removal of any adhering materials to the yolk 
surface. The egg yolk sac was pierced at one point to drain off egg yolk leaving behind the yolk 
sac. The yolk was collected in a weighed beaker. The beaker was weighed once again to 
determine the amount of yolk (12.5 g) obtained. Assuming 1 mL of yolk = 1 g as per the 
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instructions given in the kit, five times the yolk volume of delipidating agent (62.5 mL) 
provided was added to the yolk. The resulting solution was mixed gently and left to incubate at 
40C for 2 hrs. The mixture was centrifuged at 40C (10,000 xg for 15 mins). The supernatant was 
decanted and the volume was measured in a volumetric cylinder. Equal volumes of IgY 
precipitating reagent were added to the supernatant. It was stirred gently and left static at 40C 
for 2 hrs. The mixture was centrifuged for 15 mins at 10,000 xg at 40C. The pellet was 
dissolved in 150 mM PBS (pH 7.4), whose volume corresponds to the original yolk volume. 
 
2.2.5.4 Purification of IgY using T-2-immobilized amine-activated beads 
2.2.5.4.1 Immobilization of T-2 on amine-activated beads 
T-2 (5 mg) toxin was dissolved in 200 µL of DMSO and 5 mg of carbonyldiimidazole (CDI) 
was added and stirred for 1 hr at room temperature. The amine-activated beads were pre-
packed in a column and equilibrated with 10 mL of coupling buffer (0.1 M MES, 0.9% (w/v) 
NaCl, pH 4.7). The buffer was drained off and the T-2-CDI with 0.5 mL of coupling buffer was 
added and mixed on a roller for 2 hrs at room temperature and then at 40C overnight. The 
following day, the column was washed with 4 mL of wash buffer (1 M NaCl). The washing 
step was followed by equilibration of the column with 150 mM PBS (pH 7.4) containing 0.05% 
(w/v) sodium azide.  
 
2.2.5.4.2 Purification of IgY using T-2-immobilized column 
The T-2 toxin immobilized beads in the column were equilibrated with 6 mL of 150 mM PBS 
(pH 7.4). The PBS used for equilibration was drained off and 5 mL of the crude IgY (section 
2.2.5.3) solution was then added to the equilibrated column and incubated at room temperature 
for 1 hr. After incubation the column was washed with sample buffer (4 mL X 3). The bound 
IgY was eluted from the column using 8 mL of 100 mM glycine-HCl in water (pH 3.0). Each 1 
mL eluted fraction of IgY collected was neutralized with 50 µL of 1 M Tris (pH 9.0).  
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2.2.5.5 IgY analysis  
2.2.5.5.1 Indirect and competitive inhibition ELISA using anti-T-2 IgY 
A 96 well Nunc microtitre plate was coated overnight at 40C with 5 µg/mL of T-2-BSA 
conjugate. The plate was washed once with 150 mM PBS (pH 7.4), followed by blocking of the 
microtitre plate with 200 µL of 4% (w/v) milk Marvel PBS for 1 hr. Out of the six rows that 
were coated with T-2-BSA conjugate, three rows were used for the determination of the 
titration value of crude IgY. The remaining three rows were used for the titre determination of 
purified IgY. A dilution range from 1:100 to 1:512,000 of both the crude and purified IgY were 
made and 100 µL of these were added to the individual wells of the microtitre plate. The 
addition of IgY was followed by the incubation of the plate at 370C for 1 hr. Then 100 µL of 
1:1,000 dilution of anti-chicken HRP-labelled rabbit antibody in 2% (w/v) milk Marvel PBST 
were added and incubated at 370C for 1 hr. Washing of the plates was performed three times 
with PBST and PBS. TMB substrate solution (100 µL) was added and incubated at room 
temperature for 20 mins followed by stopping of the reaction with the addition of 50 µL of 1 M 
HCl. Absorbances were read at 450 nm on Tecan Saffire plate reader.     
  
2.2.5.5.2 Cross reactivity of anti-T-2 toxin IgY  
Cross reactivity of both affinity-purified and unpurified IgY were subjected to competitive 
ELISA. The ELISA procedure is similar to that outlined in section 2.5, with one exception i.e., 
the usage of 1/2,500 dilution of antibody that was pre-incubated with known concentrations 
(0.007-1 µg/mL) of antigens (T-2, HT-2, Deoxynivalenol, Zearalenone and Fumonisin B1). The 
absorbance IgY in presence of antigen was divided by the absorbance of IgY alone (A/A0). A 
semi-log plot was generated with A/A0 values on Y-axis versus log concentration of antigen on 
X-axis.   
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2.2.5.5.3 FPLC analysis of IgY 
IgY purity was analyzed by gel filtration chromatography. The Sephacryl S-200 HR column, 
(45 mL bed volume) was equilibrated with 10 mM HEPES containing 118 mM NaCl (pH 7.3) 
buffer at a flow rate of 1 mL/min for a duration of 180 mins using an AKTA explorer 100 (GE 
Healthcare, UK). Monitoring of absorbance at 280 nm revealed the presence of IgY, which was 
confirmed by running different molecular weight markers, under similar conditions, for 
calibration. 
 
2.2.5.5.4 MALDI-TOF analysis of IgY 
The mass analysis of IgY was performed by MALDI-TOF mass spectrometry (Bruker 
Analytical Systems) in University of Joseph Fourier by Prof. Eric Defrancq. The matrix 
(sinapinic acid solution) was prepared at a concentration of 15 mg/mL in acetonitrile. IgY was 
dialyzed with distilled water using Viva spin column (M. Wt. ‘cut-off’: 30 kDa) and IgY was 
made to a final concentration of 1.0 mg/mL. The IgY sample and matrix solution were mixed in 
equal amounts (1 µL each) with 0.1% (v/v) trifluro acetic acid and added on to the chip. The 
samples were allowed to dry at in a vaccum desiccator and then used for mass analysis. The 
data were acquired in the linear mode at 30 kV and analyzed using the Compass software suite 
(MALDI software).  
 
2.2.5.5.5 SDS-PAGE analysis of IgY 
The IgY sample was run on an SDS-PAGE gel under reducing and non-reducing conditions, 
before and after purification, on T-2 toxin-immobilized sepharose beads. For non-reducing 
conditions the sample was boiled with the loading dye in the absence of DTT, which is the 
reducing agent. A detailed description of the conditions for SDS-PAGE analysis was given in 
section 2.2.3.17.2. 
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2.2.5.6 Immobilization of T-2 toxin on CM5 sensor chip 
Immobilization of T-2 toxin on a CM5 chip was performed manually on the bench by first 
equilibrating the chip with HEPES buffer (50 µL) at room temperature for 15 mins. The chip 
was then surface-activated by incubating at room temperature with 1:1 mixture of 0.4 M EDC/ 
0.1 N NHS for 30 mins, and washed carefully with de-ionized water. Then, 20% (v/v) of 
Jeffamine, in 50 mM carbonate buffer (pH 8.5), was applied to the chip and incubated for 1 hr 
at room temperature and the chip was then washed once with de-ionized water. The un-reacted 
amine sites on the chip were blocked with 1 M ethanolamine (pH 8.5) for 30 mins by 
incubation at room temperature and then washed once with de-ionised water. The T-2-
carbamate was diluted in 1:1 ratio with 10 mM of sodium bicarbonate solution (pH 8.0) and 
incubated on the chip for 24 hrs at room temperature. 
 
2.2.5.7 SPR-based inhibition assay and its validation 
The CM5 chip immobilized with T-2 toxin, was docked into the Biacore machine. This was 
followed by the injection of 1/2,500 dilution of anti-T-2 IgY. Non-specific antibody (anti-AFB1 
Fab antibody) was used to confirm that the binding occurred only between the T-2 toxin and 
antibodies raised against that toxin. A 1/2,500 dilution of the anti-T-2 IgY was incubated with 
equal volumes of known amounts of T-2 toxin (ranging from 0.007-1 µg/mL) and passed over 
the sensor chip at a flow rate of 15 µL/min for 90 sec. The chip was regenerated with 15 µL of 
40 mM NaOH and 30 mM HCl after each cycle for 30 sec at a flow rate of 30 µL/min. 
Response of the IgY in the presence of varying concentrations of T-2 toxin (R) was divided by 
the responses of IgY in the absence of T-2 toxin (R0) and four parameter logistic curve was 
fitted with R/R0 value on Y-axis versus log concentration of T-2 toxin on X-axis. 
Wheat samples (10 g) were ground and extracted with 30 mL ethanol/water 85:15 (v/v) by 
constant stirring on a magnetic stirrer for 30 mins. The extract was filtered through Whatman 
Grade 1 filter paper. The filtrate was evaporated to dryness in a rotary evaporator and dissolved 
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in 10 mL HBS buffer (pH 7.4), after which known amounts of T-2 toxins (0.007-1 µg/mL) 
were added and an SPR-based inhibition assay, as described above was performed. The LOD 
(limit of blank (LOB) + 3 S.D. of LOB) and LOQ (LOB + 10 S.D. of LOB) of the assay were 
determined.    
 
2.2.6 Assay format development 
2.2.6.1 Covalent immobilization of AFB1 
2.2.6.1.1 Passivation and amine functionalization of microtitre plate surfaces 
Individual wells of the microtitre plate were first cleaned three times with 250 µL of distilled 
water. The wells were incubated with 250 µL of freshly prepared piranha solution (1:3 
H2O2:conc.H2SO4) for 1 hr with constant shaking at 37
0C. The plate was then washed three 
times with 250 µL distilled water. Then 250 µL of 5% (v/v) APTES in distilled water was 
added to each well and incubated at 600C for 1 hr. The amine-functionalized wells were washed 
three times with 250 µL of 30% (v/v) ethanol in water and once with PBS and then with 
distilled water to remove excess APTES from the wells. The plates were dried at 800C for 1 hr.  
 
2.2.6.1.2 Synthesis of AFB1-CMO-NHS ester 
AFB1 (1 mg) was dissolved in 250 µL of ethanol and 50 µL of 1 M NaOH was added. The 
mixture was then stirred for 15 mins at room temperature after the addition of 
carboxylhydroxylamine hydrochloride (10 mg). The mixture was refluxed in an oil bath for 3 
hrs, with constant stirring, followed by overnight stirring at room temperature. The solvent was 
evaporated in a Speed Vac apparatus. The residue was dissolved in 300 µL of water. The pH of 
the aqueous solution was adjusted to 9.1 using 0.5 M NaOH and then the un-reacted AFB1 was 
extracted with 500 µL of ethylacetate. The pH of aqueous layer was adjusted to 2.0 using 6 M 
HCl, followed by extraction with 500 µL of ethylacetate to obtain AFB1-CMO (aflatoxin B1- 
carboxymethyl oxime). The solvent was evaporated in a Speed Vac apparatus and the product 
was confirmed by TLC performed on silica gel plates (10 X 20 cm) with a fluorescent indicator 
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(254 nm) developed in methanol:dichloromethane (7:3). AFB1-CMO (1 mg) was dissolved in 
200 µL of dioxane. DCC (1.5 equivalents) and NHS (1.5 equivalents) were added and the 
reaction mixture was stirred overnight at room temperature. The precipitated dicyclohexyl urea 
was then removed by centrifugation at 18,625 xg for 10 mins at room temperature in an Hermle 
Z233 MK-2 centrifuge with a 220.87.V05 rotor. The presence of the NHS ester was confirmed 
by TLC using silica gel plates with a fluorescent indicator (254 nm) developed in 
methanol:dichloromethane (7:3; by volume). 
 
2.2.6.1.3 Immobilization of the AFB1-CMO-NHS ester onto microtitre plates 
The NHS ester in 1, 4-dioxane was dissolved in 1 M sodium hydrogen carbonate buffer (pH 
9.4). To determine the optimal concentration of AFB1-CMO-NHS ester for efficient signal 
generation, a checker board ELISA was performed by varying the NHS ester concentration (25, 
50, 100 and 200 µg/mL). Indirect ELISA assays were performed. Optimization of the covalent 
attachment of the ester on amine-modified plates was performed by overnight incubation of the 
individual wells with 100 µL of ester at three temperatures, namely 40C, 370C and room 
temperature. Competitive assays were performed using plates incubated at the three 
temperatures. The IC50 value, which is half the maximal inhibitory value of the antibody in the 
presence of free antigen, was determined.  
 
2.2.6.1.4 Electrospray ionization (ESI) mass analysis 
Cleavage of the AFB1-CMO-NH-(CH2)3-Si-O-polystyrene from the wells of the microtitre 
plate covalently-immobilized with AFB1 was performed through incubating the wells with 1 M 
TBAF in H2O. The cleaved TBAF product was purified using a C18 reverse phase column. The 
elution of the sample was performed using a mixture (1:1; by volume) of acetonitrile and water. 
The purified sample was dried in a Speed Vac apparatus and was dissolved in LC/MS grade 
acetonitrile and water in the ratio of 1:1 (v/v). The sample (100 µL) was injected into the ESI 
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mass spectrometer and analyzed in positive mode with a range from 300-600 Da to determine 
the molecular mass of the cleaved product.  
 
2.2.6.1.5  Fluorescence assay for the determination of the covalently immobilized AFB1 
Individual wells of the microtitre plate were incubated with 150 µL of 1 M 
tetrabutylammonium fluoride (TBAF) in H2O for 60 mins at room temperature. A similar 
incubation procedure was performed with APTES-modified, unmodified and passively 
adsorbed (AFB1-BSA conjugate-coated) wells as negative controls. A set volume of TBAF 
solution was removed from the wells and added to the individual wells of a fresh F96 Nunc 
black maxisorb microtitre plate. The fluorescence intensities were measured at 360/440 nm 
(Excitation/Emission) against standard AFB1 concentrations (2.5-25 µg/mL of AFB1). The 
loading value of AFB1 was estimated using a calibration curve. 
 
2.2.6.1.6  Indirect and competitive inhibition assay  
These two types of ELISAs were performed in accordance with the procedure outlined in 
section 2.2.3.14 except that 5 µg/mL of AFB1-BSA was used to coat the plate and AFB1 
(0.0048-5 µg/mL concentration) was used for inhibition. 
 
2.2.6.1.7 Extraction of AFB1 from corn samples and validation of competitive inhibition 
assay performed on covalently immobilized microtitre plates 
Reference corn material (TR-A100) (10 g) was extracted for 30 mins with 40 mL of 85% (v/v) 
methanol in the presence of 500 mg of celite filter aid and 500 mg of sodium chloride. The 
extract was centrifuged at 2108 xg for 30 mins at 40C and filtered using Whatman filter paper. 
The solvent was evaporated in a rotary evaporator and the residue was diluted in 40% (v/v) 
methanol in water. The concentration of AFB1 in the crude extract was quantified by 
fluorescence estimation at 360/440 nm (Excitation/Emission) using standard calibration curve 
(slope equation y = 361.7x (R2 = 0.99)) with known amounts of AFB1 (10-320 ng/mL) diluted 
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in 40% (v/v) methanol in water. Similarly 10 samples of corn (each 10 g) were extracted. The 
corn extract was used to perform competitive ELISA on AFB1 covalently immobilized 
microtitre plates (section 2.2.6.1.6). 
 
2.2.6.2 Immuno-affinity column for the detection of AFB1, AFB2 and ZEN  
2.2.6.2.1  Preparation of Immuno-column 
To confirm the covalent immobilization using allylated chemistry, the CC grade/Wakosil silica 
for covalent immobilization of protein (BSA and AFB1 antibody) was chosen. Protein was 
attached to silica through the cysteamine and disuccinic ester of sebacic acid linkers. The 
attachment of linkers to the silica was confirmed by NHS ester and amino groups on the surface 
of silica. Protein was estimated using the BCA assay. The various stages involved are as shown 
in Figure 2.4. 
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Figure 2.4: Schematic representation of the stages involved in the immobilization of recombinant 
antibodies onto the Wakosil silica and assessing the function of the column.  
 
2.2.6.2.2 Immobilization of allyloxy silane (Stage I) 
2.2.6.2.2.1 Passivation of silica 
Sixty mL of 15% (v/v) HCl were added to 7 g of silica in a 250 mL single neck round bottom 
flask. The mixture was sonicated for 3 hrs at room temperature. After sonication another 80 mL 
of 15% (v/v) HCl was added to the reaction mixture and this was refluxed overnight at 1300C 
with gentle stirring. The reaction mixture was filtered on a sintered crucible followed by four 
washes with 20 mL of distilled water. The silica was dried overnight at 1000C.  
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2.2.6.2.2.2 Allylation of silica 
Azeotropic distillation of silica (5 g) was performed with toluene (60 mL) for 30 mins and then 
silica was filtered on a sintered crucible. Toluene (60 mL) and 5 mL of allyloxysilane were 
added to the dried silica. The reaction mixture was refluxed at 1200C for 24 hrs with stirring. 
The reaction mixture was filtered on a sintered crucible and then washed with toluene (3 X 30 
mL), THF (3 X 30 mL) and acetone (2 X 20 mL). 
 
2.2.6.2.3 Immobilization of cysteamine (Stage II)   
Sixty mL of methanol and 1 g of cysteamine were added to 5 g of silica in a 150 mL round 
bottom flask. This mixture was exposed to UV illumination (λ 300 nm) for 24 hrs. The silica 
was filtered on a sintered crucible, and then washed with methanol (3 X 20 mL) and acetone (1 
X 20 mL). The silica was dried in an oven at 800C for 30 mins. Amine estimation was 
performed using the ninhydrin assay with 4 N sodium acetate and SnCl2 against the standard 
cysteamine solution.  
Amine assay procedure:  Ninety mg of ninhydrin was dissolved in 3.4 mL of ethylene glycol. 
To this, 112.5 µL of SnCl2 solution (12 mg/120 µL) and 1.125 mL of 4 N sodium acetate were 
added. One hundred µL of the assay solution was added to 25 µL of each sample, control and 
standard. All samples were assayed in triplicate. The mixture was heated to 900C for 15 mins 
then cooled to room temperature and the absorbance was read at 575 nm on a Tecan Saffire 
plate reader. 
 
2.2.6.2.4 Immobilization of sebacic acid (Stage III) 
Aminated silica (500 mg) was transferred into a 10 mL round bottom flask and then 3 mL of 
DMF and 100 mg of sebacic acid were added. The reaction mixture was stirred overnight at 
room temperature and then filtered on a sintered crucible. The silica was washed with DMF (2 
X 5 mL), methanol (1 X 5 mL) and acetone (1 X 5 mL). A control experiment was carried out 
using 500 mg of unmodified silica, which was incubated with sebacic acid in DMF overnight 
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followed by filtration and washing with DMF (2 X 5 mL), methanol (1 X 5 mL) and acetone (1 
X 5 mL). The attachment of sebacic acid was confirmed by NHS ester assay against N-
hydroxysuccinamide as standard.    
NHS ester assay procedure:  Two mL of 0.067 M phosphate buffer (pH 7.4) were added to the 
modified silica (20 mg). The reaction mixture was stirred for 3 hrs followed by filtration and 
the absorbance was read at 260 nm on a Tecan Saffire plate reader to estimate the number of 
carboxyl functional groups. 
 
2.2.6.2.5 BSA immobilization (Stage IV) 
NHS-modified silica (Stage III) (200 mg) was placed in a 10 mL round bottom flask and three 
mL of phosphate buffer (0.067 M, pH 7.6) and 20 mg of BSA were then added. The reaction 
mixture was stirred for 4 hrs at room temperature. The silica was filtered on a sintered crucible 
and then washed with phosphate buffer (3 X 4 mL). Two hundred µL of acetone was added for 
drying. An estimation of bound protein was determined by a BCA assay using BSA as the 
standard.  BSA was incubated with unmodified silica as a control. 
Assay Procedure:  BCA assay reagent was prepared as per the Pierce kit instructions (Reagent 
A 10 mL + Reagent B 0.2 mL). The standard concentrations of BSA and silica (control, 
incubated & conjugated) were prepared in 200 µL of BCA reagent. The reaction mixture was 
incubated at 370C for 30 mins followed by cooling to room temperature and the absorbance 
was read at 562 nm. 
 
2.2.6.2.6 Anti-AFB1, B2 & ZEN antibody immobilization (Stage IV) 
We observed a lower loading value for protein adsorption on CC grade silica. Therefore, 
Wakosil grade silica was selected instead of CC grade silica to improve the loading of protein. 
This silica is less porous than CC grade silica and is commercially available. The same process 
was repeated for steps 2.2.6.2.2 to 2.2.6.2.5 using anti-AFB1, B2 & ZEN recombinant 
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antibodies instead of BSA. The amount of bound antibody on silica was estimated by the BCA 
assay.  
 
2.2.6.2.7 Elution protocol for immuno-column (Stage V) 
In order to check the toxins binding capacity to the immuno-affinity column, first recombinant 
antibody coupled silica beads (200 mg) were added to the individual columns. Ten micrograms 
of AFB1, B2 and ZEN in 500 µL of PBS were added to the specific columns. The reaction 
mixtures were stirred for 2 hrs at room temperature followed by washing with PBS and PBST. 
The fluorescence intensity of these washes was measured at 360/420 nm (Emission/Excitation) 
for AFB1 or B2 and 236/440 nm (Emission/Excitation) for ZEN. Washes were repeated until a 
constant reading was observed. Once the fluorescence reading was stabilized, the toxins bound 
to the silica were eluted with 1 mL of methanol. The control experiment was performed with 
unmodified silica, which was incubated with toxins and then eluted with methanol.  
 
2.2.6.3 MBio assay for the simultaneous detection of AFB1, B2, ZEN and T-2 toxins 
2.2.6.3.1 Imprinting of cartridges with conjugates of AFB1, B2, ZEN and T-2 toxins 
The imprinting of mycotoxin conjugates (50 µg/mL) were performed using a Bio-Dot AD3200 
robotic arrayer equipped with a Bio-Jet print head dispensing 28-nanoliter droplets by            
Precision photonics with 22 dots per row in duplicates.  
 
2.2.6.3.2 Alexa-647 labelling of recombinant antibodies 
2.2.6.3.2.1 Preparation of NHS ester of 4-formylbenzoic acid  
4-formylbenzoic acid (10 mg) was dissolved in 200 µL of DMSO and then NHS (0.8 mg) and 
DCC (1.4 mg) were added. The reaction mixture was stirred for overnight at room temperature. 
The solvent was evaporated in a rotary evaporator (Buchi, Germany). The crude residue was 
loaded onto column (CH2Cl2:MeOH; 7:3) to obtain the NHS ester in 50% yield.  
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2.2.6.3.2.2 Preparation of Alexa 647 labelled antibody 
Recombinant antibody (2 mg/mL, 100 µL) in 1X PBS (pH 7.4) was added to an above NHS 
ester (0.5 mg) and then stirred at room temperature for 2 hrs followed by dialyzing (buffer 
exchanging) with sodium acetate (150 mM, pH 6.0) using desalting column (Thermo Pierce, 
0.5 mL). This was followed by addition of Alexa-647 aminooxyacetamide (10 µL, 1 mg/mL in 
DMF) and incubated for 1 hr. The mixture was dialyzed (buffer exchanged) with 1X PBS using 
Vivaspin column (M. Wt ‘cut-off’: 5 kDa). 
 
2.2.6.3.3 Direct binding assay  
Direct binding assay was perfromed by the additon of 1/100 dilution of Alexa-647 labelled  
anti-AFB1, B2, ZEN and T-2 antibodies in 4% (w/v) milk Marvel to the MBio cartridge that 
was inprinted with AFB1, B2, ZEN and T-2 BSA conjugates and incubated at room temperature 
for 20 mins. The flourescence intensity was recorded on an MBio snapshot machine.   
 
2.3 Data analysis 
 1. The IC50 value was calculated using the four parametric logistic function  
  Fifty = (Top+Baseline)/2 
  Y = Bottom + (Top-Bottom)/(1+10^((LogIC50-X)*HillSlope + log((Top- 
        Bottom)/(Fifty-Bottom)-1)))  
  2. Limit of detection (LOD) 
  LOD = LOB + 3 S.D. of LOB, where LOB is the limit of blank 
 3. Limit of quantification (LOQ) 
  LOQ = LOB + 10 S.D. of LOB, where LOB is the limit of blank 
 4. Conversion units  
  1 ppb = ng/mL = µg/kg 
 
 107 
 
 
 
 
 
 
 
Chapter 3 
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3.1 Introduction  
 
Aflatoxins are major food contaminants produced by Aspergillus species. AFB2 is toxic and  
although reports reveal the presence of AFB2 along with AFB1 (Juan et al., 2008), this issue has 
not been extensively studied. To-date, the antibodies generated for the detection of AFB2 were 
mainly monoclonal. These monoclonal antibodies exhibit a wide range of cross reactivity with 
other types of aflatoxins (Hastings et al., 1988; Cervino et al., 2008; Rieger et al., 2009). An 
attempt was made by Kalinichenko et al. (2010) to isolate an AFB2-specific antibody, through 
the generation of anti-AFB2 Fab from the parent monoclonal antibody. This resulted in a Fab 
antibody with similar cross reactivity characteristics as the parent monoclonal antibody.  
cDNA libraries are a true representation of the mRNA pool and these libraries facilitate the 
selection of highly specific antibody fragments with diverse affinities (Moroney and Pluckhun, 
2005). Hence recombinant approaches (Figure 3.1) were chosen for the generation of a specific 
and high sensitivity scFv to AFB2 for use in the development of an immuno-affinity column.  
Mice were immunized with AFB2-KLH, and the spleen used for the isolation of RNA and, 
subsequently, the antibody phage-display library was constructed to produce soluble scFv 
antibodies. The library generated was subjected to panning against AFB2-BSA, which yielded a 
number of AFB2-positive binders. The cross reactivity of the scFvs was investigated and anti-
AFB2-specific clones with no cross reactivity to other aflatoxin variants were obtained. A scFv-
E9, with an IC50 value of 8 ng/mL was selected and a SPR-based inhibition assay developed 
and applied for quantitative analysis of AFB2 in spiked almond samples.    
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Figure 3.1:  Approach employed for the generation of anti-AFB2 scFvs. The AFB2 library was 
generated from Balb/c mice immunized with a AFB2-KLH conjugate. Spleenomic RNA from a hyper-
immune mouse was used to synthesize cDNA. Variable heavy and light chains were amplified followed 
by SOE product generation and subsequent ligation and electroporation steps. The next stage was the 
selection of anti-AFB2 scFvs through biopanning, which utilizes phage for efficient propagation of 
antibody-encoding genes. Finally the analytical potential of scFvs was tested through competitive 
ELISA and SPR-based inhibition assays.     
 
3.2 Results 
3.2.1 Immune response to AFB2-KLH conjugate 
The immunization schedule, as outlined in section 2.2.2.1, was followed to elicit an immune 
response in Balb/c mice immunized with AFB2-KLH. The serum titre was determined after the 
third boost following the protocol described in section 2.2.3.1. With an indirect ELISA (Figure 
3.2), the serum titre (1/512,000) was deemed sufficient to utilize spleenomic RNA for the 
generation of a recombinant antibody library following a final intravenous boost.  
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Figure 3.2: Serum titre of a AFB2-KLH immunized mouse determined by indirect ELISA against 
AFB2-BSA. Doubling dilution of serum was added to the AFB2-BSA-coated microtitre plate and probed 
with anti-mouse-alkaline phosphatase-labelled secondary antibody (1/1,000). Finally, visualization was 
brought about through the addition of pNPP substrate. The final titre recorded against AFB2-BSA was 
in excess of 1/512,000. 
 
3.2.2 Reombinant scFv antibody library generation for AFB2    
3.2.2.1 RNA isolation and cDNA yields 
A spleen homogenized in TRIZOL reagent was used for the extraction of RNA using 
chloroform. The total yield of RNA was 11.4 µg/50 µL. RNA (4.5 ng) was used for the 
generation of cDNA (yield; 11.9 ng/µL), from which heavy and light chains were amplified 
(Figure 3.3).   
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Figure 3.3: Agarose gel showing the RNA, cDNA and amplified heavy and light chains. cDNA was 
synthesized from RNA by reverse transcription using Superscript III Kit. From the template cDNA 
variable heavy (VH) and light (VL) were amplified using the primers specific for mice and PCR products 
were run on 1% (w/v) agarose gel. The representation of the various lanes is as follows:  lane 1: 1 Kb
 
plus DNA ladder; lane 2: RNA; lane 3: cDNA; lane 4: VL and lane 5: VH. 
 
3.2.2.2 Optimization of buffer concentration 
The PCR reaction was optimized by varying the amount of MgCl2 (for heavy and light chain 
amplification) and MgSO4 (for SOE), as Mg
++ is an essential cofactor in the DNA 
polymerisation. 
 
3.2.2.2.1 Amplification of variable heavy and light chains 
For the amplification of variable heavy and light chain genes GoTaq® DNA polymerase was 
used. MgCl2 concentrations of 1, 1.5, 2 & 3 mM were used to determine the optimal 
concentration of MgCl2, for better amplification of the gene. A negative PCR reaction without 
the template cDNA was also performed. The PCR products were resolved on 1% (w/v) agarose 
gel. The presence of bands at approximately 330 bp (Figure 3.4), indicated amplification of 
variable heavy and light chains.  
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Figure 3.4: Optimization of magnesium concentration for amplification of Vk (a), Vʎ (b) and VH (c). 
The PCR reaction mixture is composed of 0.5 µL of cDNA, 100 pmol of mouse primers, 5x PCR buffer, 
200 µM dNTPs, 0.25 µL of GoTaq® DNA Polymerase and 1-3 mM of MgCl2. The PCR amplification 
conditions were as follows: initialization for 5 mins at 94
0
C; 30 cycles of denaturation; annealing and 
elongation for 15, 30, 90 sec at 94
0
, 56
0
 and 72
0
C, respectively; followed by the final elongation step for 
10 mins at 72
0
C. The representation of the various lanes is as follows: lane 1: 1 Kb plus DNA ladder; 
lane 2: negative PCR reaction; lanes 3-6: PCR products amplified using four different concentrations 
of MgCl2 (1, 1.5, 2 & 3 mM). 
 
The lack of band in the second lane of Figure 3.4 indicates lack of non-specific amplification 
(negative PCR reaction). MgCl2 (1.5 mM) was used to perform large-scale amplification (20X) 
reactions of the variable heavy and light chains. Immediately after scale-up the PCR mixtures 
were ethanol-precipitated and gel-purified using a Nucleospin Extract II kit. The final yields 
were 27.3 µg (VH), 34.2 µg (Vʎ) and 12.4 µg (Vk) per 220 µL, as determined on the 
NanodropTM (A260 nm). 
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3.2.2.2.2 Splice overlap extension (SOE) 
The amplified heavy and light chain genes were linked together using a Platinum® Taq DNA 
polymerase Hi Fidelity, in the presence of the SOE primers and dNTPs. MgSO4 concentrations 
of 1, 1.5, 2 and 4 mM were used to attain a PCR product of approximately 750 bp (Figure 3.5). 
Scale up of SOE was performed using 4 mM of SOE. The total SOE yields were 13.5 µg/ 240 
µL (SOE (k)) and 11 µg/ 240 µL (SOE (ʎ)). 
(a) (b)
850 bp
850 bp
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Figure 3.5: Optimization of MgSO4 concentration for SOE(k) (a) and SOE(ʎ) (b). The PCR reaction 
mixture is composed of 100 ng of VL and VH , 100 pmol of CSC-F and CSC-B, 10x PCR buffer, 200 µM 
dNTPs, 0.2 µL of Platinum® Taq DNA polymerase and 1-4 mM of MgSO4. The PCR amplification 
conditions were as follows: initialization for 5 mins at 94
0
C; 30 cycles of denaturation; annealing and 
elongation for 30, 30, 120 sec at 94
0
, 56
0
 and 72
0
C, respectively; followed by the final elongation step 
for 10 mins at 72
0
C. The representation of the various lanes is as follows: lane 1: 1 Kb plus DNA 
ladder; lane 2: negative PCR reaction; lanes 3-6: SOE obtained using four different concentrations of 
MgSO4 (1, 1.5, 2 & 4 mM). 
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3.2.2.2.3 Restriction digestion and ligation of SOE and plasmid 
The plasmid was digested with SfiI, XbaI and XhoI, which cuts the vector into three fragments 
consisting of the digested PCR product (1500 bp), the digested vector (3400 bp) and the stuffer 
fragment (1600 bp) (Figure 3.6). The SOE (SOE (k) 9.4 ng & SOE (ʎ) 11 ng) was digested 
with SfiI alone (Figure 3.6). Both the restriction digested plasmid and SOE (k & ʎ) were 
ethanol-precipitated and gel purified using a Nucleospin Extract II kit. The total yields of 
plasmid, SOE (k) and SOE (ʎ) after restriction digestion were 14.5 µg, 2.6 µg and 7.8 µg, 
respectively as determined on the NanodropTM (A260 nm). The SOE and plasmid (700 ng:1400 
ng) were ligated together using T4 DNA ligase for 18 hrs at 270C.   
5000 bp
2000 bp
850 bp
1 2 3 4 5
 
 
Figure 3.6: Agarose gel image showing the restriction digestion pattern of SOE and plasmid. The 
reaction mixture is composed of 10 µg of SOE, 360 units of SfiI,  20 µL of 10x reaction buffer and 3 µL 
of  100x BSA. Restriction digestion of vector was carried out using 20 µg of vector, 120 of SfiI,  20 µL 
of 10x reaction buffer and 1 µL of 100x BSA. Both SOE and vector were SfiI digested for 5 hrs at 50
0
C, 
after which the vector was further treated with XhoI, XbaI and Antarctic phosphatase. The 
representation of the various lanes is as follows: lane 1: 1 Kb plus DNA ladder; lane 2:  plasmid; lane 
3: SfiI, XbaI and XhoI restriction digested plasmid; lane 4: SOE and lane 5: SfiI restriction digested 
SOE. 
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3.2.3 Biopanning of recombinant AFB2 library    
3.2.3.1 Selection of AFB2-specific phage particles  
The ligation mixture was electroporated into XL1-Blue electrocompetent cells. An scFv 
antibody library of 2.19 X 107 cfu/mL was obtained. This was subsequently panned on AFB2-
BSA (250, 125, 50, 25 and 5 µg/mL in 1X PBS) coated surfaces of immunotubes. After each 
successive round of panning the stringency of washes were increased. Input and output phage 
titres after each round of panning were determined (Table 3.1) using the formula:  
No. of colonies X dilution factor  
              plated volume 
 
Table 3.1: Inputs and outputs from different rounds of panning 
  
Round   Input titre (cfu/mL)    Output titre (cfu/mL) 
 
Round 1 
      
      1 X 1012 
      
         9 X 107 
Round 2       3 X 1011          2 X 106 
Round 3       1 X 1011          0.8 X 104 
Round 4       1 X 1012          3 X 104 
Round 5       2 X 1012          1 X 105 
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3.2.3.2 Polyclonal phage ELISA indicating AFB2-specific phage enrichment  
Rescued phage particles, obtained after each round of panning, were analyzed for specific 
AFB2-BSA (antigen) binding activity through polyclonal phage ELISA (Figure 3.7). An 
increase in the specific signal was evident from the phage collected after subjecting to fifth 
round of panning against AFB2-BSA. Minimal background signal was obtained when phage 
was tested against BSA and milk Marvel (negative controls). The pool of phage posses 
different recombinant scFv fragments with varying affinities towards the target. These were 
infected into Top 10Fʹ cells for soluble expression. 
A
b
s
o
rb
a
n
c
e
 @
 4
5
0
 n
m
0
1
2
3
4
0 1 2 3 4 5
Rounds of panning
AFB2-BSA BSA Milk Marvel
Phage binding affinity to: 
 
 
Figure 3.7: Polyclonal phage ELISA of the AFB2-panned library against AFB2-BSA. Each of the 
analytes (AFB2-BSA, BSA & milk Marvel) were coated on a microtitre plate (in triplicate). The phage 
(1/10 dilution) from different rounds of panning were added and probed with HRP-labelled mouse anti-
M13 monoclonal antibody. Visualization with TMB solution was followed by absorbance reading. 
Significant enrichment of phage from fifth round of panning was noticed, which indicates the presence 
of more number of AFB2-positive binders.  
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3.2.3.3 Monoclonal ELISA for AFB2 positive binders 
Three hundred and eighty four individual colonies were picked, grown up and induced with 
IPTG. Each clone was tested on three different plates that were coated with either AFB2-BSA, 
BSA (negative control) and KLH (negative control). The scFv-producing clones were found to 
be highly specific to AFB2 with about 95% positive signal (Figure 3.8). No significant binding 
of the scFv-producing clones to BSA (Figure 3.9) or KLH (Figure 3.10) was recorded.  
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Figure 3.8: Graphical representation of monoclonal ELISA performed on anti-AFB2 scFv-producing 
clones against AFB2-BSA-coated microtitre plates. The ELISA was performed using colonies picked 
from the fifth round of panning. A 1/2 dilution of supernatants were added to AFB2-BSA coated and 
blocked plate. HRP-labelled rat anti-HA monoclonal (1/1,000) antibody was added followed by the 
detection using TMB solution. Figures a, b, c and d correspond to plates 1, 2, 3 and 4, respectively. The 
red line is the reference value, above which the clones were selected as AFB2-positive binders. 
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Figure 3.9: Graphical representation of monoclonal ELISA performed using anti-AFB2 scFv-
producing clones against BSA-coated microtitre plates. The supernatants (1/2 dilution) were added to 
5 µg/mL BSA coated and 4% (w/v) milk Marvel blocked plates. A 1/1,000 dilution of secondary 
antibody (HRP-labelled rat anti-HA monoclonal antibody) was added and visualization brought 
through addition of TMB. The lower absorbance (OD450nm<0.2) recorded clearly indicate lack of 
binding of the scFvs to BSA. Figures a, b, c and d correspond to plates 1, 2, 3 and 4, respectively. 
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Figure 3.10: Graphical representation of monoclonal ELISA performed with anti-AFB2 producing-
scFv clones against KLH-coated microtitre plates. ELISA plate was coated with 5 µg/mL of KLH and 
blocked with 4% (w/v) milk Marvel in PBS (pH 7.2). Diluted (1/2) supernatants were added to the wells. 
HRP-labelled rat anti-HA monoclonal antibody was used to detect binding of clones to KLH. The 
results (absorbance < 0.2 at OD450nm) clearly indicate lack of binding of the scFvs to KLH. Figures a, b, 
c and d correspond to plates 1, 2, 3 and 4, respectively. 
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3.2.3.4 Selection of anti-AFB2 scFvs  
Ten representative clones were picked from the positive clones and their AFB2 displacement 
was measured using a 1:1 mixture of 1/10 dilution of antibody and 20 µg/mL of AFB2. The 
results indicate that out of the ten anti-AFB2 scFvs only seven were able to recognize AFB2. 
Further cross reactivity studies and DNA finger printing analysis of the seven anti-AFB2 scFvs 
were carried out.     
 
3.2.3.4.1 Cross reactivity studies 
The cross reactivity of the seven anti-AFB2 scFvs to AFB1, G1, G2 and M1 was determined 
employing the procedure described in section 2.2.3.16. The IC50 value is defined as the point 
where the 50% reduction in the signal (in the presence of analyte) is noticed in comparison to 
the signal obtained in the presence of no analyte. The percentage cross reactivity was calculated 
was by taking the IC50 value of AFB2 as 100%. The calculation was done using the formula  
                % cross reactivity =           IC50 value of aflatoxins X 100 
                                                                 IC50 value of AFB2 
 
From the % cross reactivity data (Table 3.2) it was found that two scFvs (E9 and H12) were 
specifically recognizing AFB2 without exhibiting any cross reactivity to other aflatoxin 
congeners (AFB1, G1, G2 & M1). To further confirm the diversity of the clones, they were 
subjected to restriction digestion.  
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Table 3.2: Cross reactivity of seven anti-AFB2 scFvs. The cells in the table containing a dash 
indicates that the anti-AFB2 scFv does not  cross react with aflatoxin congeners    
  
                              % Cross reactivity     Clone 
   AFB1                              AFB2     AFG1    AFG2   AFM1 
 
A8 
 
     85 
 
     100 
 
      19 
 
     67 
 
     58 
D1      79      100       23      31      33 
H8      77      100       82      81      67 
H12       -      100        -       -       - 
E9       -      100        -       -       - 
A2      89      100       84      81     79 
A1      86      100       45      49     84 
 
3.2.3.4.2 DNA finger printing of anti-AFB2 scFvs 
Plasmids were isolated from all the seven scFv-expressing clones and splice overlap extension 
product (SOE) was amplified using specific primers. The digestion pattern of the SOE with an 
enzyme BstN1 was studied (Figure 3.11). Three types of digestion patterns were noticed, thus 
indicating the presence of three different types of scFvs. The digestion pattern of the two scFvs 
(E9 & H12) were similar. Later on these two scFvs (E9 & H12) were expressed in 500 mL 
culture volumes. The cells were lyzed through sonication, followed by the subsequent IMAC 
purification and buffer exchange processes.   
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1 2 3 4 5 6 7 8
 
 
Figure 3.11: DNA finger printing profile of the seven scFvs recognizing AFB2. The plasmids were 
isolated and SOE was amplified from all the clones and they were digested with BstN1 for 3 hrs at 50
0
C, 
after which they are resolved on 1% (w/v) agarose gel. The representation of the various lanes is as 
follows: lane 1: 1 Kb plus DNA ladder and  lanes 2-8: digestion pattern of scFvs- A1, A8, H8, D1, E9, 
A2 and H12 .  
 
3.2.3.5 Competitive inhibition ELISA for scFv-E9 & H12 
Competitive inhibition assay procedure outlined in section 2.2.3.15 was used to determine the 
IC50 values of the E9 and H12 clones. From Figure 3.12 it is apparent that the IC50 value of the 
scFv-H12 is higher than scFv-E9. The IC50, limit of detection and limit of quantification for 
scFv-E9 were 85, 3 & 14 ng/mL, respectively.  
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Figure 3.12: Competitive inhibition curves of scFv-E9 and H12. The scFvs (E9 & H12) were 
expressed in 500 mL culture and IMAC purified and incubated with varying concentrations of AFB2. 
The AFB2-antibody mixture was then added to the ELISA plate that was coated with 5 µg/mL of AFB2-
BSA and blocked with 4% (w/v) milk Marvel PBS. The IC50 value of scFv-E9 and H12 were recorded to 
be  85 ± 0.05 and 375 ± 0.12 ng/mL, respectively.  
 
3.2.3.6 Intra- and inter-day competitive inhibition ELISA using scFv-E9  
Purified scFv-E9 was used to develop an inhibition assay for the detection of AFB2 as 
described in section 2.2.3.15. The assay was performed using eleven AFB2 standards (0.9-1,000 
ng/mL), assayed thrice on the same day and repeated over five days. Figure 3.13 represents the 
intra- and inter-day inhibition standard cruve using SigmaPlot software. The percentage 
coefficients of variance, which indicates the precision of the both intra- and inter-day assays 
were tabulated (Table 3.3). The inter-day coefficient of variance of the assay was between 1.3 
and 10.1%.  
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Figure 3.13: Intra- (a) and inter- (b) day competitive inhibition assays with scFv-E9. A 5 µg/mL 
AFB2-BSA coating concentration was used with a 1/2,500 dilution of anti-AFB2 scFv that was 
incubated with AFB2 (0.9-1000 ng/mL). For intra-day (a) studies the S.D. was computed from 3 
validation run on the same day and inter-day (b) S.D. was determined over 5 validation runs on 5 
separate days. A 4-parameter logistic curve was fitted to the data set.     
 
Table 3.3: Intra- and inter-day coefficient of variance for the determination of free AFB2 using 
scFv-E9. Three sets of eleven standards were assayed three times on one day and five times on 
five  different days and CVs were calculated.  
 
                       Intra-day assay               Inter-day assay AFB2  
concentration 
(ng/mL) 
Back- 
calculated 
concentration 
(ng/mL)  
A/A0 %  
CVs 
%  
Accuracies 
Back- 
calculated 
concentration 
(ng/mL) 
A/A0 %  
CVs 
%  
Accuracies 
 
1000 
 
1033 
 
0.2681
 
 
3.72 
 
103.3 
 
998 
 
0.2270
 
 
7.2 
 
99.8 
500 477 0.2918
 
2.34 95.4 500 0.3576
 
3.4 100 
250 247.75 0.4356
 
2.86 99.1 235.5 0.4549
 
8.6 94.2 
125 145.87 0.7321
 
3.12 116.7 127.5 0.6549
 
1.3 102 
62.5 57 0.7448
 
2.5 91.2 64.12 0.7823
 
5.3 102.6 
31.2 27.41 0.8355
 
1.7 87.8 30.51 0.8233
 
7.2 97.8 
15.6 16.63 0.9815
 
2.01 106.6 15.6 0.9234
 
5.6 100 
7.8 7.93 0.9973
 
1.5 101.7 7.64 0.9425
 
10.1 97.9 
3.9 3.9 0.9980 5.15 100 3.86 0.9894
 
5.9 98.9 
1.9 1.89 1.0000
 
5.46 99.5 1.95 1.0425
 
5.4 102.6 
0.9 0.91 1.0040 4.11 101.1 0.9 1.0487 6.1 100 
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3.2.3.7 SDS-PAGE and western blot analysis of scFv-E9 
The purity of anti-AFB2 scFv-E9 after subjecting to IMAC purification was analyzed by SDS-
PAGE and western blotting using anti-HA HRP-labelled rat monoclonal antibody as described 
in section 2.2.3.17.2. A single band at approximately 27 kDa was visible, which represents the 
scFv (Figure 3.14).  
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Figure 3.14: SDS-PAGE (a) and western blotting (b) of scFv-E9 after subjecting to IMAC 
purification. A 12.5% SDS gel was run for 1.5 hrs at 100 V and the gel was stained with Commassie 
dye solution (Commassie blue R-250 (2 g), methanol (450 mL), acetic acid (100 mL) and water (450 
mL) and  destained overnight  at room temperature with mixture containing acetic acid, methanol and 
water in the ratio of 2:5:13. For western blotting the SDS-PAGE gel was transferred onto the 
nitrocellulose membrane for 15 mins at 15 V and the membrane was blocked with 4% (w/v) milk Marvel 
for 1 hr. This was probed with 1/5,000 dilution of anti-HA HRP-labelled rat monoclonal antibody, 
followed by visualization of band using TMB substrate. The representation of the various lanes is as 
follows: lane 1: Fermentas Pageruler plus marker and lane 2: IMAC purified E9 clone. The purified E9 
clone revealed the presence of scFv band at approximately 27 kDa.   
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3.2.3.8 Sequence of scFv-E9  
Plasmid DNA containing anti-AFB2 scFv-E9 & D1 inserts were send to Source Biosciences 
Ltd. for sequencing. The linear nucleotide sequences were subsequently translated (using 
Expasy translate tools) into amino acid sequences and presented in Figure 3.15.  
 
                      scFv-E9           C C X Q T K X X P L P A V V C L P X Q E L P T 
CDRL1  
                      scFv-D1          C X W X D R X P D W K A G S E R N A I N V S L T  
 
                      scFv-E9          T V L L V 
CDRL2       
                      scFv-D1          V E L A D N N  
 
                      scFv-E9          C L T G L D S R R   
CDRL3       
                      scFv-D1         T Q S H K F S T S V G   
 
                      scFv-E9          C T Q P S L E R T T 
CDRH1      
                       scFv-D1         C K A S Q D V G T A  
 
                      scFv-E9          L P E G R K A D R Y P V S G R V 
CDRH2      
                      scFv-D1          L I Y W A S T R H T G V P D R F T G S  
 
                      scFv-E9          C S S G G 
CDRH3      
                       scFv-D1         G A G T  
 
 
Figure 3.15: Deduced amino acid sequence of scFv-E9 and D1. The complementary determining 
regions (CDRs) were determined following Kabat rules.  
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3.2.3.9 CM5 chip immobilization with AFB2 
Immobilization of AFB2 (Figure 3.16) onto the dextran surfaces was performed as described in 
section 2.2.3.18. The carboxyl groups on the sensor chip surface were activated with mixture of 
EDC and NHS to produce reactive succinimide esters. Due to the lack of amine groups on 
AFB2, amine groups were created on the CM5 chip surface through the addition of Jeffamine. 
The carbonyl groups at position 1 of AFB2 were coupled directly to amino group of protein 
using CMO spacer (Cervino et al., 2007).  
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Figure 3.16: Schematic representation of immobilization procedure of AFB2 onto the CM5 chip. The 
first stage (a) involved in the immobilization of AFB2 onto CM5 chip was surface activation with EDC 
and NHS. In the second stage amine groups were generated through treating with Jeffamine (b). The 
third stage involves the covalent attachment of AFB2 to the amine groups on the CM5 chip (c).  
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3.2.3.10 Analysis of scFv-E9 on AFB2 immobilized sensor chip 
After immobilizing the CM5 chip with AFB2, varying dilutions (1/100, 200, 400 & 800) of 
IMAC purified scFv-E9 was passed over the sensor chip to record the optimal responses. A 
1/100 dilution of scFv-E9 (Figure 3.17) resulted in approximately 359.68 RU.  As negative 
control anti-CRP scFv antibody was passed over the AFB2 immobilized sensor chip, which 
doesn’t yield any notable responses. 
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Figure 3.17: Sensogram depicting the binding of E9 to AFB2 immobilized CM5 chip. A 1/100 dilution 
of scFv-E9 in HBS buffer was passed over flow cell 1 of the AFB2 immobilized sensor chip at a flow rate 
of 15 µL for 1 min. The net binding of response of E9 was 359.68 RU.  
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3.2.3.11 Kinetic analysis of scFv-E9 
The association (Ka) and dissociation (Kd) rate constants of the anti-AFB2-scFv-E9 were 
determined on SPR using the kinetic analysis command using varying concentrations of scFv-
E9 (43.7-350 nM). The data were evaluated using BIAevaluation software (Figure 3.18) KD 
value was found to be 2.8 (± 0.13) X 10-8 M, which indicates the nanomolar affinity to AFB2.  
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Figure 3.18: SPR-based kinetic analysis of scFv-E9. Four varying concentrations of scFv-E9 were 
injected over the AFB2 immobilized sensor chip. The values were fitted in 1:1 Langmuir binding model 
to measure the KD value.        
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3.2.3.12 SPR-based competitive inhibition assay using scFv-E9 
To assess the binding ability of anti-AFB2 scFv-E9 in solution phase, an inhibition assay was 
performed as described in section 2.2.3.21. In this assay, a 1:1 ratio of scFv-E9 was inhibited 
using varying concentration of AFB2 from 0.48-125 ng/mL at 37
0C for 30 mins. A calibration 
curve (Figure 3.19) was plotted with response units on Y-axis against known concentration of 
AFB2. The SPR analysis revealed that the scFv-E9 had an IC50 concentration of 8 ± 0.08 
ng/mL. The limits of detection and quantification were 0.9 ± 0.09 and 2.4 ± 0.1 ng/mL (Mean ± 
S.D.).   
In order to determine the accuracy and precision of the SPR-based inhibition assay, intra- and 
inter-day variability studies were performed (Figure 3.20). The results obtained from intra- and 
inter-day were presented in Table 3.4. The percentage coefficient of variance (% CVs) ranged 
from 1.7-8.9% and 0.9-8.3% as observed from intra- and inter-day studies, respectively, 
indicating good degree of precision of the SPR-based inhibition assay.  
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Figure 3.19: Representative SPR-based competitive inhibition curve for scFv-E9. A 1/100 dilution of 
scFv-E9 was incubated with 0.48-125 ng/mL of AFB2 at 37
0
C for 30 mins. This antigen antibody 
mixture was passed over the CM5 sensor chip immobilized with AFB2 toxin. The response units in the 
presence of varying concentration of AFB2 (R) along with the responses in the presence of zero AFB2 
(R0) concentration was recorded. R/R0 was calculated and the error bars indicate the standard 
deviation of three independent determinations.      
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Figure 3.20: Intra- (a) and inter-day (b) variations of SPR-based inhibition assay using scFv-E9 in 
solution.  A 1/100 dilution of anti-AFB2 scFv was incubated with 0.48-125 ng/mL of AFB2 and passed 
over the AFB2 immobilized sensor chip. The results were normalized by dividing the response units in 
presence of AFB2 (R) by the response units of zero concentration of antigen (R0) in the assay. For intra-
day (a) studies the S.D. was computed from 3 validation run on the same day and inter-day (b) S.D.s 
were determined over 5 validation runs on 5 separate days. A 4-parameter logistic curve was fitted to 
the data set.  
    
Table 3.4: Intra- and inter-day coefficient of variance (CVs) for anti-AFB2 scFv-E9 used in 
SPR-based inhibition assay described in section 2.2.3.21. CV was calculated using the formula  
% CV= (S.D./Mean) X 100. 
   
                        Intra-day assay        Inter-day assay AFB2  
concentration 
(ng/mL) 
Back- 
calculated 
concentration 
(ng/mL)  
R/R0 %  
CVs 
%  
Accuracies 
Back- 
calculated 
concentration 
(ng/mL)  
R/R0 %  
CVs 
%  
Accuracies 
 
125 
 
124.25 
 
0.3557
 
 
8.9 
 
99.4 
 
131.75 
 
0.2976
 
 
3.1 
 
105.4 
62.5 65.56 0.3998
 
6.4 104.9 57.19 0.3154
 
2.8 91.5 
31.2 29.6 0.4339
 
3.2 94.9 31.51 0.4322
 
8.3 101 
15.6 15.22 0.4975
 
7.4 97.6 17.55 0.5923
 
7.3 112.5 
7.8 7.72 0.5775
 
2.5 99 7.67 0.6234
 
0.9 98.4 
3.9 3.83 0.6910
 
6.2 98.2 3.75 0.7134
 
3.2 96.2 
2 1.97 0.7934
 
1.7 98.9 2.01 0.8232
 
1.9 100.9 
0.98 0.98 0.8715
 
4.3 100 1.05 0.9173
 
2.6 107.4 
0.49 0.5 0.9240 2.9 103.1 0.48 0.9272 4.2 97.5 
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3.2.3.13 Evaluation of matrix Spiking and recovery studies of almond samples 
Almond nut sample was extracted using 80% (v/v) methanol (Whitaker et al., 2006). Five mL 
of the almond extract was evaporated to dryness in a rotary evaporator and resuspended in 5 
mL of HBS buffer. To 1 mL of almond sample in HBS buffer AFB2 (156.25 ng/mL) was 
added, whose recovery (measured by fluorescence assay (n=3)) was found to be 84.3%.  
 
3.2.3.14 Intra- and inter-day validaton of SPR-inhibition assay using spiked almond 
samples 
The spiked samples were mixed with antibody (1:1 spiked sample/antibody) and injected (flow 
rate 15 µL) onto the surface of the sensor chip, with a contact time of 90 sec. The surface was 
regenerated with 30 mM NaOH for 30 sec twice (flow rate 30 µL/min). The precision of the 
assay was measured through performing intra-day (within runs) and inter-day (between runs) 
assay (Table 3.5 & Figure 3.21).   
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Figure 3.21: Intra- (a) and inter- (b) day validation of SPR-based competitive inhibition assay 
performed using almond spiked samples. 1/100 dilution of anti-AFB2 scFv was incubated with almond 
sample containing 0.48-125 ng/mL of AFB2 and passed over the AFB2 immobilized sensor chip. The 
results were normalized by dividing the response units in presence of AFB2 (R) by the response units  of 
zero concentration of antigen (R0) in the assay. For intra-day (a) studies the S.D. was computed from 3 
validation runs on the same day and inter-day (b) S.D.s were determined over 5 validation runs on 5 
separate days. A 4-parameter logistic curve was fitted to the data set.     
 
Table 3.5: Intra- and inter-day coefficient of variance for the determination of AFB2 in almond 
sample using SPR-based competitive inhibition assay. Three sets of nine standards were 
assayed on five different days and CVs were calculated.   
 
                     Intra-day assay                      Inter-day assay AFB2  
concentration 
(ng/mL) 
Back- 
calculated 
concentration 
(ng/mL)  
R/R0 %  
CVs 
%  
Accuracies 
Back- 
calculated 
concentration 
(ng/mL)  
R/R0 %  
CVs 
%  
Accuracies 
 
125 
 
130.5 
 
0.2642
 
 
3.2 
 
104.4 
 
128.12 
 
0.3016
 
 
6.9 
 
102.5 
62.5 57.56 0.2708
 
5.6 92.1 67.56 0.3963
 
7.3 108.1 
31.2 37 0.4525
 
8.2 118.6 29.85 0.4273
 
10.6 95.7 
15.6 15.77  0.5248
 
5.1 101.1 15.49 0.5655
 
6.2 99.3 
7.8 7.67 0.6007
 
6.7 98.3 8.12 0.6972
 
9.5 104.1 
3.9 3.67 0.7094
 
5.7 94.2 3.84 0.7684
 
3.7 98.6 
2 2.33 0.9007
 
3.2 116.5 1.89 0.8273
 
5.1 94.5 
0.98 0.98 0.9372
 
6.6 100 1.03 0.9018
 
4.0 105.3 
0.49 0.46 0.9598 8.4 95.1 0.49 0.9165 8.1 100 
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3.3 Discussion 
This chapter deals with the generation of anti-AFB2 scFv recombinant antibodies. AFB2 posses 
a carbonyl functional group that can be conjugated to carrier proteins such as BSA. The AFB2-
BSA yielded a lower serum titration values in mice (Hastings et al., 1988). In order to attain 
higher serum titer values against AFB2, an attempt was made to conjugate AFB2 to the KLH 
carrier protein using a two steps NHS ester method, which,  ultimately was proven to be an 
excellent approach for obtaining specific AFB2 antibodies with no cross reactivity to other 
aflatoxins.  
AFB2-KLH conjugate led to the generation of a very high immune response with a titre of 
1/512,000 in a Balb/c mouse. This serum titre value was deemed sufficient to utilize the 
immunized mouse for the isolation spleenomic RNA, followed by cDNA synthesis. A single 
chain Fv gene fragment was assembled together by Splice by Overlap Extension of the variable 
heavy and light chains with a ﬂexible linker. The SOE product was successfully ligated into 
pComb 3XSS vector followed by electroporation into XL1-Blue electrocompetent cells. This 
resulted in a library size of 2.19 X 107 transformants, which was within the range of the 
expected 106 and 108 transformants.  
Anticipating the presence of diverse anti-AFB2 scFvs, the antibody library was subjected to 
panning on the solid surface of an immunotube that was coated with AFB2-BSA, as stated by 
(Willats, 2002). Since the possibility of obtaining highly specific clones will be widened 
through decreasing coating concentration (Charlton et al., 2001), lower  concentrations of 
AFB2-BSA were used in successive rounds of panning. Trypsinization (Lin et al., 2000) was 
used for the elution of  bound phage from immobilized AFB2-BSA. During the panning 
procedure, the titre of the eluted phage dropped after the third and fourth rounds to 104, which 
might be due to the low amplification titres after the second and third rounds of panning, 
respectively. A slight increase in the titre of eluted phage (105) obtained from the fifth round of 
panning was noticed. The phage from each of the rounds of panning were subsequently 
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analysed by polyclonal phage ELISA. An increase in the signal of the phage obtained from 
round 5, when titrated against AFB2-BSA, indicated the presence of higher numbers of AFB2 
encoding genes.  In this instance the background values obtained against BSA and milk Marvel 
were 7 times lower than the signal obtained when the phage was titrated against AFB2-BSA. 
The phage from fifth round of panning were then infected into Top 10Fʹ cells for the soluble 
expression of antibodies following the procedure stated in section 2.2.3.13. Single scFv clones 
(384) were picked and expressed.  
The selection of scFv antibodies from a recombinant library expressed on M13 bacteriophage 
led to the isolation of set of antibodies that bound to AFB2 with high specificity. Over 95% of 
the clones tested were found to be positive-binders for AFB2-BSA. Low background values 
were obtained when clones were tested against BSA and KLH. The presence of a high number 
of positive scFv clones that specifically bind to AFB2 represents a significant enrichment of 
phage with the required antibody gene, thus, ultimately resulting in a successful panning 
procedure. 
Ten representative positive clones were selected and analysis of the lysates carried out by 
indirect and competitive ELISA, as described in section 2.2.3.15. The titre values of the scFv-
producing clones were found to be greater than 1/500. The ten scFv-producing clones were 
then assayed for their recognition of AFB2 in solution and seven (A8, D1, H8, A1, A2, E9 & 
H12) recognized AFB2. Due to the minimal differences between the aflatoxin congeners 
generation of antibody that is absolutely specific to one type of aflatoxin is highly difficult. 
Most of the antibodies developed either through immunizing AFB1 or B2 conjugates resulted in 
the generation of antibodies with either wide or narrow range of cross reactive characteristics. 
Hence cross reactivity studies were performed with four structurally similar aflatoxins (AFB1, 
G1, G2 & M1) by competitive ELISA assay described in section 2.2.3.15. These studies 
revealed the presence of five scFvs (A8, D1, H8, A1 & A2) with varying percentage cross 
reactivity to aflatoxin congeners and two scFvs (E9 & H12) without any affinity towards other 
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aflatoxin types that were tested (Table 3.2). The earlier reports suggests, that the monoclonal 
antibodies developed against AFB2 exhibit higher cross reactivity with AFB1 and, in a few 
cases, these antibodies were unable to recognize AFB2  itself. In contrast to these results, the 
scFvs developed in the present work were able to specifically recognize only AFB2, which is 
highly desirable for the development of specific assays.  
The results of cross reactivity studies, indicating the presence of different scFv types were 
further confirmed through restriction digestion of scFvs with BstN1, which also revealed the 
presence of three different sets of population in the seven competent scFvs. Further sequencing 
analysis of the scFv-E9 (no cross reactivity) and D1 (with cross reactivity) were performed to 
trace the CDR that might play a crucial role in the attributing the cross reactivity characteristic 
to the scFv. There was variation in the sequences of both scFv-E9 & D1 (Figure 3.15). Based 
on this it is hard to assess the role played by the CDRs for cross reaction.    
Large-scale expression and IMAC purification of scFv-E9 was followed by affinity (IC50) 
determination, which was 85 ng/mL. The IC50 value is higher than the earlier reported for 
monoclonal antibodies by Hastings et al. (1988) at (50 pg/mL), Rieger et al. (2009) at (0.0027 
ng/mL) and Cervino et al. (2008) at (0.042 ng/mL).  
SPR-based system is a versatile technique to determine the biomolecular interactions due to the 
low sample requirement and less time-consumption than ELISA (De Crescenzo et al., 2008). 
For the AFB2 sensor chip generation, AFB2 toxin was used instead of AFB2 protein conjugate 
in order to avoid the regeneration problems encountered by Daly et al. (2000). Amine coupling 
strategy was employed for the immobilization of AFB2 onto the CM5 chip. Varying dilutions 
of scFv-E9 were passed over the AFB2 immobilized sensor chip to determine the optimal 
response units around 300-400 RU. A 1/100 dilution of scFv-E9 produced binding response of 
359 RU. Kinetic analysis of scFv-E9 indicated the low nanomolar affinity levels. The 
competitive efficiency of scFv-E9 to AFB2 in solution phage was determined and IC50 value 
where half maximal inhibition of antibody in the presence of antigen was measured. The SPR 
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inhibition curve in Figure 3.19 revealed the IC50 value of 8 ng/mL (buffer) and 11 ng/mL 
(matrix) for scFv-E9. Intra- and inter-day variations showed that the scFv-E9 has a range of 
detection of free AFB2 from 0.48-125 ng/mL with CVs between 1.7-8.9% and 0.9-8.3%, 
respectively, which fall within the 20% limit as reported by (Findlay et al., 2000). The results 
indicate the reproducibility of the assay. To assess the feasibility of detecting AFB2 in food 
matrix, almond was purchased and spiked with known concentration of AFB2. The results of 
inter- and intra-day (Table 3.5) SPR-inhibition assay suggest that scFv-E9 can readily be used 
for the detection of AFB2 in almonds. The limit of detection increased from 0.9 ± 0.09 ng/mL 
(buffer) to 3.6 ± 0.13 ng/mL (matrix).         
In conclusion, an scFv with higher specificity towards AFB2 was isolated from the recombinant 
antibody library. To our knowledge this is the first successful recombinant anti-AFB2 scFv 
antibody without any cross reactivity to aflatoxin congeners. ELISA and SPR- based inhibition 
assay were developed with the scFv-E9 that had a IC50 of 85 & 8 ng/mL respectively, which 
falls within the maximum permissible limits of 20 ppb. This scFv was further used for the 
immuno-affinity column development described in chapter 6.    
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                Chapter 4 
 Generation of anti- 
Zearalenone murine scFv 
antibodies  
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4.1 Introduction 
Zearalenone (ZEN) is the most prevalent of the Fusarium toxins (Glenn, 2007). Cross 
reactive monoclonal antibodies against ZEN, developed to-date, were generated following the 
immunization of Balb/c mice (Dixon et al., 1987; Teshima et al., 1990) and rabbits (Burkin et 
al., 2002) with ZEN-BSA conjugates. Only one report exists for the generation of a scFv 
from a monoclonal antibody by Yaun et al. (1997). This scFv antibody exhibits higher cross 
reactivity with other structurally similar toxins to ZEN than does the parent monoclonal 
antibody. No scFv antibodies were reported for ZEN that were generated using cDNA 
libraries. Hence, it was decided to generate a highly specific anti-ZEN scFv antibody from a 
cDNA library (Figure 4.1), with the aim of isolating scFvs with little or no cross reactivity to 
ZEN variants like alpha and beta zearalenol.  
Spleenomic RNA from mice, immunized with a ZEN-KLH conjugate, was used to generate a 
recombinant scFv library, which was subsequently subjected to panning against ZEN-BSA. A 
scFv with an IC50 of 80 ng/mL was successfully isolated and incorporated into both ELISA 
and SPR-based inhibition assays. The latter was applied for the detection of ZEN in sorghum.  
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Figure 4.1: Strategy adopted for the generation of anti-ZEN scFvs. The generation of scFvs started 
with the immunization of Balb/c mice with ZEN-KLH conjugate, followed by the spleenomic RNA 
isolation and cDNA synthesis. From the cDNA variable and heavy chains of the antibody were 
amplified, followed by the ligation of the glycine-serine linked antibody chains (SOE product) into a 
vector, which was then electroporated into XL1-Blue E. coli cells. The entire ZEN library was 
biopanned on solid immunotube surfaces, which were pre-coated with ZEN-BSA. The isolated scFvs 
were incorporated into ELISA and SPR-based assays. 
 
4.2 Results 
4.2.1 Serum titre determination and cDNA synthesis 
Following immunization of Balb/c mice the serum titration against ZEN-BSA (after 3rd boost), 
as determined by indirect ELISA, was found to be in excess of 1/256,000 (Figure 4.2). The 
immune responses of the serum against BSA and KLH were also determined. However, no 
response to KLH was detected, which was not expected. The results indicate that the anti-
serum was specific to ZEN. Spleenomic RNA was isolated from the immunized mouse after a 
final intravenous boost (after 4th boost). RNA (4.5 ng) was used for the generation of cDNA 
(yield; 137.6 ng/µL), from which variable heavy and light chain genes were amplified using 
specific primers defined for use with mice (Kabat et al., 1991; Kettleborough et al., 1993).  
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Figure 4.2: Serum titre of ZEN-KLH-immunized mouse, determined by indirect ELISA against ZEN-
BSA. Serum dilutions (1/100 to 1/512,000) were added to the immuno-plate coated with ZEN-BSA, BSA 
and KLH. A 1/1,000 dilution of AP-labelled goat anti-mouse IgG was added followed by visualization 
with pNPP. The figure shows that there was a very low signal, when the serum titration was performed 
against KLH. The higher signal of the serum generated against ZEN-BSA conjugate is indicative of the 
immune response of the mouse to ZEN.  
 
4.2.2 Amplification of variable heavy and light chain genes 
Optimal conditions for amplification of the heavy and light chain genes were determined using 
1, 1.5, 2 & 3 mM of MgCl2. Due to the presence of a single band in Figure 4.3, 1 mM of MgCl2 
was selected for the large-scale (20X) reactions to amplify Vk, Vʎ and VH, respectively. 
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Figure 4.3: Optimization of the magnesium concentration for the amplification of Vk (a), Vʎ (b) and 
VH (c). The PCR reaction mixture is composed of 0.5 µL of cDNA, 100 pmol of mouse primers, 5x PCR 
buffer, 200 µM dNTPs, 0.25 µL of GoTaq® DNA Polymerase and 1-3 mM of MgCl2. The PCR 
amplification conditions were as follows: initialization for 5 mins at 94
0
C; 30 cycles of denaturation; 
annealing and elongation for 15, 30, 90 sec at 94
0
, 56
0
 and 72
0
C, respectively; followed by the final 
elongation step for 10 mins at 72
0
C. The representation of the various lanes is as follows: lane 1: 1 Kb 
plus DNA ladder; lane 2: negative PCR reaction; lanes 3-6: PCR products amplified using four 
different concentrations of MgCl2 (1, 1.5, 2 & 3 mM). 
 
4.2.3 Splice overlap extension (SOE) of the amplified heavy and light chain genes 
The amplified heavy and light chain genes were linked by an SOE-PCR reaction. The optimal 
amplification condition was set up by running a MgSO4 gradient (1, 1.5, 2 & 4 mM); (Figure 
4.4). A MgSO4 concentration of 2 mM, in the case of SOE (ʎ) and 4 mM for SOE (k), were 
used for the further amplification of the SOE products. The yields were 13.4 & 10.9 µg/240 µL, 
respectively.  
 
 
(b) 
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850 bp 
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Figure 4.4: Optimization of MgSO4 concentration for SOE product generation. Figure 4.4(a) 
indicates SOE (ʎ) and 4.4(b) represents SOE (k). The PCR reaction mixture is composed of 100 ng of VL 
and VH were mixed with 100 pmol of CSC-F and CSC-B, 10x PCR buffer, 200 µM dNTPs, 0.2 µL of 
Platinum® Taq DNA polymerase and 1-4 mM of MgSO4. The PCR amplification conditions were as 
follows: initialization for 5 mins at 94
0
C; 30 cycles of denaturation; annealing and elongation for 30, 
30, 120 sec at 94
0
, 56
0
 and 72
0
C, respectively; followed by the final elongation step for 10 mins at 72
0
C. 
The representation of the various lanes is as follows: lane 1: 1 Kb plus DNA ladder; lane 2: negative 
PCR reaction; lanes 3-6: SOE obtained using four different concentrations of MgSO4 (1, 1.5, 2 & 4 
mM). 
 
4.2.4 SfiI restriction digestion and ligation of SOE into pComb 3XSS 
The vector (pComb 3XSS) was restriction digested with SfiI, XhoI, XbaI and Antarctic 
phosphatase. The SOE products (ʎ and k) were restriction digested with SfiI alone. The 
restriction digested vector and SOE products were ethanol-precipitated overnight followed by 
purification using a Nucleospin Extract II kit, after running the products (SOE and vector) on 
0.5% (w/v) agarose gel. The SOE product was ligated into the vector at a ratio of 3:1.  
 
4.2.5 Electroporation and biopanning 
The ligated mixture (4 µL) was electroporated into XL1- Blue electrocompetent cells. A library 
size of 1.05 X 108 was obtained. The input and output titres after each round of the panning 
were recorded (Table 4.1). To determine the presence of scFv-expressing genes in the cells, a 
colony pick PCR (Figure 4.5) was performed using randomly picked clones from the titration 
plates. The PCR product was resolved on a 1% (w/v) agarose gel, which indicated the presence 
of a scFv insert in all of the clones selected.  
1 2 3 4 5 6 
(a) 
1 2 3 4 5 
850 bp 
(b) 
850 bp 
6 
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Table 4.1: Input and output titres of phage collected from six rounds of panning of the ZEN 
library against ZEN-BSA conjugate using M13K07 as the helper phage for the enrichment of 
scFv recognizing ZEN 
  
Round Input titre (cfu/mL)     Output titre (cfu/mL) 
 
Round 1 
 
         1 X 1011 
 
                1 X 107 
Round 2          2 X 1011                 1 X 107 
Round 3          2 X 1011                 5 X 105 
Round 4          1 X 1011                 5 X 105 
Round 5          9 X 1011                 1  X 104 
Round 6          4 X 1011                  2 X 106 
850 bp
1 2 3 4 5 6 7
 
 
Figure 4.5: Colony pick PCR of randomly selected clones from the ZEN-panned library. A single 
bacterial colony carrying the required scFv insert was amplified using the primers designed for SOE 
generation under the PCR conditions described for SOE-PCR reaction.The amplification of a band at 
approximately 750 bp indicates the presence of the scFv  insert. The representation of the various lanes 
is as follows: lane 1: 1 Kb plus DNA ladder; lane 2-7: amplification of inserts in randomly picked 
colonies. 
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4.2.6 Polyclonal phage ELISA  
Rescued phage, from each round of panning, were screened against ZEN-BSA to determine the 
binding activity to ZEN. The binding of phage to BSA and milk Marvel was also determined. 
The bar chart generated from the polyclonal phage ELISA data indicate higher reactivity of the 
phage, obtained from round 5 & 6 (Figure 4.6) of panning, toward ZEN-BSA. An increase in 
the reactivity of phage towards BSA and Marvel was also noticed, which was still low, when 
compared to the signal obtained when phage titration was performed against ZEN-BSA. The 
phage from rounds 5 & 6 were solubly expressed through infecting the phage into Top 10Fʹ 
cells.   
 
A
b
s
o
rb
a
n
c
e
 @
 4
5
0
 n
m
0
1
2
3
4
0 1 2 3 4 5 6
Rounds of panning
ZEN-BSA BSA Milk Marvel
Binding affinity of phage to:
 
 
Figure 4.6: Polyclonal phage ELISA of the ZEN-panned library against ZEN-BSA. Each of the 
analytes (ZEN-BSA, BSA and milk Marvel) were coated on the microtitre plate (in triplicate). The phage 
(1/2 dilution) from the six rounds of panning were analyzed against the three analytes. HRP-labelled 
mouse anti-M13 monoclonal antibody (1/1,000 dilution) was added, followed by the addition of TMB 
solution. Significant enrichment of the phage was seen in rounds 5 and 6, which indicates the presence 
of ZEN-positive binders.     
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4.2.7 Monoclonal ELISA using solubly expressed anti-ZEN scFv producing clones 
Indirect ELISA was performed using individual clones (384) that were grown and induced with 
IPTG. The plates were freeze-thawed (X3 times) and the culture was spun down and the lysates 
tested against ZEN-BSA. The results indicate that even though a significant enrichment of the 
phage was evident from the results of polyclonal phage ELISA, the number of ZEN-positive 
binders were low (Figure 4.7). 
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Figure 4.7: Graphical representation of monoclonal ELISA of anti-ZEN solubly expressed clones 
against ZEN-BSA-coated microtitre plates. Dilutions (1/2) of supernatants were added to the ZEN-
BSA-coated and milk Marvel-blocked immunoplate. A chromogenic reporter (HRP-labelled rat anti-HA 
monoclonal antibody) and its visualizer (TMB) were added and the absorbance read on a Tecan Saffire 
II plate reader.  Figures a, b, c and d correspond to plates 1, 2, 3 and 4, respectively. The red line is the 
reference value, above which the clones were selected as being ZEN-positive binders. 
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4.2.8 Immuno-reactivity of the anti-ZEN scFv-P2A2 
The immunoreactivity of scFv-P2A2 (with highest displacement or best expression profile as 
determined from preliminary analysis) was evaluated through ELISA (indirect and competitive 
indirect ELISA). The titre value of scFv-P2A2 as determined by indirect ELISA, was in excess 
of 1/60,000. An inhibition ELISA was developed using scFv-P2A2, where the optimal dilution 
(1/800) of the scFv was incubated with 0.004-5 µg/mL of ZEN in the ratio of 1:1. The 
absorbance of antibody recorded in the presence of analyte (A) was divided by the absorbance 
of antibody in the absence of analyte (A0). A semi-log plot was drawn with A/A0 on the Y-axis 
against concentration of ZEN on the logarithmic X-axis (Figure 4.8). The mid-inflection point, 
where half-maximal inhibition (IC50 value) of 200 ± 0.05 ng/mL (Mean ± S.D.) was 
determined. The limit of detection and quantification were 10 ± 0.07 ng/mL and 28 ± 0.09 
ng/mL. The blank value was determined by recording absorbance of antibody in the presence 
of zero analyte (n=20). The formulae used for the calculating the LOD and LOQ were: 
LOD = Blank value + 3 S.D. of blank value  
LOQ = Blank value + 10 S.D. of blank value       
Precision of the competitive inhibition ELISA developed using scFv-P2A2 was determined 
through intra- and inter-day validation (Figure 4.9) and represented as percentage CVs (Table 
4.2). For intra-day variation the assay was repeated three times on the same day and inter-day 
variations were assessed by performing the assay on five different days. The CVs for both 
intra- and inter-day assays were below 7.43 and 11.34%, respectively (Table 4.2).   
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Figure 4.8: Inhibition ELISA for the detection of Zearalenone using scFv-P2A2. The ELISA plate 
was coated with 5 µg/mL of ZEN-BSA and blocked with 4% (w/v) milk Marvel. Decreasing 
concentrations of ZEN were incubated with 1/800 dilution of anti-ZEN scFv-P2A2 in a ratio of 1:1 for 
30 mins at 37
0
C prior to the addition of the mixture to the previously blocked microtitre plate. This was 
then probed with anti-HA HRP-labelled secondary antibody, followed by visualization with TMB. The 
inhibition curve generated indicates a decrease in antibody binding with increasing concentration of 
ZEN. The IC50 value of scFv-P2A2 was 200 ng/mL. 
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Figure 4.9: Intra- and inter-day competitive inhibition ELISA using scFv-P2A2. A 5 µg/mL ZEN-BSA 
coating concentration was used with a 1/800 dilution of anti-ZEN scFv that was incubated with ZEN 
(0.004-5 µg/mL). For intra-day (a) studies the S.D. was computed from 3 validation runs on the same 
day and inter-day (b) S.D. was determined over 5 validation runs on 5 separate days. A 4-parameter 
logistic curve was fitted to the data set.     
 
Table 4.2: Intra- and inter-day assays coefficient of variance (CVs) for anti-ZEN scFv in 
buffer. CVs were computed from the 3 replicate analyses carried out on the same (intra-day) 
and on five different days (inter-day).  
  
                  Intra-day assay                      Inter-day assay ZEN   
concentration 
(ng/mL) 
Back- 
calculated 
concentration 
(ng/mL)  
A/A0 %  
CVs 
%  
Accuracies 
Back- 
calculated 
concentration 
(ng/mL)  
A/A0 %  
CVs 
%  
Accuracies 
  
5000 
 
4965 
 
0.0938
 
 
4.45 
 
99.3 
 
4950 
 
0.1832
 
 
7.54 
 
99 
2500 2610 0.1984
 
2.46 104.6 2580 0.2936
 
5.77 103.2 
1250 1260 0.2910
 
6.33 101 1210 0.3133
 
1.34 97.4 
625 607 0.3933
 
3.56 97.2 656 0.4729
 
8.43 105 
312.5 312 0.5874
 
7.43 100 305 0.5183
 
4.56 98 
156.25 158 0.7527
 
1.34 101.6 152 0.6292
 
9.43 97.8 
78.125 79 0.8542
 
3.56 102 74 0.7253
 
11.3 95.2 
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4.2.9 Cross reactivity of anti-ZEN scFv-P2A2 
Cross reactivity studies were carried out using the scFv-P2A2 and two structurally related ZEN 
(α-Zearalenol and β-Zearalenol). Inhibition curves were generated for all the three analytes 
tested (ZEN, α-Zearalenol and β-Zearalenol) in the same way as for ZEN, as described in 
section 4.2.7. The percentage cross reactivity was calculated by taking the IC50 value of clone 
when tested against ZEN as 100% and through substituting in the formula 
                                                  IC50 against ZEN derivative X 100 
Percentage cross reactivity =               IC50 against ZEN 
  
The results (Table 4.3) indicates that scFv-P2A2 was highly specific to ZEN with least cross 
reactivity to other ZEN types i.e., α-Zearalenol and β-Zearalenol.  
Table 4.3: Cross reactivity studies of scFv-P2A2 by competitive inhibition ELISA and its cross 
reactivity comparison with other reported anti-ZEN antibodies.  
  
Cross reactivity percentage Reference  Type of antibody 
α-Zearalenol   β-Zearalenol  
 
Reported antibodies 
Monoclonal antibody  
scFv (generated from  
monoclonal antibody) 
 
Monoclonal antibody 
Polyclonal antibody 
Monoclonal antibody 
Monoclonal antibody 
Polyclonal antibody 
Monoclonal antibody 
Monoclonal antibody 
 
Developed antibody  
scFv-P2A2 
 
 
26 
 
82 
 
42 
0.15 
0.9 
3.6 
3.14 
0.65 
108.1 
 
 
<0.01 
 
 
11 
 
26 
 
< 1 
<0.02 
<0.1 
14.4 
1.96 
0.94 
119.3 
 
 
0.1 
 
 
(Yuan et al., 1997) 
 
(Yuan et al., 1997) 
 
(Burmistrova et al., 2009) 
(Burkin et al., 2002) 
(Teshima et al., 1990) 
(Dixon  et al., 1987) 
(Gao et al., 2011) 
(Gao et al., 2011) 
(Ferreira Junior et al., 2012) 
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4.2.10 SDS-PAGE and western blotting of scFv-P2A2 
Commassie staining of the SDS-PAGE gel was performed as described in section 2.2.4.10.3. 
Western blot analysis was carried out using the scFv-P2A2 to demonstrate that the secondary 
anti-HA could specifically detect the purified scFv. The purified scFv was electrophoresed 
using SDS-PAGE and then transferred onto nitrocellulose, which was blocked with 4% (w/v) 
milk Marvel and probed with anti-HA-HRP-labelled rat monoclonal antibody. Figure 4.10 
indicates that the secondary antibody (anti-HA) enabled specific detection of scFv. A single 
band was visible at approximately 24 kDa. 
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Figure 4.10: SDS-PAGE (a) and western blotting (b) of scFv-P2A2 after subjecting to IMAC 
purification. A 12.5% SDS gel was run for 1.5 hrs at 100 V and the gel was stained with Commassie 
dye solution (Commassie blue R-250 (2 g), methanol (450 mL), acetic acid (100 mL) and water (450 
mL) and  destained overnight  at room temperature with mixture containing acetic acid, methanol and 
water in the ratio of 2:5:13. For western blotting the SDS-PAGE gel was transferred onto the 
nitrocellulose membrane for 15 mins at 15 V and the membrane was blocked with 4% (w/v) milk Marvel 
for 1 hr. This was probed with 1/5,000 dilution of anti-HA HRP-labelled rat monoclonal antibody, 
followed by visualization of band using TMB substrate. The representation of the various lanes is as 
follows: lane 1: Fermentas Pageruler plus marker and lane 2: IMAC purified P2A2 clone. The purified 
P2A2 clone revealed the presence of scFv band at approximately 24 kDa.   
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4.2.11 Sequencing of scFv-P2A2 
Plasmid DNA of scFv-P2A2 was sent to Source Biosciences for sequencing. The linear 
nucleotide sequencing results were translated into amino acid sequences using the Expasy 
translate tool. The CDRs are represented in Figure 4.11.  
 
CDRL1      C X A S G Y X F T 
 
CDRL2      I G A I Y P G 
 
CDRL3      C A R S R G W D G Y X G Q G 
 
CDRH1     C K A S G Y S F T 
 
CDRH2     G L E W I G A I Y P G N S D T N Y N 
 
CDRH3     C A R S R G W D G Y W G Q G T T L T 
 
 
Figure 4.11: Deduced amino acid sequence of scFv-P2A2. The heavy and light chain CDRs present in 
the scFv-P2A2 are shown. 
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4.2.12 Zearalenone immobilization on CM5 sensor chip 
Standard amine coupling chemistry leads to stable bonding between toxins and activated sensor 
chip surfaces (Tudos et al., 2003). This approach was adopted for the immobilization of ZEN-
CMO-NHS synthesized using the procedure described in section 2.2.4.11. The ZEN-CMO-
NHS was attached to the amine groups generated on a CM5 chip surface through treatment 
with Jeffamine (Figure 4.12).   
CM5 Chip
Carboxyl groups
CM5 ChipCM5 Chip
NH
CONHCONH
NH2
CONH
NH2
CONH
NH2
NH
CONH
NH
CONH
Zearalenone (ZEN)
Jeffamine
(a) (b) (c)
 
 
Figure 4.12: Schematic representation of immobilization of ZEN onto CM5 sensor chip. The first 
stage (a) involved in the immobilization of ZEN onto CM5 chip was surface activation with EDC and 
NHS. In the second stage amine groups were generated through treating with Jeffamine (b). The third 
stage involves the covalent attachment of ZEN to the amine groups on the CM5 chip (c).  
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4.2.13 Binding analysis of P2A2 to ZEN-immobilized CM5 sensor chip 
The optimal antibody dilution was determined by passing 1/50, 1/100, 1/200/ 1/400 and 1/800 
dilutions of IMAC-purified anti-ZEN scFv-P2A2 over the ZEN-immobilized sensor chip. A 
1/100 dilution P2A2 scFv yielded a binding response of 110 RU (Figure 4.13). The binding 
specificity of the ZEN-immobilized chip was tested using an anti-AFB2 scFv (negative control) 
(1/200 dilution, flow rate of 15 µL/min for 3 mins). Negligible binding (< 10 RU) of anti-AFB2 
scFv indicates that there was no binding between the anti-AFB2 scFv and ZEN, which was 
covalently attached to the CM5 chip. Surface regeneration conditions were optimized using 
NaOH concentrations ranging from 10-50 mM and it was found that 20 mM is required for 
efficient chip regeneration (flow rate 30 µL/min for 30 sec).      
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Figure 4.13: Sensogram depicting the binding of P2A2 scFv to ZEN-immobilized CM5 sensor chip. 
The scFv-P2A2 was passed over flowcell 2 of ZEN-immobilized CM5 chip at a flow rate of 15 µL/min 
for 3 mins. The net response units achieved by P2A2 were 110 RU. 
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4.2.14 SPR-based kinetic analysis of scFv-P2A2  
The Ka and Kd values were 5.72 X 10
4 M-1s-1and 2.28 X 10-5 s-1, respectively for scFv-P2A2. 
Thus the calculated KD value for P2A2 scFv/ZEN interaction was 3.9 X 10
-10 M (Figure 4.14) 
(KD = Kd/Ka).  
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Figure 4.14: Kinetic analysis of scFv-P2A2. The dissociation of varying concentrations (1.25-10 nM) 
of P2A2 clone was used to perform kinetic analysis. The data obtained was fitted into Langmuir 1:1 
fitting model and the KD value was found to be 3.9 X 10
-10 
M after normalization.   
 
4.2.16 SPR-based solution-phase ZEN binding assay using scFv-P2A2 
An inhibition assay for the detection of ZEN was developed using a ZEN-immobilized CM5 
chip and anti-ZEN scFv-P2A2. To assess the binding ability of P2A2 scFv to ZEN in solution, 
free ZEN standards, ranging from 0.004-1 µg/mL were mixed with 1/100 dilution of scFv-
P2A2 in the ratio of 1:1 and incubated for 30 mins at 370C. The samples were then passed 
randomly over the sensor chip and the response units of the scFv in the presence of each 
individual concentration of ZEN was divided by the response units of the scFv alone in the 
absence of free ZEN (Figure 4.15).   
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Figure 4.15: SPR-based competitive inhibition curve of scFv-P2A2 in solution. The R/R0 was 
obtained by dividing response units obtained at 9 different ZEN concentrations (0.004-1 µg/mL) by the 
RU response of scFv-P2A2 without ZEN. A 4-parameter logistic curve was fitted to the data set and 
each point is the mean of three replicate measurements.     
 
Intra and inter-day variability studies (Figure 4.16) were carried out to assess the 
reproducibility of the SPR-based inhibition assay. Intra-day variations were measured by 
repeating the assay three times on one day and mean response units of antibody bound to each 
varying concentration of ZEN was plotted against log concentration of ZEN. The percentage 
variations of intra-day studies were represented as percentage coefficient of variance (% CVs), 
which were below 6%. Like-wise, inter-day variation was assessed by repeating the inhibition 
assay on five different days with variability determined to be less than 9%. The CVs for intra- 
and inter- day variability studies (Table 4.4) indicates the reproducibility of the assay.   
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Figure 4.16: Intra- (a) and inter-day (b) variations of SPR-based inhibition assay using scFv-P2A2 
in solution. A 1/100 dilution of anti-ZEN scFv was incubated with 0.004-1 µg/mL of ZEN and passed 
over the ZEN-immobilized sensor chip. The results were normalized by dividing the response units in 
presence of ZEN (R) by the response units of zero concentration of antigen (R0) in the assay. For intra-
day (a) studies the S.D. was computed from 3 validation runs on one day and inter-day (b) S.D.s were 
determined over 5 validation runs on 5 separate days. A 4-parameter logistic curve was fitted to the 
data set.     
 
Table 4.4: Intra- and inter-day assays coefficient of variance (CVs) for anti-ZEN scFv in 
buffer. Percentage CVs were computed from the 3 replicate analyses carried out on the same 
(intra-day) and on five  different days (inter-day).  
  
                   Intra-day assay                    Inter-day assay ZEN  
concentration 
(ng/mL) Back- 
calculated 
concentration 
(ng/mL)  
R/R0 %  
CVs 
%  
Accuracies 
Back- 
calculated 
concentration 
(ng/mL)  
R/R0 %  
CVs 
%  
Accuracies 
 
125 
 
122 
 
0.3419
 
 
5.35 
 
97.6 
 
123 
 
0.3933
 
 
1.35 
 
98.4 
62.5 67 0.4425
 
3.12 108 67 0.5874
 
8.75 107.7 
31.25 32 0.5419
 
1.35 101.3 29 0.6527
 
6.33 93.3 
15.625 17 0.7251
 
3.42 110.2 14 0.7542
 
3.56 88.5 
7.812 9 0.9760
 
2.46 116.5 9 0.9723
 
7.53 111 
3.906 4 0.9792 5.24 93.7 4 0.9953 6.68 99 
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4.2.16 Extraction of ZEN from sorghum and its application in SPR-based inhibition assay 
A sorghum reference sample with 48.6 ± 0.03 ng/mL ZEN obtained from Triology laboratories 
was extracted using the procedure described in section 2.2.4.13. The mean recovery of ZEN 
from the 10 extractions was 42.5 ± 0.2 ng/mL (Mean ± S.D.). The working concentration of the 
SPR-based inhibition assay using sorghum extract was set to 3.9-125 ng/mL. For intra-day 
validation the assay was run three times on the same day and inter-day assays were performed 
on five different days (Figure 4.17). The mean response units were recorded and the responses 
of antibody in the presence of varying concentrations of ZEN were divided by the responses of 
antibody in the absence of ZEN. The IC50 value was found to be 22 ± 0.02 ng/mL.  The CVs 
for intra- and inter-day assays fall below 7% and 12%, respectively (Table 4.5). The limit of 
detection of 7.8 ± 0.07 ng/mL was measured through determining responses of antibody in the 
presence of ZEN-free sorghum sample, where n=20. The limit of quantification was 13 ± 0.03 
ng/mL (Mean ± S.D.).           
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Figure 4.17: Intra- and inter-day SPR-inhibition assay using sorghum samples along with scFv-
P2A2. A 1/100 dilution of anti-ZEN scFv was incubated with sorghum sample containing 0.004-1 
µg/mL of ZEN and passed over the ZEN immobilized sensor chip. The results were normalized by 
dividing the response units in presence of ZEN (R) by the respone units of zero concentration of antigen 
(R0) in the assay. For intra-day (a) studies the S.D. was computed from 3 validation runs on one day 
and inter-day (b) S.D. was determined over 5 validation runs on 5 separate days. A 4-parameter 
logistic curve was fitted to the data set.     
 
Table 4.5: Intra- and inter-day assays coefficient of variance (CVs) for anti-ZEN scFv in 
matrix. CVs were computed from the 3 replicate analyses carried out on the same (intra-day) 
and on three different days (inter-day).  
  
                    Intra-day assay                     Inter-day assay ZEN 
concentration 
(ng/mL) 
Back- 
calculated 
concentration 
(ng/mL)  
R/R0 % 
CVs 
%  
Accuracies 
Back- 
calculated 
concentration 
 (ng/mL) 
R/R0 % 
CVs 
%  
Accuracies 
 
62.5 
 
59 
 
0.3425
 
 
1.45 
 
95.2 
 
61 
 
0.3372
 
 
8.97 
 
98.4 
31.25 32 0.5419
 
3.12 103.2 31 0.4446
 
9.24 100 
15.625 14 0.6518
 
2.24 87.5 13 0.5251
 
11.2 81.2 
7.812 9 0.9760
 
1.45 112.5 8 0.8700
 
3.56 108.3 
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4.3 Discussion 
The work presented in this chapter describes the generation of a murine scFv phage display 
library to produce soluble anti-ZEN scFv antibodies and characterization of the scFv by 
ELISA, SDS-PAGE, western blotting and SPR-based analysis. Earlier Balb/c mice were 
immunized with ZEN-BSA. After the serum titre value reached 1/30,000 (data not shown), the 
spleenomic RNA was used for the synthesis of cDNA, followed by the amplification of heavy 
and light chains for linking them through glycine-serine for SOE formation. The generated 
antibody-phage library was subjected to panning on an ELISA plate coated with varying 
concentrations of ZEN-KLH conjugates. Unfortunately, scFvs that could recognize ZEN were 
not isolated from this library. The failure to isolate anti-ZEN scFvs may be mainly attributed to 
the low immune response of the mice (<1/30,000) and also the lower surface area on microtitre 
plate, which was used for performing biopanning.  
To attain a higher titration value, ZEN-KLH conjugate was used as an immunogen instead of 
ZEN-BSA. Following the standard immunization protocol with ZEN-KLH conjugate, an 
immune response of 1/256,000 was achieved. Comparing the immune response attained upon 
administering BSA and KLH conjugates of ZEN, synthesized employing the two-step NHS 
ester method, resulted in a 8.5 fold increase in the titration values of the sera from Balb/c mice, 
which was mainly due to presence of a larger number of ZEN molecules on the surface of the 
KLH molecule, when compared to BSA, as is evident from the results of MALDI-TOF and 
TNBS assays (Refer Appendix III). The immune response was considered to be of sufficient 
level for the isolation of spleenomic RNA from which the scFv library was subsequently 
generated, using a set of primers (designed for chimeric antibody generation) and optimized 
PCR reactions.      
The other parameter that was taken into consideration to successfully isolate anti-ZEN scFvs 
was the usage of immunotubes for biopanning (Kehoe et al., 2006), which have a larger surface 
area for efficient binding of the phage to the surface that has adsorbed ZEN-BSA conjugate. 
 164 
During the panning procedure a significant drop in the phage output titre to 104 from 107, after 
the fifth round of panning, was noticed. The phage output after the 6th round of panning 
increased to 106, which represents the higher amplification titres. The selected phage antibodies 
were expressed using E. coli host expression system (Top 10Fʹ), which is considered an 
effective expression system when compared to others like B. subtilis and B. brevis. Less than 
50% of the scFv-producing clones were found to yield ZEN-positive binders.  
Five representative scFvs (P1C6, P1G2, P2A2, P2H9 and P2G2) were analysed through 
indirect and competitive ELISA adopting the procedure described in section 2.2.4.9. The titre 
values of all the clones were found to be higher than 1/50. These scFvs were assayed to 
determine the affinity towards ZEN in solution, and, all of the five scFvs were found to 
recognize ZEN. The IC50 of scFv-P2A2 (80 ng/mL) was lower when compared to the other 
scFvs and, hence, further analysis of P2A2 was carried out. The cross reactivity profile of scFv-
P2A2 with alpha and beta zearalenol was analyzed (competitive indirect ELISA), indicating 
minimal cross reactivity.   
In contrarst to the SPR developed by Urraca et al. (2005) and Choi et al. (2009) for the 
detection of ZEN, ZEN was immobilized directly onto the surface of the amine-activated CM5 
chip using a slightly modified immobilization procedure from that developed by Van der Gaag 
et al. (2003). In the initial phase of the SPR assay development the scFv-P2A2 was passed over 
the surface of a ZEN-immobilized sensor chip to determine the optimal response units. The 
affinity of scFv-P2A2 was evaluated through kinetic analysis using varying concentrations of 
scFv, which resulted in Ka and Kd  values of 5.72 X 10
4 M-1s-1and 2.28 X 10-5 s-1, respectively. 
Thus the calculated KD value for scFv-P2A2/ZEN interaction was 3.9 nM (Figure 4.14).  
For the determination of optimal range of ZEN for SPR-based inhibition assay a range of ZEN 
concentrations were prepared and pre-mixed with scFv-P2A2. The samples were then passed 
over the surface of sensor chip followed by regeneration steps with 20 mM NaOH in between 
the runs. A standard calibration curve was generated from the ratio of mean binding slope of 
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standard ZEN to the standard scFv-P2A2 (without ZEN) against log concentration of ZEN. The 
range of detection for the scFv was found to be 0.0039-1 µg/mL. 
Direct coupling of ZEN was performed by Van der Gaag et al. (2003), but their assay was not 
validated using ‘Real’ sample to determine the feasibility of the assay for food analysis. In the 
present studies the assay was proven to be applicable for the detection of ZEN in sorghum and 
the assay may be applied for other types of foods. The detection limits of the SPR assays 
developed to-date were 0.01 ng/mL (Van der Gaag et al., 2003), 0.3 ng/mL (Choi et al., 2009) 
and 0.007 ng/mL (Urraca et al., 2005). The SPR-based inhibition assay developed using scFv-
P2A2 has a limit of detection of 7.8 ng/mL (matrix).    
In conclusion, an anti-ZEN scFv that is highly specific to ZEN was developed and applied in an 
ELISA and SPR-based inhibition assays with IC50 values of 200 & 10 ng/mL, respectively. 
which falls within the 200 ng/mL maximum permissible limits for ZEN. The SPR-based assay 
was proven to be feasible for the detection of ZEN in sorghum samples. To our knowledge this 
is the first reported SPR-based inhibition assay developed using scFv for the specific detection 
of ZEN. The limit of detection is far lower than the permissible limits of 200 ng/mL, which 
would make this antibody useful for ZEN analytical purposes. Furthermore, this scFv was used 
to generate an immuno-affinity column described in chapter 6.   
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Chapter 5 
Generation and 
characterization of anti-T-2 
toxin IgY  
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5.1 Introduction 
T-2 toxin is not inactivated by food processing techniques (Sokolovic et al., 2008). Due to its 
high incidence, the regulatory authorities in the EU are trying to set maximum permissible 
levels for T-2 in food and feed (http://services.leatherheadfood.com/eman/FactSheet 
.aspx?ID=79).  
To-date, avian species were rarely used for the development of antibodies against mycotoxins 
and only one report exists, for the successful antibody generation in chickens against T-2 toxin 
(Jaszczuk et al., 1995). Egg yolk-derived antibodies offer potential applications in various 
fields including therapeutics (Lee, 2002), immuno-diagnostics (Sunwoo et al., 2006) and food 
toxin detection (Allen and Smith, 1987). The various advantages offered by the utilization of 
egg yolk antibodies, including the reduction in the need for sacrifice of animals, the presence of 
large concentrations of antibodies in eggs (Hau and Hendriksen, 2005) and resistance of IgY to 
acid and heat (Losch et al., 1986), make the utilization of IgY a viable alternative source for 
generating polyclonal antibodies, with sensitivities comparable to anti-T-2 monoclonal 
antibodies developed to-date. Monoclonal antibody-based assays generated for the detection of 
T-2 toxin have detection limits between 0.05-100 ng/mL (Gendloff et al., 1984; Barna-Vetro et 
al., 1994; Kononenko et al., 1999; Takumi et al., 2004). These antibodies exhibited cross 
reactivity with other mycotoxins. Hence, there is a need to develop an affinity purification 
technique capable of isolating anti-T-2 specific (mono-specific) IgY.  
It was decided to generate and affinity purify an anti-T-2 toxin IgY (from egg yolk) with 
subsequent incorporation into a Biacore-based competitive inhibition assay format (Figure 5.1) 
based on reported immunoassays using IgY for detection of other mycotoxins such as ZEN 
(Pichler et al., 1998) and DON (Schneider et al., 2000).  
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Figure 5.1:  Multi-stage approach adopted for isolation of mono-specific anti-T-2 IgY and its 
subsequent incorporation into SPR-based inhibition assay. In the first stage IgY was isolated from the 
eggs of T-2 KLH immunized chicken. The second stage comprises of synthesis of T-2 toxin immobilized 
amine-activated beads for subjecting the IgY to affinity purification to isolate T-2 specific IgY with 
minimal cross reactivity to other mycotoxins. After affinity purification the purity, identity and 
molecular mass of IgY was analyzed by FPLC, SDS-PAGE and MALDI-TOF, respectively. The 
specificity and sensitivity of IgY was determined by ELISA’s. Later SPR-based inhibition assay was 
developed and validated.  
 
5.2 Avian immune response to T-2 toxin 
Following immunization of a leghorn chicken with T-2-KLH-adjuvant emulsion mixture four 
times, the antibody response was evaluated through determining the antigen-specific titre of the 
serum. Positive and negative controls were incorporated to confirm the specific immune 
response towards T-2 toxin. The pre- and post-immunization serum titre of the chicken was 
determined against T-2-BSA, KLH and BSA. As expected, there was a response of the serum 
against KLH. A semi-log plot was generated with the reciprocal of serum dilutions (X-axis) 
against absorbance values @ 450 nm (Y-axis). From the graph (Figure 5.2) an antibody titre of 
1/120,000 was found after the fourth boost.  
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Figure 5.2: Immune response of T-2 KLH conjugate immunized chicken. Doubling dilution of 
immune and pre-immunization sera (1/100 to 1/512,000) were tested against T-2 BSA, BSA and KLH in 
duplicate. A 1/1,000 dilution of HRP-labelled rabbit anti-chicken Ig secondary antibody was added, 
followed by the visualization with TMB solution. The immune response was recorded to be in excess of 
1/120,000.  
 
5.3 Isolation, affinity purification and analysis of anti-T-2 IgY  
5.3.1 Isolation of anti-T-2 IgY from egg yolks 
Chicken eggs collected after the fourth boost were used for the isolation of anti-T-2 toxin IgY. 
A commercial kit was used for IgY isolation, following the protocol outlined in section 2.2.5.3 
of chapter 2. The re-suspended IgY precipitate was quantified on the NanodropTM. The 
concentration of IgY obtained was 10 mg/mL. The overall yield of IgY from one egg was 
approximately 120 mg. Subsequently, mono-specific IgY was attained after subjecting the IgY 
to affinity purification on T-2 toxin-immobilized amine-activated sepharose beads.  
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5.3.2 Immobilization of T-2 toxin on amine-activated beads 
The immobilization procedure, described in section 2.2.5.4 of chapter 2, was adopted for 
covalent linkage of T-2 toxin to the beads. A T-2 toxin carbonyldiimidazole derivative (T-2 
carbamate), which has greater capacity for coupling to the amine-activated beads (Hermanson, 
1996) was prepared through activating hydroxyl group at the C3 position of T-2 toxin with 
carbonyldiimidazole (CDI) and used for immobilization. The sequential steps involved in T-2 
toxin immobilization onto the amine-activated beads are depicted in Figure 5.3. Free amine 
groups were estimated using the Ninhydrin test. A decrease in the number of free amine groups 
after T-2 immobilization was established. A colorimetric determination of the amine-activated 
beads was carried out through reading the absorbance @ 280 nm on Tecan Saffire plate reader. 
The difference in the absorbance value of T-2 immobilized beads and un-immobilized beads 
indicates the utilization of amine groups for the coupling of T-2 toxin. 
 
5.3.3 Affinity purification of IgY using T-2 toxin-immobilized amine-activated beads 
The T-2 toxin-immobilized beads were equilibrated with PBS. After equilibrating the column, 
10 mg of IgY were added and incubated for 2 hrs at 40C, followed by washing the column with 
PBS. The bound IgY was eluted using 8 mL of 100 mM glycine-HCl in water (pH 3.0). One 
mL eluted fractions of IgY were collected and neutralized with 50 µL of 1 M Tris (pH 9.0). 
The percentage recovery of IgY was 10-20% (calculation based on equation = (amount of IgY 
added to the beads – amount of IgY recovered) X 100 / amount of IgY added to the beads). 
This loss can be attributed to the elimination of IgY that is not specific to the T-2 toxin.  
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Figure 5.3: T-2 toxin immobilization on amine-activated beads. The T-2 toxin was first reacted with 
carbonyldiimidazole and the reaction mixture was added to the amine-activated beads in the presence 
of coupling buffer.  
  
5.3.4 ELISA assay using anti-T-2 toxin IgY  
5.3.4.1 Indirect ELISA 
An indirect ELISA assay (Figure 5.4) was performed on a microtitre plate coated overnight at 
40C with T-2-BSA or BSA. Equal starting concentrations (1 mg/mL) of IgY (before and after 
affinity purification) were used to perform the assay. Varying dilutions of IgY from 1/100 to 
1/512,000 were used. From the semi-log plot drawn with the reciprocal IgY dilution values on 
X-axis against absorbance @ 450 nm (Y-axis), a 50% increase in the titre value of pure IgY 
after affinity purification was recorded. Overall, the titre values before and after affinity 
purification were 1/80,000 and 1/120,000, respectively.  
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Figure 5.4: Titration of anti-T-2 IgY. Varying dilutions of IgY before and after affinity purification 
were tested against T-2-BSA and BSA. HRP-labelled rabbit anti-chicken Ig (1/1,000 dilution) was 
added followed by the addition of TMB solution. The error bars indicates S.D. of the results obtained 
from the experiments where n=3 independent determinations. The absorbance of BSA-coated wells was 
taken as background values.   
 
5.3.4.2 Competitive indirect ELISA (CI-ELISA)  
CI-ELISA (Figure 5.5) was performed using a 1/1,000 dilution of IgY that was incubated for 
30 mins with varying concentrations (0.004-2.5 µg/mL) of T-2 toxin. In this experiment, the 
toxin conjugate (T-2-BSA) was immobilized on the immunoplate. Competition for antibody 
binding occurs between the immobilized toxin and the free toxin added (Section 2.2.5.5). A 
semi-log plot was drawn with A/A0 (A= absorbance of antibody inhibited with varying 
concentration of T-2 toxin & A0= absorbance of antibody with no T-2 toxin) on Y-axis against 
concentration of T-2 toxin on a logarithmic X-axis. The mid inflection point (IC50 value) was 
40  and 80 ng/mL when IgY before and after affinity purification, respectively were used.  
For intra- and inter-day assay variations (Figure 5.6), each concentration was assayed three 
times on the same day and five times on different days, respectively. The mean absorbance of 
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bound antibody for each antigen concentration was plotted against log concentration of antigen. 
The percentage CVs (coefficient of variance) for inra- and inter-day assays were below 8 and 
11%, respectively (Table 5.1).   
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Figure 5.5: Competitive inhibition curve of anti-T-2 IgY. A 1/1,000 dilution of both mono-specific and 
crude IgY were incubated for 30 mins at 37
0
C with varying concentration of T-2 toxin (0.004-2.5 
µg/mL)  in the ratio of 1:1. The error bars indicates standard deviation (S.D.) calculated where n=3 
independent determinations. 
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Figure 5.6: Intra- and inter-day variation of competitive ELISA for T-2 toxin using affinity purified 
mono-specific IgY. A 5 µg/mL T-2-BSA coating concentration was used with a 1/1,000 dilution of anti-
T-2 IgY that was incubated with a T-2 toxin (0.004-2.5 µg/mL). For intra-day (a) studies the S.D. was 
computed from 3 validation runs on the same day and inter-day (b) S.D. was determined over 5 
validation runs on 5 separate days. A 4-parameter logistic curve was fitted to the data set.     
 
Table 5.1: Intra- and inter-day coefficient of variance for the determination of free T-2 toxin 
using anti-T-2 IgY. Three sets of ten standards were assayed on five different days and CVs 
were calculated.  
  
                           Intra-day assay                    Inter-day assay T-2 toxin   
concentration 
(ng/mL) 
Back- 
calculated 
concentration 
(ng/mL)  
A/A0 %  
CVs 
%  
Accuracies 
Back- 
calculated 
concentration 
(ng/mL)  
A/A0 %  
CVs 
%  
Accuracies 
 
312.5 
 
347 
 
0.1965
 
 
7.59 
 
111.2 
 
318 
 
0.2210
 
 
9.56 
 
101.9 
156.25 149 0.2471
 
2.89 95.5 156 0.3483
 
5.22 100 
78.125 84 0.4069
 
1.61 107.7 81 0.5084
 
1.45 103.8 
39.062 39 0.5260
 
2.59 100 35 0.6950
 
5.65 89.7 
19.531 19 0.6722
 
6.15 100 18 0.7074
 
6.67 94.7 
9.765 8 0.7815
 
2.35 88.9 10 0.8226
 
4.77 111.1 
4.882 4 0.9654 1.39 100 4 0.8783 5.67 100 
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5.3.4.3 Cross reactivity studies 
The cross reactivity of anti-T-2 toxin IgY for HT-2, deoxynivalenol, zearalenone, fumonisin B1 
were determined employing the procedure described in section 2.2.5.5.2. The cross reactivity is 
defined as the point where the 50% reduction in the signal (in the presence of analyte) is 
noticed in comparison to the signal obtained in the presence of no analyte. The percentage cross 
reactivity was calculated by taking the IC50 value against T-2 toxin as 100%. The calculation 
was done using the formula  
                % cross reactivity =           IC50 value of mycotoxins X 100 
                                                              IC50 value of T-2 toxin 
 
From the % cross reactivity data (Table 5.2) it was found that affinity purification of IgY led to 
a decrease in the cross reactivity percentage of IgY to HT-2 toxin and also to the other 
mycotoxins.  
Table 5.2: Cross reactivity profile of anti-T-2 IgY before and after affinity purification  
 
                                % Cross reactivity                   Toxin 
Before affinity purification                       After affinity purification 
                 
                  T-2 
 
100% 
 
100% 
                 HT-2 46% 5% 
           Deoxynivalenol  0.2%   0.11% 
             Zearalenone 0.15%  0.12 % 
            Fumonisin B1 0.32%   0.21% 
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5.3.5 IgY confirmatory tests 
5.3.5.1 FPLC and SDS-PAGE analyis of IgY 
IgY (M.wt. ̴ 180 kDa) was analysed on FPLC using size exclusion chromatography. A set of 
molecular weight markers (Ovalbumin (43,000 Da), Conalbumin (75,000 Da), Aldolase 
(158,000 Da), Ferritin (440,000 Da)) were injected into the FPLC. The chromatogram (Figure 
5.7(a)) was generated, which indicates that the peak of IgY corresponds to approximately 180 
kDa.  
To confirm IgY purity and identity, SDS-PAGE analysis (Figure 5.7(c)) under reducing and 
non-reducing conditions were performed. Under reducing conditions two bands corresponds to 
the light chain ( ̴ 24 kDa) and heavy chain ( ̴ 65 kDa) were seen. One band at approximately 180 
kDa was identified when SDS-PAGE gel was run under non-reducing conditions.  
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Figure 5.7: FPLC and SDS-PAGE analysis of IgY. Equal concentrations of IgY, before and after 
affinity purification, were used. A range of  molecular weight markers were also injected,  in parallel,  
to confirm the IgY peak through comparing the peak positions obtained from the chromatogram (Figure 
(a)). Figure (b) indicates retention time of calibration standards versus the retention of IgY .The 
estimated molecular weight of IgY was  ̴ 180 kDa. Figure (c) represents the SDS-PAGE gel of the IgY 
under reducing and non-reducing conditions. The representation of the various lanes is as follows: lane 
1: Sigma wide range molecular weight markers; lanes 2 & 3:  non-reduced IgY before and after 
purification and lanes 4 & 5: reduced IgY before and after purification, respectively.    
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5.3.5.2 MALDI-TOF analysis 
The molecular mass of purified IgY was analyzed through MALDI-TOF analysis (Figure 5.8), 
which indicates the presence of four different fragments in the whole IgY molecule. The 
molecular mass of the light chain of the IgY is approximately 31,000-37,000 Da. The heavy 
chain’s molecular mass is approximately 69,000-85,000 Da. The mass of the intact IgY 
molecule is approximately 165,000-172,000 Da.  
4,000 8,0000 12,000 16,000 18,000
mass/charge (m/z)
In
te
n
s
. 
[a
.u
.]
0
100
200
300
400
500
1
6
5
0
5
9
.8
1
1
6
8
9
5
7
.8
6
1
7
2
4
3
0
.0
9
8
5
0
1
4
.1
1
6
9
0
0
8
.4
4
3
4
4
4
2
.6
6
3
1
7
2
7
.5
3
3
1
9
1
6
.7
6
3
2
1
5
8
.1
2
3
7
3
7
5
.7
9
3
6
9
5
8
.2
1
3
6
7
7
5
.6
8
3
6
6
9
7
.4
7
Light chain of IgY 
Heavy chain of IgY 
Intact full length IgY 
 
 
Figure 5.8: MALDI-TOF analysis of the anti-T-2 toxin IgY. The IgY (1 mg/mL) and sinnapic acid 
were mixed in the ratio of 1:1 and added to the chip surface in the presence of trifluroacetic acid. From 
the figure it can be seen that besides the intact IgY, there are also fragmented portions of IgY. The 
arrows indicates the major peaks of the IgY.  
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5.4 Immobilization of T-2 toxin on CM5 sensor chip 
Analysis of the binding of anti-T-2 toxin IgY was performed using the Biacore™ 3000 
biosensor. Prior to anti-T-2 toxin IgY assay, the CM5 chip was immobilized with T-2 toxin 
(Figure 5.9). The various steps involved in this process were, priming of CM5 chip with HBS 
buffer, followed by surface activation with 1:1 ratio of EDC-NHS. The EDC-NHS surface 
activated CM5 chip was then incorporated with amine groups through the addition of 
Jeffamine, followed by the immediate blockage of un-reacted amine groups with ethanolamine. 
Then a T-2-CDI mixture was added leading to the generation of T-2 toxin immobilized CM5 
chip. 
CM5 Chip
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CONH
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Figure 5.9: Schematic representation of T-2 toxin immobilization on a CM5 sensor chip. The first 
stage (a) involved in the immobilization of T-2 toxin onto CM5 chip was surface activation with EDC 
and NHS. In the second stage amine groups were generated through treating with Jeffamine (b). The 
third stage involves the covalent attachment of T-2 toxin to the amine groups on the CM5 chip (c).  
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5.5 Analysis of anti-T-2 toxin IgY on T-2 toxin immobilized sensor chip 
After immobilization of T-2 toxin on sensor chip, the affinity purified anti-T-2 IgY was passed 
over the sensor chip. Figure 5.10 shows that anti-T-2 IgY recognizes T-2 toxin in its 
unconjugated form. A negative control antibody (anti-CRP scFv antibody) was also used in 
order to prove the specific binding the anti-T-2 toxin IgY on the CM5 chip.   
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Figure 5.10: Sensogram depicting the binding of anti-T-2 toxin IgY to T-2 toxin. A 1/2,500 dilution of 
anti-T-2 toxin IgY was passed over the flow cell 1 of T-2 toxin immobilized sensor chip, which resulted 
in a net binding response of 202 RU. The exact response units were measured through subtracting the 
RU obtained when non-specific antibody was passed over the surface.     
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5.6 Solution phage T-2 toxin binding assay 
In this assay anti-T-2 IgY was prevented (inhibited) from binding to the immobilized T-2 toxin 
through the addition of varying concentrations of T-2 toxin (0.007-1 µg/mL) in solution (Figure 
5.11). The SPR analysis revealed that the anti-T-2 toxin IgY had an IC50 value of 42 ng/mL 
(Figure 5.11). The LOD and LOQ of anti-T-2 toxin IgY was 8 ± 0.15 ng/mL and 12 ± 0.21 
ng/mL. Intra- (n=3) and inter-day (n=5) assays were performed and graph was plotted using the 
mean A/A0 (A= absorbance of antibody in presence of T-2 toxin and A0= absorbance of 
antibody alone) against concentration of T-2 toxin (Figure 5.12). The percentage coefficient of 
variance (%  CVs ) for both intra- and inter-day assays are presented in Table 5.3.       
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Figure 5.11: SPR-inhibition curve of the anti-T-2 toxin IgY. The R/R0 was calculated by dividing the 
response units obtained at 8 different T-2 toxin concentrations (0.007-1 µg/mL) by the response units 
obtained upon passing anti-T-2 toxin IgY alone, without T-2 toxin. A 4- parameter logistic curve was 
fitted to the data set using SigmaPlot software. The error bars indicates the S.D. of three replicate 
measurements. 
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Figure 5.12: Intra- (a) and inter- (b) day SPR-inhibition calibration curves in solution. A 1/2,500 
dilution of anti-T-2 IgY was incubated with 0.007-1 µg/mL of T-2 toxin and passed over the T-2 toxin 
immobilized sensor chip. The results were normalized by dividing the response units in presence of T-2 
toxin (R) by the response units of zero concentration of antigen (R0) in the assay. For intra-day (a) 
studies the S.D. was computed from 3 validation runs on the same day and inter-day (b) S.D. was 
determined over 5 validation runs on 5 separate days. A 4-parameter logistic curve was fitted to the 
data set.     
 
Table 5.3: Intra- and inter-day coefficient of variance for the determination of free T-2 toxin  
using anti-T-2 IgY. Three sets of eight standards were assayed on five different days and CVs 
were calculated.  
  
                        Intra-day assay                  Inter-day assay T-2 toxin  
concentration 
(ng/mL) 
Back- 
calculated 
concentration 
(ng/mL) 
R/R0 % 
 CVs 
%  
Accuracies 
Back- 
calculated 
concentration 
(ng/mL)  
R/R0 %  
CVs 
%  
Accuracies 
 
1000 
 
1113 
 
0.0440
 
 
2.72 
 
111.3 
 
1046 
 
0.1283
 
 
3.21 
 
104.6 
500 510 0.0730
 
6.33 102 446 0.1296
 
11.43 89.2 
250 249 0.1130
 
8.93 99.6 293 0.2977
 
2.47 117.2 
125 123 0.2260
 
3.02 98.4 117 0.3268
 
3.63 93.6 
62.5 73 0.4746
 
8.08 117.7 61 0.4690
 
6.12 98.4 
31.25 27 0.5711
 
1.31 87.1 31 0.6402
 
1.45 100 
15.625 19 0.9900
 
5.45 126.7 16 0.8390
 
8.35 106.7 
7.8125 6 0.9976 2.45 85.7 7 0.9936 7.67 100 
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5.7 Spiking of wheat samples with T-2 toxin 
Wheat samples (10 grams) were ground and extracted with 30 mL ethanol/water 85:5 (v/v) by 
constant stirring on a magnetic stirrer for 30 mins. The extract was filtered using Whatman 
Grade 1 filter paper. The filtrate was evaporated to dryness in a rotary evaporator and dissolved 
in 10 mL HBS buffer (pH 7.4). T-2 toxin was then added. The percentage recovery (n=3) 
attained from SPR inhibition analysis when the wheat sample extract was spiked with 1 µg/mL 
of T-2 toxin was 100%. 
 
 5.8 Intra- and inter-day validation of SPR inhibition assay using wheat sample extract  
Affinity purified anti-T-2 IgY was used to develop an inhibition assay for the detection of T-2 
toxin, as described in section 2.2.5.7. The assay was performed using wheat sample extract 
spiked with T-2 toxin ranging from 0.007-1 µg/mL, assayed in triplicate and repeated over five 
days. Figure 5.13 represents the intra-day inhibition standard cruve (four parametric fit) using 
SigmaPlot software. The percentage coefficient of variance, which are indicative of the 
precision of the both inter- and intra-day assays (Figure 5.13) were tabulated (Table 5.4). The 
inter-day coefficient of variance between 1.7 and 5.4% (Table 5.4). The limit of detection and 
limit of quantification (LOQ = LOB + 10 X S.D. of LOB) were 11 ± 0.23 and 23 ± 0.31 ng/mL 
(Mean ± S.D.). 
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Figure 5.13: Intra-day and inter-day calibration curves of SPR-based inhibition assay using mono-
specific IgY. A 1/2,500 dilution of anti-T-2 IgY was incubated with spiked wheat sample extract 
containing 0.007-1 µg/mL of T-2 toxin and passed over the T-2 toxin immobilized sensor chip. The 
results were normalized by dividing the response units in presence of T-2 toxin (R) by the response units 
of zero concentration of antigen (R0) in the assay. For intra-day (a) studies the S.D. was computed from 
3 validation runs on the same day and inter-day (b) S.D. was determined over 5 validation runs on 5 
separate days. A 4-parameter logistic curve was fitted to the data set.     
     
Table 5.4: Intra- and inter-day coefficient of variance for the determination of T-2 toxin  in 
spiked wheat sample extract using anti-T-2 IgY. Three sets of eleven standards were assayed on 
five different days and CVs were calculated.  
  
                        Intra-day assay                     Inter-day assay T-2 toxin  
concentration 
(ng/mL) 
Back- 
calculated 
concentration 
(ng/mL) 
R/R0 %  
CVs 
%  
Accuracies 
Back- 
calculated 
concentration 
(ng/mL) 
R/R0 %  
CVs 
%  
Accuracies 
 
125 
 
126 
 
0.2200
 
 
3.57 
 
100.8 
 
124 
 
0.2260
 
 
3.67 
 
99.2 
62.5 66 0.4700
 
4.28 106.4 62 0.4746
 
5.12 100 
31.25 31 0.6700
 
1.31 100 31 0.6711
 
2.45 100 
15.625 16 0.9990
 
2.45 106.7 15 0.9900
 
3.65 100 
7.8125 6 1.0122 1.45 85.7 6 1.0356 2.67 85.7 
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5.9 Discussion 
T-2 immunogens induce slower immune response in both rabbits and mice due to the instability 
of the hemisuccinate (HS) of T-2 (a T-2 derivative that was commonly synthesized to perform 
conjugation) and also due to immunosuppressive effects (Hunter et al., 1985). To circumvent 
this problem, the conversion of T-2 to T-2-HS was avoided. Instead, an alternative strategy of 
conjugating T-2 to the carrier protein using the CDI method, employing a slightly modified 
procedure developed by (Xiao et al., 1995) was adopted. An immune response of 1/120,000 
was obtained, which was higher than the earlier reported response obtained through 
immunizing a rabbit with a T-2-KLH conjugate synthesized following EDC-NHS ester 
chemistry (Wang et al., 2010). The five factors that might influence the immune response, 
including the dose and molecular weight of the antigen, type of adjuvant used, route of 
immunization, frequency of immunization and intervals between immunizations (Schade and 
Hinak, 1996), were taken into consideration when developing avian anti-T-2 toxin antibodies.  
Based on the finding of (Schwarzkopf et al., 2000), that an antigen concentration ranging from 
10 µg/mL to 1 mg/mL has to be used to generate a good immune response, 200 µg/mL of the 
T-2 KLH conjugate (1 mL volume of T-2 conjugate Fruends adjuvant emulsion) was 
administered to the chicken. Fruend’s adjuvant is cost-effective for eliciting immune responses 
in laboratory animals. This is the most commonly used adjuvant for the production of 
antibodies in chickens. A combination of Fruends’s complete adjuvant (FCA) and Fruend’s 
incomplete adjuvant (FIA) was used for the successful generation of an antibody response (Li 
et al., 2006). 
The egg yolks are the main reservoir of IgY (Kovacs-Nolan and Mine, 2005). Eggs from a host 
with hyper-immune serum to T-2 toxin were used for the isolation of polyclonal IgY. The 
affinity purification technique can be used for the isolation of mono-specific antibodies from a 
polyclonal antibody pool (Josic et al., 1994).  To-date, most of the IgY purification techniques 
are mainly FPLC-based methods. A T-2 toxin affinity column with 1.3 mg/mL of T-2 and 
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loading value of 22 µmol amine per millilitre of beads was developed and used for affinity 
purification with an average IgY recovery of 10-20%, which may be associated with the 
presence of 2-10% antigen-specific antibodies in egg yolk (Ferreira Junior et al., 2012). Since 
pH plays a role in  antibody elution (Kang and Bae, 2004), the effect of pH on the elution of 
the anti-T-2 IgY antibody was determined over a pH range from 2.0-11.0 and the optimized 
yield was obtained at pH 3.0 (data not shown). Under the above specified conditions the 
column was used for five successive purifications with minimal loss in the column binding 
efficiency. The affinity-purified IgY was evaluated through indirect, CI-ELISA and SPR-based 
inhibition assays. An increased titre after affinity purification with reduction in the cross 
reactivity of IgY towards HT-2 toxin from 46 to 5% was recorded, which apparently indicates 
the elimination of immunoglobulins that are not specific to T-2 toxin from the IgY pool. The 
decreased cross reactivity of IgY after subjecting to affinity purification on T-2 immobilized 
ligand indicates that this purification technique can readily be applied for the isolation of 
mono-specific antibodies in order to increase the specificity of immunoassay without changing 
the intrinsic properties of the antibody itself.  
The identity and molecular mass of the IgY were confirmed by FPLC, SDS-PAGE analysis and 
MALDI-TOF. The results of all these three assays indicate the presence of IgY of 
approximately 180 kDa molecular weight. The MALDI-TOF data reveals the presence of a 
heavy (68 kDa) and light chain (31-37 kDa) fragment, which can be seen when SDS-PAGE was 
run under reducing conditions. The MALDI-TOF data obtained in the present work are similar 
to the results obtained by (Sun et al., 2001).     
The purified IgY was used for the development of two types of assays: an CI-ELISA and SPR-
based inhibition assay. The IC50 of anti-T-2 toxin IgY before and after affinity purification as 
determined by both the assays was found to be 40 ± 0.1 and 80 ± 0.4 ng/mL, respectively  
which falls with in the range of detection of assays developed for T-2 detection using 
monoclonal antibodies. The SPR assay was validated using wheat sample extract that had been 
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spiked (post extraction) with known amounts of T-2 toxin (0.007-1 µg/ml). The IC50 of IgY in 
buffer and matrix were 30 ± 0.1 ng/mL and 32 ± 0.1 ng/mL (Mean ± S.D., n=3), respectively. 
Limit of blank (LOB) was determined by analysis of 20 blank wheat sample extract without 
any T-2 toxin. The limit of detection and quantification were 8 ± 0.15 ng/mL (buffer) and 11 ± 
0.23 ng/mL (matrix) and 12 ± 0.21 ng/mL (buffer) and 23 ± 0.31 ng/mL (matrix) (Mean ± S.D., 
n=3), respectively. The precision of the assay was determined by intra- (n=3) and inter-day 
(n=5) assays, which showed a CV less than 6%, and is well within the range of the acceptable 
CVs of 20%. The results indicate that the IgY can be successfully used for the detection of T-2 
toxin in wheat sample extract with detection levels within the permissible limits of 100 ng/mL 
(Riazipour et al., 2009).  
To summarize, a purification method utilizing antigen-immobilized sepharose in conjunction 
with affinity chromatographic techniques was developed and applied successfully for the 
isolation of mono-specific antibodies from polyclonal pool of anti-T-2 IgY. Further the 
application of mono-specific anti-T-2 IgY for detection of T-2 toxin in wheat was 
demonstrated.     
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Chapter 6 
Immunoassays for the 
detection of aflatoxin B1, B2, 
ZEN and T-2 toxins 
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6.1 Introduction 
This chapter focuses on the development of immunoassays for the detection of mycotoxins 
AFB1, B2, ZEN and T-2 toxin. A mycotoxin quantification techniques i.e., ELISA assay on 
AFB1 covalently-immobilized microtitre plates was developed. An isolation technique 
(immuno-affinity column) for the specific isolation of AFB1, B2 and ZEN, using their 
respective recombinant antibodies immobilized on silica particles, was also established. The 
approaches adopted for the generation of mycotoxin immunoassays are depicted in Figure 6.1.     
 
ELISA using 
covalently immobilized 
aflatoxin B 1 
• -OH functional group 
incorporation
• Amine group ( -NH2) generation
• Covalent attachment of aflatoxin 
B1 on microtitre plates
• Competitive inhibition ELISA 
assay
• Utilization of  aflatoxin B1-
contaminated corn sample 
extract for assay performance  
evaluation
Immuno-affinity 
column  
• Covalent immobilization of 
recombinant antibodies onto 
silica particles
• Binding of free antigen to the 
antibody immobilized silica
• Quantification  of eluted 
mycotoxins by fluorescence 
Mbio platform
• Imprinting of mycotoxin
conjugates on the surface of 
cartridge
• Alexa 647 labelling of 
recombinant antibody
• Direct binding  assay
Immunoassays
 
Figure 6.1: Approaches adopted for the development of immunoassays. Two quantitative approaches 
(ELISA on covalently immobilized AFB1 on microtitre plates and the MBio system) and one isolation 
technique (immuno-affinity column) were developed. Prior to ELISA assay performance the AFB1 was 
covalently linked to amine-functionalized microtitre plates. The ELISA assay was performed in both 
buffer and matrix to evaluate the feasibility of the developed assay for food analysis. Immuno-affinity 
columns for the specific isolation of AFB1, B2 and ZEN were developed individually by immobilizing the 
anti-AFB1, B2 and ZEN antibodies onto silica particles. The stability, reusability and recovery rates of 
mycotoxins from the column was evaluated. The MBio platform is an array-based assay, measuring 
fluorescence intensity using planar wave guide technology. BSA conjugates of AFB1, B2, ZEN and T-2 
were imprinted onto the MBio cartridge. Alexa 647 labelled recombinant (AFB1, B2 and ZEN) and 
polyclonal (T-2 toxin) antibodies were used.    
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6.1.1 Covalent immobilization of AFB1  
Amide linkage is one of the most stable methods for immobilizing haptens onto the surface of 
microtitre plates (Orbulescu et al., 2006). Therefore, amide linkage was selected for the 
covalent immobilization of carboxylated AFB1 on amine-activated plates. Amine activation can 
be achieved using hydrophilic spacer arms such as 3-aminopropyl diisopropyl ethoxysilane, 3-
glycidoxypropyl diisopropylethoxysilane or 3-aminopropyl triethoxysilane. The proof of 
concept of the covalent immobilization approach was studied by indirect and competitive 
ELISAs using a recombinant anti-AFB1 Fab antibody fragment with a HA tag (Stapleton et al., 
2007) for the detection of AFB1.  
 
6.1.1.1 Results 
6.1.1.1.1 Optimization and implementation of AFB1 immobilization on microtitre plates   
The covalent attachment of AFB1 (Figure 6.2) on the microtitre plate was optimized through 
varying the AFB1-CMO-NHS ester concentration and temperature. A checker-board 
competitive inhibition ELISA was performed to determine the optimal amount of AFB1-CMO-
NHS ester for covalent immobilization. It was found that 50 µg/mL of ester was more effective 
in producing an optimal absorbance response, with minimal undesirable background and better 
‘signal-to-noise’ ratios (S/N ratio). The selection of the optimal covalent linkage temperature 
was performed by overnight incubation at 40C, 370C and room temperature (RT) after addition 
of the AFB1 ester in 1 M carbonate buffer (pH 9.5). It was found that usage of 50 µg/mL of 
ester at 40C incubation was optimal for the generation of an ideal AFB1-covalently immobilized 
plate. Incubation at 370C and room temperature reduced the efficiency of the covalent linkage 
of AFB1 which may be due to increased hydrolysis of NHS ester at higher temperatures leading 
to reduced amine reactivity.  
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Figure 6.2: Schematic representation of AFB1 immobilization and assay format development. The 
wells of the microtitre plate were activated for the generation of hydroxyl functional groups. (b) 
Addition of 3-aminopropyltriethoxy silane (APTES) led to the formation of amine groups (c). The 
modified AFB1-CMO-ester was attached to the surface through amide bonding (d). Two alternative 
procedures were performed on these plates. One set of plates was first reacted with 0.2 M formaldehyde 
to block the unreacted amine groups (e). Anti-AFB1 antibody, its chromogenic reporter anti-HA-HRP 
and substrate 3,3´, 5,5´ – tetramethylbenzidine dihydrochloride (TMB) solution were added (f). Another 
set of plates was used for estimation of the level of AFB1 immobilized on the surface, through cleaving 
Si-O- bond from the surface of the modified microtitre plate using 1 M tetrabutyl ammonium fluoride 
(TBAF). The cleaved product (g) was used for quantification of the covalently-immobilized AFB1 by 
fluorescence and the molecular weight of the cleaved compound was determined using ESI mass 
spectroscopy. 
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6.1.1.1.2 Confirmation of AFB1 immobilization and estimating the amount of covalently 
immobilized AFB1 
The degree of covalent linkage was determined by quantifying the amount of covalently- 
immobilized AFB1 released following cleavage, using a fluorescence-based assay. The 
cleavage of the AFB1 from the surface of the microtitre plate was performed through the 
addition of 1 M TBAF, which cleaves the polystyrene–O–Si bond between the AFB1 and 
polystyrene surfaces under neutral conditions. A standard calibration curve was plotted from 
the fluorescence values of standard AFB1 concentrations at 360/440 nm (Excitation/Emission) 
(Figure 6.3(a)). Simultaneously, the fluorescence of the cleaved product was also determined. 
An initial loading value of AFB1 of 0.73 nmol/cm
2 was calculated. The molecular weight of the 
cleaved product was determined by ESI mass spectroscopy. The chromatogram of the cleaved 
product from the mass spectroscopy data showed a major peak at 503.6 (Figure 6.3(b)), which 
corresponds to AFB1-CMO-NH-(CH2)3-Si(OH)3 (Calculated: 504 Da, Observed: 503.6 Da). 
From this it can be concluded that neither free AFB1 (M.Wt. 312.27) nor the ester of AFB1- 
CMO-COOH (M.Wt. 385) was present on the surface of the covalently-immobilized plate. 
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Figure 6.3: Fluorescence (a) and ESI mass (b) analysis of the cleaved AFB1 that was covalently 
immobilized on the surface of the microtitre plate. The covalently linked AFB1 was cleaved from the 
surface using 1 M tetrabutyl ammonium fluoride (TBAF). The amount of covalently-immobilized AFB1 
was determined through substituting the fluorescence value of cleaved product into the plot equation 
drawn using varying concentrations of AFB1 (2.5-25 µg/mL). An ESI mass spectrum in positive mode 
was performed to determine the molecular mass of the cleaved product. The molecular weight of the 
cleaved product corresponds to 503.6 Da, which represents AFB1-CMO-NH-(CH2)3-Si-O-polystyrene. 
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6.1.1.1.3 Functionality of AFB1-covalently immobilized microtitre plates  
After successful covalent attachment of the AFB1 on the microtitre plate surface, the next step 
was immunoassay format development. In the process of assay development, the initial step is 
blockage of non-specific binding sites. The un-reacted NH2 groups were blocked using 0.2 M 
formaldehyde. The blockage of the plates was followed by the determination of functionality of 
the microtitre plate using indirect and competitive inhibition ELISAs with the anti-AFB1 Fab 
antibody that was generated in our lab. An anti-CRP recombinant antibody, which should not 
bind to the hapten or its conjugate was used as a control. The absence of signal without anti-
AFB1 antibody in the assay, indicated its specificity. The negative control experiments were 
performed by coating the microtitre plate with milk Marvel and BSA, in the case of the AFB1 
conjugate passively-adsorbed plate, and formaldehyde and PBS, in the case of the AFB1 
covalently-immobilized plates. Three types of AFB1 conjugates i.e, AFB1-BSA, AFB1-OVA 
and AFB1-KLH conjugates were used. Due to the lack of variation in the antibody recognition 
characteristic when assays were performed using either KLH, BSA and OVA conjugates of 
AFB1, further competitive inhibition ELISAs were performed on microtitre plates with the 
passively-adsorbed AFB1-BSA conjugate. Negative control studies showed no non-specific 
binding. The IC50 value was estimated from the mid-point inflection of the maximum value, on 
each curve. The IC50 results were 27 ± 2.7 ng/mL (Mean ± S.D.; n=3) and 77 ± 2.6 ng/mL 
(Mean ± S.D.; n=3) in the case of covalently-immobilized AFB1 and passively-adsorbed AFB1-
BSA conjugate, respectively (Figure 6.4).  
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Figure 6.4: Representative standard curve for the competitive ELISA. The assay was performed in 
triplicate on the microtitre plates with covalently- ( ) immobilized AFB1 and passively- ( ) adsorbed 
AFB1-BSA conjugate. A 1:10,000 dilution of the anti-AFB1 Fab antibody was used for the inhibition 
using a free AFB1 concentration ranging from 0.0048-2.5 µg/mL. The error bars represents the 
standard deviation (n = 3). 
6.1.1.1.4 Cross reactivity profile of antibody tested on AFB1 covalently and passively 
adsorbed microtitre plates 
Cross reactivity studies were performed on both covalently-immobilized and passively-
adsorbed plates by CI-ELISA (section 2.2.6.1.6) using 0.0048-2.5 µg/mL of AFB2, G1 and G2 
and 0.009-10 µg/mL Zearalenone, Fumonisin B1 and T-2 toxins. It is evident from the results 
that the antibody is specific to AFB1 in comparison to other aflatoxin variants, as indicated by 
the cross reactivity data presented in Table 6.1. The lack of cross reactivity to other mycotoxins 
such as Zearalenone, Fumonisin B1 and T-2 toxin (data not shown) indicates the specificity of 
the antibody to aflatoxins.  
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Table 6.1: Cross reactivity profile of the antibody when assayed on AFB1-covalently 
immobilized and AFB1-BSA passively adsorbed microtitre plates  
 
AFB1-covalently immobilized plate    AFB1-BSA passively adsorbed plate Mycotoxin 
IC50 value  
  (ng/mL ± SD) 
a
 
 
% cross reactivity 
b
 
  IC50 value  
   (ng/mL ± SD)
 a
   
 
% cross reactivity 
b
 
 
AFB1 
 
   20 ± 0.6 
 
     100% 
 
    72 ± 0.2 
 
        100% 
AFB2  1,000 ± 0.9        2%   1,600 ± 0.4           4% 
AFG1    110 ± 0.7       18%     240 ± 0.8           30% 
AFG2  1,500 ± 0.6         1%   1,700 ± 0.7            4% 
 
a
  IC50 value is a measure of the amount of AFB1 required to inhibit the anit-AFB1 Fab antibody by half 
the maximum inhibition value.  
 
b  
% cross reactivity is calculated using the formula IC50 value of AFB1/ IC50 value of test mycotoxin X 
100 
 
6.1.1.1.5 Effect of varying conditions on ELISA assay performance 
The effect of incubation times of the primary and secondary antibodies on the assay sensitivity 
was investigated (Figure 6.5). The sensitivity of the assay performed on microtitre plate with 
covalently-immobilized AFB1 remains unaltered, with the increase in incubation time from 20 - 
120 mins. From the analysis it was found that 60-80 mins of incubation time is required for 
attaining the desired sensitivity levels when passively-adsorbed AFB1-BSA conjugate 
microtitre plates were used.  
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Figure 6.5: Studies on the effect of incubation time on the performance of the competitive inhibition 
assay. The primary and secondary antibodies were incubated individually for 20, 40, 60, 80, 100 & 120 
mins on different sets of microtitre plates with covalently- ( ) immobilized AFB1 and passively-( ) 
adsorbed AFB1-BSA conjugate. The IC50 value of the assay at various incubation times was the same in 
the case of covalently- immobilized AFB1. With regard to passively adsorbed AFB1-BSA the IC50 value 
at 20 and 40 mins of incubation was higher than the normal IC50 value which is attained after 60-80 
mins of incubation. This shows that the optimal incubation time was 20 mins and 60-80 mins for 
covalently- immobilized AFB1 and passively-adsorbed AFB1-BSA, respectively. Individual points on the 
graph represent the mean ± S.D.  of three determinations.    
 
The effect of the number of washes on the assay performance was analyzed through increasing 
the washes from 3 to 12 with PBST and PBS (to remove unbound reagents). From the values 
obtained it can be deduced that stringent washing does not affect the sensitivity of the assay 
performed (Table 6.2). The results obtained (Table 6.2), indicate a increase in the IC50 value of 
assay with increasing methanol concentration from 0% to 40% (v/v) i.e., from 75 ± 2.5 ng/mL 
(Mean ± S.D.; n=3) to 125 ± 2 ng/mL (Mean ± S.D.; n=3) in the case of passively-adsorbed 
AFB1-BSA conjugate. The sensitivity of the assay performed on the microtitre plate with 
covalently-immobilized AFB1 remains unaltered up to 40% (v/v) methanol, after which the 
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assay sensitivity was reduced drastically. Furthermore, the effect of pH (Table 6.2) was studied, 
which shows that increase of pH from 6 to 9 has no significant impact on the assay 
performance using either type of microtitre plates (covalenly-immobilized AFB1 or passively-
adsorbed AFB1-BSA conjugate microtitre plates)  
Table 6.2:  Evaluation of the factors altering the assay performance (n=3) 
 
        IC50 value
a 
(ng/mL ± S.D.) 
 
                       Factor 
Covalently  
immobilized AFB1 
      Passively 
 adsorbed AFB1-BSA 
Number of washes with both PBST & PBS 
                            3  
                            6  
                            9  
                            12  
 
        17 ± 1 
        25 ± 1 
        25 ± 1 
        22 ± 1 
 
          72 ± 1 
          80 ± 1 
          75 ± 1 
          77 ± 1 
 
                 Methanol (v/v) 
                           0%  
                          10%  
                          20%  
                          30%  
                          40%  
 
        22 ± 2 
        32 ± 1 
        35 ± 1 
        25 ± 2 
        33 ± 2 
 
 
            75 ± 3 
          110 ± 1 
          112 ± 2 
          115 ± 2 
          125 ± 2 
                           pH 
                            6 
                          7.4 
                            9 
 
        22 ± 1 
        28 ± 1 
        26 ± 1 
 
           79 ± 1 
           80 ± 1 
           74 ± 2 
a 
IC50 value  is a measure of the amount of AFB1 required to inhibit the anti-AFB1 Fab antibody by half 
the maximum inhibition value. The units are ng/mL ± S.D. of the value obtained from experiments 
performed in triplicate. The IC50 values of both the covalently-immobilized AFB1 and passively-
adsorbed AFB1-BSA conjugate were compared under varying experimental conditions. 
 
6.1.1.1.6 Analysis of the storage stability and re-usability of the covalently-immobilized 
AFB1 microtitre plates  
To determine the storage stability of the microtitre plates that were covalently-immobilized 
with AFB1 and passively-adsorbed with AFB1-BSA conjugate, competitive inhibition assays 
were performed every alternative day on both these plates stored in a vacuum dessicator. The 
results show that the covalently-immobilized AFB1 and passively-adsorbed AFB1-BSA 
conjugate microplates were stable up to 14 and 10 days, respectively, (Figure 6.6) with a 
significance of  p = 0.0002  (Student’s t-test). 
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Figure 6.6: Storage stability of the AFB1-immobilized microtitre plates. Both the covalently- (■) 
immobilized AFB1 and passively- (■) adsorbed AFB1-BSA conjugate microtitre plates were placed in a 
vacuum dessicator over a period of 15 days and competitive assays were performed every alternative 
day. The covalently-immobilized AFB1 was stable upon storage up to 14 days. The assays performed on 
the microtitre plates, with passively-adsorbed AFB1-BSA, have given inconsistent results showing the 
degradation of the conjugate upon storage after 10 days. The points on the graph represent mean where 
n = 3 and the error bars represent the standard deviation. 
 
The re-usability of the microtitre plates was tested by treating the plates with a chaotropic 
mixture of 8 M urea, sodium dodecyl sulfate and mercaptoethanol. The IC50 value of the assay 
performed on the non-chaotropic-treated microtitre plate was considered as 100%. The 
percentage variation in the sensitivity of the assay performed on both microtitre plates with 
covalently-immobilized AFB1 and passively-adsorbed AFB1-BSA conjugate, was analyzed 
using the formula (obtained value/initial value) X 100. Upon successive usages, after treatment 
with the dissociation buffer, the percentage binding retention when compared to the initial 
100% are 96%, 96%, 84%, 80% and 60% in the case of covalently-immobilized microtitre 
plate, whereas it was 75%, 73.3%, 50% and inconsistent values from the fourth usage onwards, 
in the case of passively-adsorbed plates (Figure 6.7).  
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Figure 6.7: Comparative analysis of percentage binding retention for AFB1 covalently or non-
covalently attached to plates. The AFB1-immobilized microtitre plates were regenerated with 
chaotropic agents after the performance of a competitive inhibition enzyme-linked immunoassay. 
Binding retention value of 60-100% was observed in the assay performed on the covalently-immobilized 
AFB1 ( ). With regard to the assay performed on the microtitre plate with passive ( ) adsorption of 
AFB1-BSA there was 0% binding retention after the fifth chaotropic treatment. The results are the mean 
± S.D. for three determinations. 
 
6.1.1.1.7 Extraction of AFB1 from corn and its utilization for validating immunoassay 
developed on AFB1 covalently-immobilized plates 
The amount of recovered aflatoxin from the reference corn material (TR-A100) was quantified 
by fluorescence estimation at 360/440 nm (Excitation/Emission) using a standard calibration 
curve (slope equation y = 361.7x (R2 = 0.99)) with known amounts of AFB1 (10-320 ng/mL) 
diluted in 40% (v/v) methanol in water.  The certified level of aflatoxins in the corn sample 
(TR-A100) was 3.7 µg/Kg and the obtained values (fluorescence estimation) were 3.5 ± 0.9 
µg/Kg (Mean ± S.D.; n=10). The corn extract was used to perform CI-ELISA on AFB1 
covalently-immobilized microtitre plates (section 2.2.6.1.6). The limit of blank (LOB) was 
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determined through recording the absorbance value of twenty blank samples. The limit of 
detection (LOD) was calculated using the formula LOB + 3 X S.D. of LOB. The IC50 value of 
the CI-ELISA performed on AFB1- covalently immobilized plate using corn matrix was 35 ± 
1.1 ng/mL with LOD 12 ± 2.3 ng/mL (Mean ± S.D.; n=3). The trueness of the assay was 
evaluated through performing intra- (n=3) and inter-day (n=5) assay using the corn extract and 
represented as percentage coefficient of variance (% CVs) (Table 6.3).  
Table 6.3: Intra- (n=3) and inter-day (n=5) validation of CI-ELISA assay performed on AFB1 
covalently immobilized microtitre plates using corn reference material 
 
                     Intra-day assay             Inter-day assays AFB1  
concentration 
(ng/mL) 
Back- 
calculated  
concentration 
(ng/mL) 
% CVs % Accuracies Back- 
calculated  
concentration 
(ng/mL) 
% CVs % Accuracies 
 
2500 
 
2100 
 
2.4 
 
84 
 
2300 
 
5.1 
 
92 
1250 1320 1.4 105.6 1290 3.7 103.2 
625 611 5.2 97.8 620 2.8 99.2 
312.5 297 1.9 95 289 5.2 92.5 
156.25 163.2 0.7 104.5 159.2 4.9 101.9 
78.125 75.2 1.8 96.3 76.9 2.0 98.5 
39.062 39 4.7 100 41 1.7 105.1 
19.531 18 2.6 94.7 19 5.3 100 
9.765 10 1.9 111.1 9 1.9 100 
4.882 5 4.6 104.2 4.3 1.6 89.6 
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6.1.2 Immuno-affinity column for the isolation of AFB1, B2 and ZEN 
The aim of this phase of the research was to use specific recombinant antibodies, immobilized 
on silica in a column format, for the simultaneous capture, subsequent elution and analysis of 
mycotoxins. Mycotoxins were added to antibodies bound to silica in the column, incubated for 
2 hrs, eluted and quantified. Stability and re-usability studies were undertaken and the 
feasibility of using column evaluated.  
 
6.1.2.1 Immobilization of anti-AFB1, AFB2 and ZEN recombinant antibodies onto the 
silica 
The aminated silica was generated through the treatment of allylated silica (formed as a result 
of treating silica with allylmethoxysilane in the presence of toluene) with a cysteamine linker 
under UV light. The initial amine loading value, as determined by the ninhydrin assay, was 
1092 µmole of amines/g of silica beads. The NHS groups were incorporated onto the silica 
surface through treating the aminated silica with sebacic acid. The recombinant antibodies can 
then be attached to the NHS groups on the silica, leading to the formation of silica beads 
immobilized with antibodies.  
 
6.1.2.2 Evaluation of functionality of individual immuno-affinity columns (IACs)  
6.1.2.2.1 Determination of antigen binding to the affinity columns 
The antigen binding capacity of AFB1, B2 and ZEN immuno-affinity columns (each containing 
200 mg of either anti-AFB1 or AFB2 or ZEN antibody-immobilized silicas) were assessed 
individually by applying 1 mL of 0.3-8 µg/mL of AFB1, B2 and ZEN antigens. From Table 6.4, 
it can be seen that the maximum antigen binding capacities of AFB1 (with 176.28 µg of anti-
AFB1 Fab antibody/200 mg of silica), B2 (with 127.6 µg of anti-AFB2 scFv/200 mg of silica) 
and ZEN (with 152.8 µg of anti-ZEN scFv/200 mg of silica) columns were 4, 5.4 and 6.7 µg, 
respectively.  
 
 203 
Table  6.4: Antigen binding capacity of anti-AFB1, B2 and ZEN immuno-affinity columns (n=3)   
                              Amount of mycotoxins eluted (µg/mL) Amount of mycotoxins 
added (µg/mL) 
   AFB1    AFB2 Zearalenone 
 
0.3 
 
0.2 ± 0.11 
 
0.2 ± 0.21 
 
0.2 ± 0.06 
0.6 0.5 ± 0.09 0.5 ± 0.17 0.5 ± 0.31 
1.2 1.1 ± 0.25 1.1 ± 0.08 1.2 ± 0.27 
2 1.9 ± 0.1 1.9 ± 0.14 1.9 ± 0.18 
4 3.9 ± 0.28 3.9 ± 0.09 3.9 ± 0.28 
6 3.9 ± 0.14 5.1 ± 0.27 5.9 ± 0.18 
8 4 ± 0.08 5.4 ± 0.04 6.7 ± 0.21 
 
6.1.2.2.2 Effect of percentage methanol on elution potential and re-usability of the 
immuno-affinity column 
The role played by the methanol percentage used in elution of mycotoxin (Table 6.5) was 
evaluated by measuring the % recovery. For this 20, 40, 60, 80 and 100% (v/v) methanol were 
used for eluting AFB1, B2 and ZEN from their respective immuno-affinity columns. The 
amount of mycotoxins eluted using 100% (v/v) methanol was taken as 100% and percentage 
recoveries attained with other methanol concentration were calculated using the formula  
                         Amount of mycotoxins eluted using varying methanol concentration    X 100 
% Recovery =           Amount of mycotoxins eluted using 100% (v/v) methanol  
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Table  6.5: Mycotoxins percentage recovery using varying methanol concentration (n=3)  
                                    % Recovery  % methanol used  
for elution 
   AFB1    AFB2 Zearalenone 
 
20 
 
48  ± 0.2 
 
49 ± 0.8 
 
41 ± 0.4 
40 79 ± 0.7 83 ± 0.7 89 ± 0.8  
60 83 ± 1 85 ± 1.5 92 ± 0.7 
80 92 ± 0.6 93 ± 1.7  94 ± 1.9 
100 100 ± 1.8 100 ± 0.4 100 ± 0.3 
 
To facilitate multiple usages of a single immuno-affinity columns for subsequent extraction, the 
role of methanol elution on column efficiency, as determined by number of re-uses, was 
evaluated. Table 6.5 indicates that the % recoveries of the three myctoxins using 20% (v/v) 
methanol falls below 50%.  Hence further studies on the re-use were performed using methanol 
concentrations above 20% for elution. The percentage recovery of mycotoxins after each 
successive re-usage with 40, 60, 80 and 100% (v/v) methanol for up to 15 re-uses was 
evaluated. This indicated that using 40% (v/v) methanol the columns could be used more times 
(13 times for AFB1 & B2 column and 15 times for ZEN column) with percentage recoveries 
above 75%.  
 
6.1.2.2.3 Protein estimation after successive usages of columns 
The silica beads (5 mg) obtained after 15 usages were dried in a vacuum desiccator. The 
amount of antibody bound to the silica surface was estimated by the BCA assay against BSA 
standard, as described in section 2.2.6.2.5. These results demonstrated that after 15 reuses 
(using 40% methanol for eluting), there is a decrease in the amount of protein bound to the 
silica surface (Table 6.6). 
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Table 6.6: Amount of protein bound to silica before and after fifteen  uses using 40% methanol 
for elution (n=3) 
        Amount of antibody bound to 5 mg of silica Type of antibody immobilized 
Prior to first use  
(µg/5 mg of silica) 
After reusing 15 times 
(µg/5 mg of silica) 
 
Anti-AFB1 Fab  
 
4.40 ± 1.1 
 
 
2.57 ± 0.9 
 
Anti-AFB2 scFv 3.19 ± 0.8 
  
1.74 ±  1.3 
Anti-ZEN scFv 3.82 ± 1.5 1.94 ± 1.1 
 
6.1.2.2.4 Storage stability studies of the immuno-affinity columns 
To check the stability of silica at varying temperatures, 5 mg of dried silica beads were stored 
at room temperature, 40C and 370C for 24 hrs.  The amount of antibody bound on the silica was 
estimated by BCA assay against BSA as a standard. Unmodified silica was used as a control for 
the assay. The silica was stable at most of the conditions, although a slight decrease in the 
absorbance was noted after incubation at 370C for 24 hrs as shown in Figure 6.8. This study 
reveals that the covalent conjugation of antibody through amide bonds on silica beads is very 
stable.  
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Figure 6.8: Stability of silica-bound protein stored for 24 hrs at different temperatures by BCA assay 
(n=3). 
 
6.1.2.3 Multi-analyte immuno-affinity column 
6.1.2.3.1 IACs washing 
After assessing the maximum antigen binding and methanol tolerance of the individual IACs, a 
multi-analyte column was designed with equal amounts (3 X 200 mg = 600 mg) of silicas 
immobilized with three different recombinant antibodies. To the multi-analyte column 8 µg of 
AFB1, B2 and ZEN antigens dissolved in 1 mL were added individually, followed by incubation 
for an hour and washing with 1X PBS (1 mL) for 10 times to ensure complete removal of 
unbound or loosely bound mycotoxins (AFB1, B2 and ZEN) where steady fluorescence reading 
(360/440 nm for AFB1 or B2 and 236/440 nm for ZEN) was recorded (Figure 6.9).  
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Figure 6.9: Graphical representation of the washing AFB1, B2 and ZEN immuno-affinity columns. 
To each of the immuno-affinity column 8 µg of mycotoxins were added. After 10 subsequent washes with 
1X PBS, the fluorescent reading was stabilized. The stabilized fluorescent reading indicates the removal 
of loosely bound or excess of mycotoxin from the immuno-affinity column. The negative controls in this 
experiment include fluorescence readings of methanol and 1X PBS.  
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6.1.2.3.2 Quantification of eluted AFB1, B2 and ZEN from multi-analyte IAC 
After subjecting the multi-analyte column to washing (section 6.1.2.3.1) the antigens bound to 
the antibodies on the silica surface were eluted using 40% (v/v) methanol. Quantification of the 
AFB1, B2 and ZEN eluted from the column was determined by fluorescence assay. The 
fluorescence intensity of varying concentrations (0.125-16 µg/mL) of AFB1, AFB2 and ZEN 
standards in 40% (v/v) methanol was determined followed by the generation of calibration 
curves for each individual mycotoxin. The fluorescence intensity of eluted myctoxins were 
substituted in the slope equations of calibration curve generated using AFB1, B2 and ZEN 
standard (Figure 6.10) to determine the amount of eluted mycotoxins. The amount of eluted 
AFB1, B2 and ZEN from IAC were recorded as 3.9 ± 1.9, 5.3 ± 0.9 and 6.2 ± 1.5 µg/mL, 
respectively.  
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Figure 6.10: Calibration curve for AFB1, B2 and ZEN (0.125-16 µg/mL). The amount of eluted AFB1, 
B2 and ZEN were calculated by substituting the fluorescence reading of the eluants in their respective 
slope equations.   
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6.1.2.3.3 Re-usability of multi-analyte immuno-affinity column   
The re-usability of the multi-analyte column (Figure 6.11) was tested by quantifying the eluted 
amounts of AFB1, B2 and ZEN from the immuno-affinity columns (200 mg each of silicas 
immobilized with three different antibodies) up to 15 times. The elutions of mycotoxins from 
unmodified silica were also tested (negative control).  The re-usability was assessed by 
measuring the change in the percentage recovery upon successive uses using the formula % 
recovery = amount of mycotoxin recovered after first use/amount of mycotoxin recovered 
during the first usage X 100. The results indicate that the generated multi-analyte immuno-
affinity column could be used for extraction of AFB1, B2 and ZEN up to 6 times with minor 
loss in the binding capability. The repetitive washing steps might have resulted in the cleavage 
of the covalently bound antibodies from the silica surfaces.   
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Figure 6.11: Performance of immuno-affinity columns after fifteen successive uses. The three 
immuno-affinity columns were used for 15 times and the recoveries of mycotoxins were evaluated. A 
50% loss in the activity of the immuno-affinity column was noticed after subjecting the AFB1, B2 and 
ZEN columns to 13, 13 and 15 times of re-uses, respectively.   
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      6.1.2.3.4 Protein estimation of the multi-analyte column 
The silica beads containing three antibodies (5 mg) obtained after 15 usages from the above 
step were dried in vacuum desiccator. The amount of antibody bound to the silica surface was 
estimated by BCA assay against BSA standard, as described in section 2.2.6.2.5. The amount of 
antibodies bound to silica prior to first use was 11.41 ± 1.2 µg/ 5 mg of silica, but whereas after 
using the silica in an mutli-analyte column for 15 times the amount of bound antibodies 
decreased to 6.25 ± 0.9 µg/ 5 mg of silica. These results demonstrate that after 15 reuses, there 
is a almost 50% loss in the amount of bound protein, which will decrease the efficiency of the 
multi-analyte immuno-affinity column. 
 
6.1.3 Preliminary results of MBio assay 
6.1.3.1 Direct binding assay 
The utility of Alexa-647 labelled anti-AFB1, B2, ZEN and T-2 toxin antibodies was determined 
by performing direct binding assays using the MBio cartridges that were imprinted with 50 and 
100 µg/mL of AFB1, B2, ZEN and T-2 toxin BSA conjugates along with controls such as BSA-
647 (positive control), buffer and microcystin conjugates (negative control) (Figure 6.12).  
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Figure 6.12: Layout of the MBio cartridge imprinted with varying concentrations of conjugates. 
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The preliminary results of the direct binding assay, which was determined by the addition of 
1/100 dilution of Alexa-647 labelled anti-AFB1, B2, ZEN and T-2 toxin antibodies to the 
cartridge, recorded a fluorescence intensity much higher than the background fluroscence 
values (Table 6.7), thus indicating that preliminary studies refer the assay works.   
Table 6.7: Normalized values obtained upon addition of anti-AFB1, B2, ZEN and T-2 antibodies 
labeled with ALEXA-647   
 
Imprinted content  Signal obtained  
(fluorescence intensity)  
 
BSA-647 (positive control) 
 
83.74 
Buffer (negative control) 4.68 
Microcystin LR- BSA (negative control) 10.73 
Microcystin LR- OVA (negative control) 8.45 
AFB1-BSA     50 µg/mL 
                         5 µg/mL 
674.86 
95.47 
AFB2-BSA     100 µg/mL 
                         50 µg/mL 
624.46 
434.88 
ZEN-BSA      100 µg/mL 
                         50 µg/mL 
520.31  
329.12 
T-2-BSA      100 µg/mL 
                       50 µg/mL 
77.59  
43.43 
 
6.1.4 Discussion 
The covalent immobilization strategy of haptens involves, the generation of hydroxyl 
functional groups. Piranha solution (Wang et al., 2008) is generally useful for the generation of 
hydroxyl groups and this was used for these microtitre plates. Amine (NH2) groups were 
incorporated by surface modification with APTES (3-aminopropyltriethoxy silane). To avoid 
multi-layers of APTES on the surface, the plates were washed thoroughly with 30% (v/v) 
ethanol and PBS. As baking allows the formation of stable cross-linked attachment of APTES 
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to the surface (Srinivasan et al., 2011), the plates were then incubated at 800C for 2 hrs. After 
800C incubation, AFB1-CMO ester was added to the individual wells of the microtitre plate. 
The amide bond formation, which governs the covalent linkage of AFB1 to the modified 
surfaces of the microtitre plate, was achieved through overnight incubation of the plates with 
AFB1-CMO ester at 4
0C.  
The utilization of the covalently-immobilized plates was initiated through blocking the plates 
with formaldehyde. Usage of formaldehyde leads to the formation of Schiff’s bases (Adhuwalia 
and Agarwal, 2001), which will block the unreacted amine groups.  The blockage of such 
groups leads to reduced background in the ELISA assay. The lower antibody binding (60%) 
was noticed when covalently immobilized plates were used (Figure 6.4). This might be due to 
the reversible nature of the Schiff’s base reaction. Under reversible conditions not all of the 
Schiff’s bases gets bound to the amine group on the antibody surface, leading to the reduction 
in the signal. The results of indirect ELISA testing indicate a 2.7-fold greater sensitivity when 
compared to the passively-adsorbed AFB1-BSA conjugate. The specificity of the assays 
developed on AFB1 covalently immobilized and AFB1-BSA passively adsorbed microtitre 
plates as determined by cross reactivity studies indicate that the percentage cross reactivity 
exhibited by the antibody was lower when tested on AFB1-covalently immobilized surfaces.   
The key benefits with these covalently-immobilized microtitre plates is that they eliminate 
longer incubation steps, thus reducing the assay time. In contrast, decreasing the incubation 
time to 20 mins, led to a decreased assay sensitivity (IC50 value) from 79 ± 1.34 ng/mL (Mean 
± S.D.; n=3) to 100 ± 0.98 ng/mL (Mean ± S.D.; n=3) for the assays performed on passively-
adsorbed AFB1-BSA conjugate microtitre plates. In comparison, the overall assay time with the 
covalently-immobilized AFB1 was 75 mins, which is three times less than that required for the 
passively-adsorbed AFB1-BSA conjugate. 
Further studies were performed to check the robustness of the assay through investigation of 
the various physiochemical factors that may affect the sensitivity of the assay through stringent 
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washes with PBST & PBS, organic solvent concentration and pH. This suggests that the level 
of hapten availability on surfaces for antibody binding is not affected through stringent washes 
performed on the plates that were covalently-immobilized with AFB1 or passively-adsorbed 
with AFB1-BSA conjugate. In many analytical sample preparation regimes, AFB1 will be 
extracted from food matrices by methanol, so the effect of methanol concentration on the 
sensitivity of assay was deemed an important parameter to evaluate. In conclusion, the usage of 
more methanol (above 40%) decreased the sensitivity of the assay by two-fold when the 
passively-adsorbed AFB1-BSA conjugate was used, whereas no significant effect on the 
sensitivity of the assay performed on the covalently-immobilized AFB1 was detected. 
Alterations in pH of the diluents used during the performance of an inhibition assay, 
demonstrated no significant impact on the assay sensitivity performed on both microtitre plate 
formats. It can be deduced that both covalently-immobilized AFB1 and passively-adsorbed 
AFB1-BSA conjugate are stable with regard to assay sensitivity over the range of pH 6-9. 
Storage studies indicate that the covalently-immobilized plates were more stable than the 
passively-adsorbed microtitre plates. The re-usability of the microtitre plates was tested by 
treating the plates with a chaotropic mixture of 8 M urea, sodium dodecyl sulfate and 
mercaptoethanol. This mixture was chosen as ideal in comparison to other dissociation buffers 
used e.g. Tris-HCl and 2 M NaOH, due to its efficient regeneration effects and its facilitating 
the re-usage capabilities of the assay. Lower absorbance values with higher background signal 
were noted with an increase in the number of re-usages. The microtitre plates that were 
covalently-immobilized with AFB1 could be re-used for four times with an average agreement 
of 89% for four successive re-uses.  
The % CVs obtained in both intra- and inter-day assays performed using corn extract instead of 
buffer were less than 5. It is apparent from the results that the corn matrix has not significantly 
affected the robustness and sensitivity of the CI-ELISA performed on covalently-immobilized 
AFB1 microtitre plates. Despite of the matrix effect, the sensitivity of assay developed on 
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AFB1-covalently immobilized microtitre plate are within the FDA action levels of 20 ppb 
(ng/g) and this assay can readily be used for the detection of aflatoxin B1 in corn samples and 
might be used for the detection of AFB1 in other food matrices.  
The utilization of immuno-affinity columns for the isolation of mycotoxins from food is 
gaining importance. Most of the reported immuno-affinity columns developed so far use either 
polyclonal or monoclonal antibodies. The larger size of both polyclonal and monoclonal 
antibodies when compared to recombinant antibodies, might affect antigen binding when the 
antibodies are immobilized on silica particles. Hence usage of recombinant antibodies of 
smaller size provides a powerful alternative to overcome the limitations of the usage of the 
larger antibody formats (Inui et al., 2009).  In the present study the silica was immobilized with 
highly sensitive recombinant anti-AFB1, B2 and ZEN recombinant antibody fragment.  
The nature of solid support plays a crucial role in antibody binding. While selecting the support 
material considerable attention has to be paid to strategies for minimizing steric hindrances of 
the attached antibody fragment, which will reduce the active sites of the antibodies (Rejeb et 
al., 2001). Various solid supports can be used, but in the present work the wakosil silica was 
selected due to its rigid nature and also it permits higher flow rates and higher pressures than 
other solid supports. Smaller pore sized silica (100 A0) was chosen due to the smaller size of 
the recombinant antibody fragment (Clarke et al., 2000).  
The choice of eluting solvent is important as many solvents will play a significant role in the 
reduction of antibody binding capacity upon successive elution steps. As mild acidic and basic 
conditions are inefficient in eluting small molecular weight compounds (Sanvicens et al., 
2006), methanol elution is a useful quantitative analyte recovery method from the column 
(Delaunay et al., 2000). After significant washing the column, the bound AFB1, B2 and ZEN 
were eluted using 40% (v/v) methanol. The amount of AFB1, B2 and ZEN eluted from the 
multi-analyte column were 3.9 ± 1.9, 5.3 ± 0.9 and 6.2 ± 1.5 µg/mL, respectively. The antigen 
binding capacity of the column developed in the present work is higher than the earlier reported 
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immuno-affinity columns for the isolation of ochratoxin (Uchigashima et al., 2012) and 
aflatoxins (Uchigashima et al., 2009).  
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7.1 Conclusions    
7.1.1 Anti-mycotoxin antibodies generation 
Initially the antigens (AFB2, ZEN and T-2 toxins) were conjugated to carrier proteins 
(BSA/KLH), characterized (hapten density per carrier protein molecule) by MALDI-TOF 
(mycotoxin-BSA conjugates) and TNBS analysis by Dr. Om Prakash. Following conjugate 
characterization their immuno-potential was assessed by injecting them into Balb/c mice. The 
results (Appendix IV) of the serum titre of all these mice post-immunization showed that 
mycotoxin-KLH conjugates are efficient in generating good immune responses, which is 
necessary for the isolation of specific antibodies.  
In chapter 3, generation of anti-AFB2 scFvs and their subsequent incorporation into assay 
formats was described. A murine AFB2 scFv library was generated from the spleen of a AFB2-
KLH-immunized mouse. His-tagged anti-AFB2 scFvs were purified using immobilized metal 
affinity chromatography.  Cross reactivity studies were performed to find the scFv that was 
highly specific to AFB2 with minimal or no cross reaction to aflatoxin variants, which revealed 
that out of 7 scFvs tested only 2 scFvs were able to specifically recognize AFB2. A surface 
plasmon resonance (SPR) kinetic study revealed that anti-AFB2 scFv-E9 has nanomolar affiniy 
for AFB2. The analytical sensitivity of SPR-inhibition assay (indicated as IC50) was lower than 
that of a competitive inhibition ELISA developed using the scFv. The limit of detection of the 
SPR-based inhibition assay using spiked almond extract was noted as 3.6 ng/mL, which was 
within the range of the expected maximum permissible limits of 20 ng/mL. 
Chapter 4 outlines, the generation and utilization of anti-ZEN antibodies for the development of 
ELISA and SPR-based inhibition assays.  Recombinant libraries were constructed from the 
spleens of mice immunized with both ZEN-BSA and KLH conjugates. No anti-ZEN scFvs 
were isolated from the recombinant library generated from spleen of ZEN-BSA immunized 
mice. Subsequent attempts were made to build the ZEN scFv library utilizing the genomic 
material obtained from ZEN-KLH immunized mouse. A positive indication in the polyclonal 
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phage ELISA indicates the presence of ZEN recognizing scFvs. A few clones from the 
biopanning process were analysed for the presence of scFv genome, which indicated presence 
of 100% carry over of the scFv genome in the expressing clones. Monoclonal ELISA results 
indicated that 25% of the clones were ZEN-positive. The anti-ZEN scFv-P2A2 exhibited 
minimal cross reactivity when compared to the earlier reported anti-ZEN antibodies. A 
competitive inhibition ELISA demonstrated that the selected scFv-P2A2 had an IC50 value of 
200 ng/mL. SPR kinetic study revealed a KD of 3.9 X 10
-10 M for the anti-ZEN scFv-P2A2. The 
IC50s of SPR-based inhibition assay in solution and sorghum matrix were 10 and 22 ng/mL, 
respectively. The sensitivity of the SPR-inhibition assay is lower than that of the competitive 
inhibition ELISA in both solution and sorghum matrix. The detection limits of both SPR-
inhibition and competitive indirect ELISA assay were within the required limits of 200 ng/mL 
(ppb also) for ZEN. 
In chapter 5, the production, affinity purification and characterization of anti-T-2 IgY for use in 
the development of a SPR-based inhibition assay was described. A Leghorn chicken was used 
as the host for the generation of antibodies against T-2 toxin. To our knowledge this is the 
second successful attempt using chicken (rarely used species for the generation of anti-
mycotoxin antibodies) as an immune host for the development of anti-T-2 toxin antibodies. T-2 
toxin-specific IgY was isolated through subjecting the IgY to affinity purification on T-2 toxin- 
immobilized amine-activated beads. A 50% increase in the titration value with a significant 
decrease in the percentage cross reactivity of the IgY to other tested mycotoxins was noticed 
after affinity purification of IgY on T-2 toxin-immobilized beads. SPR-based inhibition assay 
with IC50 of 42 ng/mL (sensitivity of SPR was the same as that of ELISA) was developed and 
applied for the detection of T-2 toxin in spiked wheat sample extracts. Optimized ELISA and 
SPR assays were highly reproducible. The results of the SPR assay indicate that this assay can 
be used for the T-2 toxin detection in wheat samples with detection limits below that required 
(100 ng/mL). 
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      7.1.2 Immunoassay development 
The first section (section 6.1.1) of chapter 6, focuses on the development of a competitive 
inhibition ELISA for the detection of AFB1 using AFB1 covalently-immobilized microtitre 
plates and an anti-AFB1 recombinant Fab antibody fragments. This covalent immobilization 
strategy can potentially be applied for various haptens with carboxyl groups. The competitive 
assay developed on the microtitre plate with covalently immobilized AFB1 was 2.7-fold more 
sensitive that the conventional approaches and also the assay time was reduced to 75 mins. The 
modified plates were able to sustain activity up to 40% (v/v) with methanol. The covalently-
immobilized AFB1 are stable up to 14 days when placed in vaccum dessicator at room 
temperature, which makes the usage of these modified plates more attractive. The re-usability, 
storage stability and reduced assay time, make the usage of these AFB1 covalently-immobilized 
microtitre plates attractive for use in detection of AFB1 in corn samples. 
7.1.3 Development of immuno-affinity columns  
The second section (section 6.1.2) of chapter 6, deals with the development of an extraction 
technique (immuno-affinity column) using recombinant antibodies immobilized on silica beads.  
Initial studies were conducted with an anti-AFB1 Fab antibody using Wakosil and CC grade 
silica. The results demonstrated better performance with Wakosil silica. Further recombinant 
antibodies developed against AFB2 and ZEN were immobilized onto the Wakosil silica. The 
Wakosil silica immobilized with three antibodies, was used in the construction of a multi-
analyte immuno-affinity column. The results show that this column posses binding affinity at 
µg levels, which is higher compared to the ng affinity of the immuno-affinity columns currently 
employed for mycotoxin extraction. The developed column can be re-used up to 6 times for 
AFB1, B2 and ZEN with minimal loss in the extraction efficiency. Such a column could have  
major application in the extraction of mycotoxins from food samples followed by specific 
detection of individual mycotoxins (i.e., AFB1, B2 and ZEN). Existing polyspecific antibodies  
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used in such an approach, with less affinity for individual toxins such as those highlighted, 
could lead to under extraction and hence underestimation of actual levels in food samples.   
In summary, this work highlights the potential use of immunoassays for the detection of food 
contaminants. The research also demonstrates the ease of using scFvs derived from immune 
phage display libraries in a variety of sensitive and specific assay formats for the detection and 
extraction of AFB1, B2 and ZEN. Furthermore, the feasibility of using affinity-purified 
polyclonal IgY for the specific detection T-2 toxin was also demonstrated. The usage of 
immuno-affinity column can be used as efficient sample clean up process, which can further be 
analyzed using analytical techniques.          
 
7.2 Future work 
The developed multi-analyte column will be used for the extraction of AFB1, B2 and ZEN from 
contaminated food samples, followed by the HPLC analysis of the recovered toxins from the 
column. The MBio array assay, where preliminary analysis was carried out for the detection of 
AFB1 (data not shown), will be further evaluated using a multiplex assay for the simultaneous 
detection of AFB1, B2, ZEN and T-2. The feasibility of using the MBio array assay for the 
detection of mycotoxins in food material will be studied.     
 
 
 
 
 
 
 
 
 
 223 
 
 
 
 
 
 
 
 
 
Chapter 8  
              Bibliography 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 224 
Abi-Ghanem, D., Waghela, S. D., Caldwell, D. J., Danforth, H. D. and Berghman, L. R. 
(2008) Phage display selection and characterization of single-chain recombinant antibodies 
against Eimeria tenella sporozoites. Vet. Immunol. Immunopathol. 121(1-2), 58-67. 
Adhuwalia, V. K. and Agarwal, R. (2001) Comprehensive organic chemistry preparation and 
quantitative analysis, 281 pp, Universities press, Hyderabad, India. 
Agag, B. I. (2004) Mycotoxins in foods and feeds 3-zearalenone. Ass. Univ. Bull. Environ. Res. 
7(2), 159-176. 
Ahmad, Z. A., Yeap, S. K., Ali, A. M., Ho, W. Y., Alitheen, N. B. and Hamid, M. (2012) scFv 
antibody: principles and clinical application. Clin. Dev. Immunol. 2012, 1-15. 
Ahmadzadeh, V., Majidi, J., Chaparzadeh, N., Abdolalizadeh, J. and Aliparasti, M. R. (2011) 
Production and purification of polyclonal anti-hamster immunoglobulins in rabbits. African J. 
Biotechnology 10(3), 363-367. 
Akshaya, S. A., Anesh, R. K., Brinda, R., Deepika, G., Gandharvin, K., Gayatri, D. K., 
Lakshmi, S., Nanditha, S., Narayani, N., Priyadharshini, R., Rohini, M. N., Rosa, R., Shruthi, 
S. R., Shruti, B., Sophi, R. and Ravi, M. (2008) In vivo Murine to in vitro Human Lymphocyte 
Immunizations-The changing face of Hybridoma Technology. Advanced biotech, 7(4), 26-34. 
Alisa, M. C. (1984) Laboratory techniques in biochemistry and molecular biology, Monoclonal 
antibody technology-The Production and Characterization of Rodent and Human Hybridomas, 
4-16 pp, Volume 13, Burdon, R. H and van Knippenberg, P. H. (eds.)., Elsevier Science 
Publishers, Amsterdam, Netherlands. 
 
Allen, J. C. and Smith, C. J. (1987) Enzyme-linked immunoassay kits for routine food 
analysis. Trends in Biotechnol.  5(7), 193-199. 
Anfossi, L., Calderara, M., Baggiani, C., Giovannoli, C., Arletti, E. and Giraudi, G. (2010) 
Development and application of a quantitative lateral flow immunoassay for fumonisins in 
maize. Anal. Chim. Acta 682(1-2), 104-109. 
 225 
Anfossi, L., D'Arco, G., Calderara, M., Baggiani, C., Giovannoli, C. and Giraudi, G. (2011) 
Development of a quantitative lateral flow immunoassay for the detection of aflatoxins in 
maize. Food Addit. Contam. 28(2), 226-234. 
Appell, M., Maragos, C. M. and Kendra, D. F. (2008) Molecularly imprinted polymers for 
mycotoxins, In: Food contaminants, 152-159 pp, Volume 1001, American Chemical Society 
Symposium Series, Washington, U.S.A. 
Asao, T., Buchi, G., Abdel-Kader, M. M., Chang, S. B., Emily, L. W. and Wogan, G. N. 
(1965) The Structures of Aflatoxins B and G1. J. Am. Chem. Soc. 87(4), 882-886. 
Awadalla, S. A., Hegazy, S. M., Awad, Y. L. and Attia, A. N. (1991) Detoxification of 
aflatoxins in some food commodities and poultry ration. Vet. Medical J. Giza 39(3), 909-919. 
Azcona-Olivera, J. I., Abouzied, M. M., Plattner, R. D., Norred, W. P. and Pestka, J. J. (1992) 
Generation of antibodies reactive with fumonisins B1, B2, and B3 by using cholera toxin as the 
carrier-adjuvant. Appl. Environ. Microbiol. 58(1), 169-173. 
Barbas, C. F. I., Dennis R, B., Jamie K, S. and Gregg J, S. (2001) Phage Display: A 
Laboratory Manual, Cold Spring Harbor Laboratory Press, New York, U.S.A. 
Barna-Vetro, I., Gyongyosi, A. and Solti, L. (1994) Monoclonal antibody-based enzyme-
linked immunosorbent assay of fusarium T-2 and zearalenone toxins in cereals. Appl. Environ. 
Microbiol. 60(2), 729-731. 
Barna-Vetro, I., Szabo, E., Fazekas, B. and Solti, L. (2000) Development of a sensitive 
ELISA for the determination of fumonisin B1 in cereals. J. Agric. Food. Chem. 48(7), 2821-
2825. 
Bennett, G. A., Megalla, S. E. and Shotwel, O. L. (1984) Method of analysis for 
deoxynivalenol and zearalenone from cereal grains. J. AOCS 61(9), 1449-1453. 
Bennett, J. W. and Klich, M. (2003) Mycotoxins. Clin. Microbiol. Rev. 16(3), 497-516. 
 226 
Berthiller, F., Schuhmacher, R., Adam, G. and Krska, R. (2009) Formation, determination and 
significance of masked and other conjugated mycotoxins. Anal. Bioanal. Chem. 395(5), 1243-
1252. 
Berthiller, F., Schuhmacher, R., Buttinger, G. and Krska, R. (2005) Rapid simultaneous 
determination of major type A- and B-trichothecenes as well as zearalenone in maize by high 
performance liquid  chromatography–tandem mass spectrometry. J. Chromatogr. A 1062(2), 
209-216. 
Betina, V. (1984) Mycotoxins, production, isolation, separation and purification (developments 
in food science), 517 pp, Elsevier Science Publishers, Amsterdam, Netherlands.  
Binder, E. M., Heidler, D., Schatzmayrg, G., Thimm, N., Fuchs, E., Schuh, M., Krska, R. and 
Binder, J. (2001) Microbial detoxification of mycotoxins in animal feed, In: Mycotoxins and 
Phycotoxins in perspective at the turn of the millenium, Proceedings of the 10th International 
IUPAC Symposium on Mycotoxins and Phytotoxins; May 20-25, 2000, 271-277 pp, De Koe, 
W.J., Sampson, R.A., Van Egmond, H.P., Gilbert J., Sabino, M. (eds.)., Garuja, Brazil. 
 
Bohs, B., Seidel, V. and Lindner, W. (1995) Analysis of selected mycotoxins by capillary 
electrophoresis. Chromatographia 41(11-12), 631-637. 
Bouaziz, C., Martel, C., Sharaf el dein, O., Abid-Essefi, S., Brenner, C., Lemaire, C. and 
Bacha, H. (2009) Fusarial toxin-induced toxicity in cultured cells and in isolated mitochondria 
involves PTPC-dependent activation of the mitochondrial pathway of apoptosis. Toxicol. Sci. 
110(2), 363-375. 
Brichita, J., Hnilova, M. and Viskovic, T. (2005) Generation of hapten-specific recombinant 
antibodies : antibody phage display technology : a review. Vet. Med. Czech 50(6), 231-252. 
Bunaciu, D. M. (2010) Developing an HPLC-ESI-MS/MS method for simultaneous 
determination of mycotoxins in maize flour and other matrices. Institute of Chemistry, 
University of Tartu, Estonia, Master's thesis. 
 227 
Burkin, A. A., Kononenko, G. P. and Soboleva, N. A. (2002) Group-specific antibodies 
against zearalenone and its metabolites and synthetic analogs. Prikl. Biokhim. Mikrobiol. 38(2), 
194-202. 
Burmistrova, N. A., Goryacheva, I. Y., Basova, E. Y., Franki, A. S., Elewaut, D., Van 
Beneden, K., Deforce, D., Van Peteghem, C. and De Saeger, S. (2009) Application of a new 
anti-zearalenone monoclonal antibody in different immunoassay formats. Anal. Bioanal. Chem. 
395(5), 1301-1307. 
Cervino, C., Knopp, D., Weller, M. G. and Niessner, R. (2007) Novel aflatoxin derivatives and 
protein conjugates. Molecules 12(3), 641-653. 
Cervino, C., Weber, E., Knopp, D. and Niessner, R. (2008) Comparison of hybridoma 
screening methods for the efficient detection of high-affinity hapten-specific monoclonal 
antibodies. J. Immunol. Methods 329(1-2), 184-193. 
Charlton, K., Harris, W. J. and Porter, A. J. (2001) The isolation of super-sensitive anti-hapten 
antibodies from combinatorial antibody libraries derived from sheep. Biosens. Bioelectron. 
16(9-12), 639-646. 
Choi, G. H., Lee, D. H., Min, W. K., Cho, Y. J., Kweon, D. H., Son, D. H., Park, K. and Seo, 
J. H. (2004) Cloning, expression, and characterization of single-chain variable fragment 
antibody against mycotoxin deoxynivalenol in recombinant Escherichia coli. Protein Expr. 
Purif. 35(1), 84-92. 
Choi, S. W., Chang, H. J., Lee, N., Kim, J. H. and Chun, H. S. (2009) Detection of 
mycoestrogen zearalenone by a molecularly imprinted polypyrrole-based surface plasmon 
resonance (SPR) sensor. J. Agric. Food Chem. 57(4), 1113-1118. 
Chun, H. S., Choi, E. H., Chang, H. J., Choi, S. W. and Eremin, S. A. (2009) A fluorescence 
polarization immunoassay for the detection of zearalenone in corn. Anal. Chim. Acta 639(1-2), 
83-89. 
Ciegler, A. (1978) Trichothecenes: occurrence and toxicosis. J. Food Prot. 41(5), 399-403. 
 228 
Clarke, W., Beckwith, J. D., Jackson, A., Reynolds, B., Karle, E. M. and Hage, D. S. (2000) 
Antibody immobilization to high-performance liquid chromatography supports. 
Characterization of maximum loading capacity for intact immunoglobulin G and Fab 
fragments. J. Chromatogr. A  888(1-2), 13-22. 
Cole, R. J. (1989) Technology of aflatoxin decontamination, In: Mycotoxins and phycotoxins 
'88, 177 pp, Natori, S., Hashimoto, K., Uueno, Y. (eds.)., Elsevier Science Publishers, 
Amsterdam, Netherlands. 
 
Cole, R. J. and Cox, R. H. (1981) The Trichothecenes, In: Handbook of Toxic Fungal 
Metabolites, 152-263 pp, Cole, R. J. and Cox, R. H. (eds.)., Academic press, New York, U.S.A. 
Conroy, P. J., Hearty, S., Leonard, P. and O'Kennedy, R. J. (2009) Antibody production, 
design and use for biosensor-based applications. Semin. Cell Dev. Biol. 20(1), 10-26. 
Coker, R. (2000) Aflatoxins and mycotoxins: chromatography, In: Encyclopedia of separation 
science, 1873-1888 pp, Volume 1, 1st edition, Academic press, California, U.S.A.  
Creppy, E. E. (2002) Update of survey, regulation and toxic effects of mycotoxins in Europe. 
Toxicol. Lett. 127(1-3), 19-28. 
Croteau, S. M., Prelusky, D. B. and Trenholm, L. H. (1994) Analysis of trichothecene 
mycotoxins by gas chromatography with electron-capture detection. J. Agric. Food Chem. 
42(4), 928-933. 
Cui, X., Liu, M. and Li, B. (2012) Homogeneous fluorescence-based immunoassay via inner 
filter effect of gold nanoparticles on fluorescence of CdTe quantum dots. Analyst  137, 3293. 
 
Daly, S. J., Keating, G. J., Dillon, P. P., Manning, B. M., O'Kennedy, R., Lee, H. A. and 
Morgan, M. R. (2000) Development of surface plasmon resonance-based immunoassay for 
aflatoxin B1. J. Agric. Food Chem. 48(11), 5097-5104. 
De Bellis, D. and Schwartz, I. (1990) Regulated expression of foreign genes fused to lac: 
control by glucose levels in growth medium. Nucleic Acids Res. 18(5), 1311. 
 229 
De Crescenzo, G., Boucher, C., Durocher, Y. and Jolicoeur, M. (2008) Kinetic 
characterization by surface plasmon resonance-based biosensors: principle an emerging trends. 
Cell. Mol. Bioeng. 1, 204-215. 
De Saeger, S. and Van Peteghem, C. (1996) Dipstick enzyme immunoassay to detect fusarium 
T-2 toxin in wheat. Appl. Environ. Microbiol. 62(6), 1880-1884. 
Delaunay, N., Pichon, V. and Hennion, M. C. (2000) Immunoaffinity solid-phase extraction 
for the trace-analysis of low-molecular-mass analytes in complex sample matrices. J. 
Chromatogr. B 745(1), 15-37. 
DeSilva, B., Smith, W., Weiner, R., Kelley, M., Smolec, J., Lee, B., Khan, M., Tacey, R., Hill, 
H. and Celniker, A. (2003) Recommendations for the bioanalytical method validation of 
ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm. Res. 
20(11), 1885-1900. 
Devi, K. T., Mayo, M. A., Reddy, K. L., Delfosse, P., Reddy, G., Reddy, S. V. and Reddy, D. 
V. (1999) Production and characterization of monoclonal antibodies for aflatoxin B1. Lett. 
Appl. Microbiol. 29(5), 284-288. 
Dixit, C. K., Vashist, S. K., MacCraith, B. D. and O'Kennedy, R. (2011) Multisubstrate-
compatible ELISA procedures for rapid and high-sensitivity immunoassays. Nature Protoc. 
6(4), 439-445. 
Dixon, D. E., Warner, R. L., Ram, B. P., Hart, L. P. and Pestka, J. J. (1987) Hybridoma cell 
line production of a specific monoclonal antibody to the mycotoxins zearalenone and alpha-
zearalenol. J. Agric. Food Chem. 35, 122-126. 
Eke, Z., Kende, A. and Torkos, K. (2004) Simultaneous detection of A and B trichothecenes 
by gas chromatography with flame ionization or mass selective detection. Microchem. J. 78(2), 
211-216. 
Ellenhorn, M. J. and Barceloux, D. G. (1988) Medical toxicology: Diagnosis and treatment of 
human poisoning 1312-1314 pp, Merck Index, 12th edition, Elsevier Science Publisher, New 
York, U.S.A.  
 230 
Eremin, S. A., Ryabova, I. A., Yakovleva, J. N., Yazynina, E. V., Zherdev, A. V. and 
Dzantiev, B. B. (2002) Development of a rapid, specific fluorescence polarization 
immunoassay for the herbicide chlorsulfuron. Anal. Chim. Acta 468(2), 229-236. 
Eva, M. B. (2007) Managing the risk of mycotoxins in modern feed production. Animal Feed 
Science and Technol. 133(1-2), 149-166. 
FAO (2001) Manual on the application of the HACCP system in mycotoxin prevention and 
control, Food and Nutrition Paper 73, Food and Agricultural Organization of the United 
Nations, Rome, Italy.  
Ferreira Junior, A., Santiago, F. M., Silva, M. V., Ferreira, F. B., Macedo Junior, A. G., 
Mota, C. M., Faria, M. S., Filho, H. H., Silva, D. A., Cunha-Junior, J. P., Mineo, J. R. and 
Mineo, T. W. (2012) Production, characterization and applications for toxoplasma gondii-
specific polyclonal chicken egg yolk immunoglobulins. PLoS One 7(7), e40391. 
Findlay, J. W., Smith, W. C., Lee, J. W., Nordblom, G. D., Das, I., DeSilva, B. S., Khan, M. 
N. and Bowsher, R. R. (2000) Validation of immunoassays for bioanalysis: a pharmaceutical 
industry perspective. J. Pharm. Biomed. Anal. 21(6), 1249-1273. 
Frederick, M. O., De Lamo Marin, S., Janda, K. D., Nicolaou, K. C. and Dickerson, T. J. 
(2009) Monoclonal antibodies with orthogonal azaspiracid epitopes. Chembiochem. 10(10), 
1625-1629. 
Fukuda, S., Nagahara, A., Kikuchi, M. and Kumagai, S. (1994) Preparation and 
characterization of anti-fumonisin monoclonal antibodies. Biosci. Biotechnol. Biochem. 58(4), 
765-767. 
Galaverna, G., Dall’Asta, C., Corradini, R., Dossena, A. and Marchelli, R. (2008) 
Cyclodextrins as selectors for mycotoxin recognition. World Mycotoxin Journal 1(4), 397-406. 
Gao, Y., Yang, M., Peng, C., Li, X., Cai, R. and Qi, Y. (2011) Preparation of highly specific 
anti-zearalenone antibodies by using the cationic protein conjugate and development of an 
indirect competitive enzyme-linked immunosorbent assay. Analyst 137(1), 229-236. 
 231 
Garrido, N. S., Iha, M. H., Santos Ortolani, M. R. and Duarte Favaro, R. M. (2003) 
Occurrence of aflatoxins M1 and M2 in milk commercialized in Ribeirao Preto-SP, Brazil. Food 
Addit. Contam. 20(1), 70-73. 
Gathumbi, J. K., Usleber, E. and Martlbauer, E. (2001) Production of ultrasensitive antibodies 
against aflatoxin B1. Lett. Appl. Microbiol. 32(5), 349-351. 
Gendloff, E. H., Pestka, J. J., Swanson, S. P. and Hart, L. P. (1984) Detection of T-2 toxin in 
fusarium sporotrichioides-infected corn by enzyme-linked immunosorbent assay. Appl. 
Environ. Microbiol. 47(5), 1161-1163. 
Glenn, A. E. (2007) Mycotoxigenic fusarium species in animal feed. Animal Feed Science and 
Technol. 137(3-4), 213-240. 
Guan, D., Li, P., Zhang, Q., Zhang, W., Zhang, D. and Jiang, J. (2011) An ultra-sensitive 
monoclonal antibody-based competitive enzyme immunoassay for aflatoxin M1 in milk and 
infant milk products. Food Chem. 125(4), 1359-1364. 
Hans, P., Egmond, V. and Paulsch, W. E. (1986) Determination of mycotoxins. Pure & AppI. 
Chem. 58(2), 315-326. 
Hastings, K. L., Tulis, J. J. and Dean, J. H. (1988) Production and characterization of a 
monoclonal antibody to aflatoxin B2. J. Agric. Food Chem. 36, 404-408. 
Hau, J. and Hendriksen, C. F. (2005) Refinement of polyclonal antibody production by 
combining oral immunization of chickens with harvest of antibodies from the egg yolk. ILAR 
Journal 46(3), 294-299. 
Hawlisch, H., Muller, M., Frank, R., Bautsch, W., Klos, A. and Kohl, J. (2001) Site-specific 
anti-C3a receptor single-chain antibodies selected by differential panning on cellulose sheets. 
Anal. Biochem. 293(1), 142-145. 
Hermanson, G. T. (1996) Bioconjugate techniques, 154-155 pp, 1st edition, Academic press, 
London, U.K. 
 232 
Hoogenboom, L. A., Polman, T. H., Neal, G. E., Verma, A., Guyomard, C., Tulliez, J., 
Gautier, J. P., Coker, R. D., Nagler, M. J., Heidenreich, E. and Delort-Laval, J. (2001) 
Genotoxicity testing of extracts from aflatoxin-contaminated peanut meal, following chemical 
decontamination. Food Addit. Contam. 18(4), 329-341. 
http://ec.europa.eu/food/fs/sc/scf/out74_en.pdf. 
      http://www.icrisat.org/aflatoxin/aflatoxin.asp. 
 
http://micotoxinas.com.br/boletim36.pdf. 
http://www.micotoxinas.com.br/aflafacts.pdf. 
http://services.leatherheadfood.com/eman/FactSheet .aspx?ID=79.  
 
Huang, B., Han, Z., Cai, Z., Wu, Y. and Ren, Y. (2010) Simultaneous determination of 
aflatoxins B1, B2, G1, G2, M1 and M2 in peanuts and their derivative products by ultra-high-
performance liquid chromatography-tandem mass spectrometry. Anal. Chim. Acta 662(1), 62-
68. 
Hunter, K. W., Jr., Brimfield, A. A., Miller, M., Finkelman, F. D. and Chu, S. F. (1985) 
Preparation and characterization of monoclonal antibodies to the trichothecene mycotoxin T-2. 
Appl. Environ. Microbiol. 49(1), 168-172. 
Hussein, H. S. and Brasel, J. M. (2001) Toxicity, metabolism, and impact of mycotoxins on 
humans and animals. Toxicology 167(2), 101-134. 
Hust, M., Maiss, E., Jacobsen, H. J. and Reinard, T. (2002) The production of a genus-specific 
recombinant antibody (scFv) using a recombinant potyvirus protease. J. Virol. Methods 106(2), 
225-233. 
IARC (2002) Overall evaluations of carcinogenicity to human, monographs on the evaluation 
of carcinogenic risk to humans. IARC (International Agency for Research on Cancer) 
monographs 82, 1-36. 
 233 
Inui, H., Takehara, A., Doi, F., Nishi, K., Takai, M., Miyake, S. and Ohkawa, H. (2009) A 
scFv antibody-based immunoaffinity chromatography column for clean-up of bisphenol A-
contaminated water samples. J. Agric. Food Chem. 57(2), 353-358. 
Jaszczuk, D. K., Marquardt, R. R., Frohlich, A. A., Clarke, J., Xiao, H. and Abramson, D. 
(1995) Detection and quantification of the T-2 mycotoxin by ELISA utilizing toxin-specific 
polyclonal antibodies raised in chickens. Food Agric. Immunol. 7(3), 243-252. 
Jonsson, U., Fagerstam, L., Ivarsson, B., Johnsson, B., Karlsson, R., Lundh, K., Lofas, S., 
Persson, B., Roos, H., Ronnberg, I., Sjölander, S., Stenberg, E., Stahlberg, R., Urbaniczky, C., 
Ostlin, H. and Malmqvist, M.  (1991) 'Real-time' biospecific interaction analysis using surface 
plasmon resonance and a sensor chip technology. Biotechniques 11(5), 620-627. 
 
Josic, D., Lim, Y. P., Strancar, A. and Reutter, W. (1994) Application of high-performance 
membrane chromatography for separation of annexins from the plasma membranes of liver and 
isolation of monospecific polyclonal antibodies. J. Chromatogr. B 662(2), 217-226. 
Juan, C., Zinedine, A., Molto, J. C., Idrissi, L. and Manes, J. (2008) Aflatoxins levels in dried 
fruits and nuts from Rabat-sale area, Morocco. Food Control 19, 849-853. 
Kabat, E. A., Wu, T. T., Reid-Miller, M., Perry, H. M., Gottesman, K. S. and Foeller, C. 
(1991) Sequence of proteins of immunological interest, 5th edition, US Department of Health 
and Human Services, NIH, Maryland, U.S.A. 
Kadota, T., Takezawa, Y., Hirano, S., Tajima, O., Maragos, C. M., Nakajima, T., Tanaka, T., 
Kamata, Y. and Sugita-Konishi, Y. (2010) Rapid detection of nivalenol and deoxynivalenol in 
wheat using surface plasmon resonance immunoassay. Anal. Chim. Acta 673(2), 173-178. 
Kalinichenko, A. A., Toporova, V. A., Panina, A. A., Aliev, T. K., Kriukova, E. A., 
Shemchukova, O. B., Solopova, O. N., Pozdniakova, L. P., Sveshnikov, P. G., Dolgikh, D. A. 
and Kirpichnikov, M. P. (2010) Development and characterization of antibodies to aflatoxins. 
Bioorg. Khim. 36(1), 122-132. 
 234 
Kang, S. I. and Bae, Y. H. (2004) pH-dependent elution profiles of selected proteins in HPLC 
having a stationary phase modified with pH-sensitive sulfonamide polymers. J. Biomater. Sci. 
Polym. Ed. 15(7), 879-894. 
Karu, A. E., Bell, C. W. and Chin, T. E. (1995) Recombinant antibody technology. ILAR 
Journal 37(3), 132-141. 
Kehoe, J. W., Velappan, N., Walbolt, M., Rasmussen, J., King, D., Lou, J., Knopp, K., Pavlik, 
P., Marks, J. D., Bertozzi, C. R. and Bradbury, A. R. (2006) Using phage display to select 
antibodies recognizing post-translational modifications independently of sequence context. 
Mol. Cell Proteomics 5(12), 2350-2363. 
Keller, N. P., Turner, G. and Bennett, J. W. (2005) Fungal secondary metabolism-from 
biochemistry to genomics. Nature Rev. Microbiol. 3(12), 937-947. 
Kenneth, L. H., Jerry, J. T. and Jack, H. D. (1988) Production and characterization of a 
monoclonal antibody to aflatoxin B2. J. Agric. Food Chem. 36(2), 404-408. 
Kettleborough, C. A., Saldanha, J., Ansell, K. H. and Bendig, M. M. (1993) Optimization of 
primers for cloning libraries of mouse immunoglobulin genes using the polymerase chain 
reaction. Eur. J. Immunol. 23(1), 206-211. 
Kobayashi, N., Karibe, T. and Goto, J. (2005) Dissociation-independent selection of high-
affinity anti-hapten phage antibodies using cleavable biotin-conjugated haptens. Anal. Biochem. 
347(2), 287-296. 
Kohler, G. and Milstein, C. (1975) Continuous cultures of fused cells secreting antibody of 
predefined specificity. Nature (Lond.)  256(5517), 495-497. 
Kononenko, G. P., Burkin, A. A., Soboleva, N. A. and Zotova, E. V. (1999) Immunoenzyme 
assay for detection of T-2 toxin in contaminated grain. Prikl. Biokhim. Mikrobiol. 35(4), 457-
462. 
Kovacs-Nolan, J. and Mine, Y. (2005) Microencapsulation for the gastric passage and 
controlled intestinal release of immunoglobulin Y. J. Immunol. Methods 296(1-2), 199-209. 
 235 
Lauer, B., Ottleben, I., Jacobsen, H. J. and Reinard, T. (2005) Production of a single-chain 
variable fragment antibody against fumonisin B1. J. Agric. Food Chem. 53(4), 899-904. 
Leemhuis, H., Stein, V., Griffiths, A. D. and Hollfelder, F. (2005) New genotype-phenotype 
linkages for directed evolution of functional proteins. Curr. Opin. Struct. Biol. 15(4), 472-478. 
Lewis, L., Onsongo, M., Njapau, H., Schurz-Rogers, H., Luber, G., Kieszak, S., Nyamongo, J., 
Backer, L., Dahiye, A. M., Misore, A., DeCock, K., Rubin, C. and Kenya aflatoxicosis 
investigation group (2005) Aﬂatoxin contamination of commercial maize products during an 
outbreak of acute aﬂatoxicosis in Eastern and Central Kenya. Environ. Health Perspect. 
113(12), 1763-1767. 
Li, X., Shuai, J. and Fang, W. (2006) Protection of Carassius auratus gibelio against infection 
by Aeromonas hydrophila using specific immunoglobulins from hen egg yolk. J. Zheijiang 
Univ. Sci. B7, 922-928. 
Liao, J. Y. and Li, H. (2010) Lateral flow immunodipstick for visual detection of aflatoxin B1 
in food using immuno-nanoparticles composed of a silver core and a gold shell. Microchim. 
Acta 171, 289-295. 
Lin, Y., Weisdorf, D. J., Solovey, A. and Hebbel, R. P. (2000) Origins of circulating 
endothelial cells and endothelial outgrowth from blood. J. Clin. Invest. 105(1), 71-77. 
Liu, Y., Lou, Y., Xu, D., Qian, G., Zhang, Q., Wu, R., Hu, B. and Liu, F. (2009) Production 
and characterization of monoclonal antibody for class-specific determination of O,O-dimethyl 
organophosphorus pesticides and effect of heterologous coating antigens on immunoassay 
sensitivity. Microchem. J. 93(1), 36-42. 
Losch, U., Schranner, I., Wanke, R. and Jurgens, L. (1986) The chicken egg, an antibody 
source. J. Veterinar. Med. B 33(8), 609-619. 
Lou, J. and Marks, J. D. (2010) Affinity maturation by chain shuffling and site directed 
mutagenesis, In: Antibody Engineering, Springer Protocols, 377-396 pp, Volume 1, 2nd edition, 
Kontermann, R., Dubel, S. (eds.)., Springer-Verlag, Germany. 
 236 
Maragos, C. M. (2004) Detection of moniliformin in maize using capillary zone 
electrophoresis. Food Addit. Contam. 21(8), 803-810. 
Maragos, C. M. (2009) Recent advances in the development of novel materials for mycotoxin 
analysis. Anal. Bioanal. Chem. 395(5), 1205-1213. 
Maragos, C. M. and Greer, J. I. (1997) Analysis of aflatoxin B1 in corn using capillary 
electrophoresis with laser-induced fluorescence detection. J. Agric. Food Chem. 45(11), 4337-
4341. 
Maragos, C. M. and McCornmick, S. P. (2000) Monoclonal antibodies for the mycotoxins 
deoxynivalenol and 3-acetyldeoxynivalenol. Food Agric. Immunol. 12, 181-192. 
Maragos, C. M. and Plattner, R. D. (2002) Rapid fluorescence polarization immunoassay for 
the mycotoxin deoxynivalenol in wheat. J. Agric. Food Chem. 50(7), 1827-1832. 
Maynard, J. and Georgiou, G. (2000) Antibody engineering. Ann. Rev. Biomed. Eng. 2, 339-
376. 
Mehan, V. K. and Gowda, C. L. L. (1996). Aflatoxin contamination problems in groundnut in 
Asia: proceedings of the first Asia working group meeting, 27-29th May, International Crops 
Research Institute for the Semi-Arid Tropics, Andhra Pradesh, India. 
Meucci, V., Razzuoli, E., Soldani, G. and Massart, F. (2010) Mycotoxin detection in infant 
formula milks in Italy. Food Addit. Contam. Part A Chem. Anal. Control Expo Risk Assess 
27(1), 64-71. 
Miller, J. D. (1998) Global significance of mycotoxins, IX IUPAC International Symposium 
on  mycotoxins and phycotoxins in Rome, Italy. Miraglia, M, van Egmond, H. P, Brera, C, 
Gilbert, J (eds.)., Alaken INC, Colorado, U.S.A. 
Moghaddam, A., Lobersli, I., Gebhardt, K., Braunagel, M. and Marvik, O. J. (2001) Selection 
and characterization of recombinant single-chain antibodies to the hapten aﬂatoxin B1 from 
naive recombinant antibody libraries. J. Immunol. Methods 254, 169–181. 
 237 
Moghaddam, A., Borgen, T., Stacy, J., Kausmally, L., Simonsen, B., Marvik, O. J., Brekke, O. 
H. and Braunagel, M. (2003) Identification of scFv antibody fragments that specifically 
recognise the heroin metabolite 6-monoacetylmorphine but not morphine. J. Immunol. Methods 
280(1-2), 139-155. 
Molinelli, A., Grossalber, K., Fuhrer, M., Baumgartner, S., Sulyok, M. and Krska, R. (2008) 
Development of qualitative and semiquantitative immunoassay-based rapid strip tests for the 
detection of T-2 toxin in wheat and oats. J. Agric. Food Chem. 56(8), 2589-2594. 
Monbaliu, S., Van Poucke, C., Van Peteghem, C., Van Poucke, K., Heungens, K. and De 
Saeger, S. (2009) Development of a multi-mycotoxin liquid chromatography/tandem mass 
spectrometry method for sweet pepper analysis. Rapid Commun. Mass Spectrom. 23(1), 3-11. 
Moroney, S. and Pluckhun, A. (2005) Modern antibody technology: The impact on drug 
development, In Modern Biopharmaceuticals: Design, Development and Optimization, 1147-
1186 pp, Knablein. J (ed.)., Wiley-VCH Verlag GmbH, Germany. 
Munkvold, G. P. (2003) Cultural and genetic approaches to managing mycotoxins in maize. 
Ann. Rev. Phytopathol. 41, 99-116. 
Nasir, M. S. and Jolley, M. E. (2002) Development of a fluorescence polarization assay for the 
determination of aflatoxins in grains. J. Agric. Food Chem. 50(11), 3116-3121. 
Ngundi, M. M., Shriver-Lake, L. C., Moore, M. H., Lassman, M. E., Ligler, F. S. and Taitt, C. 
R. (2005) Array biosensor for detection of ochratoxin A in cereals and beverages. Anal. Chem. 
77(1), 148-154. 
O'Kennedy, R., Townsend, S., Donohoe, G., Leonard, P., Hearty, S. and Byrne, B. (2010) 
Speedy, small, sensitive and specific-reality or myth for future analytical methods. Anal. Lett. 
43, 1630-1648. 
O'Neil, M. J., Smith, A. and Heckelman, P. E. (2001). The Merck Index, Merck & Co, New 
Jersy, U.S.A.  
 238 
Orbulescu, J., Constantine, C. A., Rastogi, V. K., Shah, S. S., Defrank, J. J. and Leblanc, R. 
M. (2006) Detection of organophosphorus compounds by covalently immobilized 
organophosphorus hydrolase. Anal. Chem. 78(19), 7016-7021. 
Otieno, A. C. and Mwongela, S. M. (2008) Capillary electrophoresis-based methods for the 
determination of lipids-a review. Anal. Chim. Acta 624(2), 163-174. 
Palencia, E., Torres, O., Hagler, W., Meredith, F. I., Williams, L. D. and Riley, R. T. (2003) 
Total fumonisins are reduced in tortillas using the traditional nixtamalization method of Mayan 
communities. Am. Society. Nutrition. Sciences 133, 3200-3203. 
Pavao, A. C., Soares Neto, L. A., Ferreira Neto, J. and Leao, M. B. C. (1995) Structure and 
activity of aflatoxins B and G. J. Mol. Struct. (Theochem) 337, 57-60. 
Petrenko, V. A. and Vodyanoy, V. J. (2003) Phage display for detection of biological threat 
agents. J. Microbiol. Methods 53(2), 253-262. 
Pichler, H., Krska, R., Szekacs, A. and Grasserbauer, M. (1998) An enzyme-immunoassay for 
the detection of the mycotoxin zearalenone by use of yolk antibodies. Fresenius J. Anal. Chem. 
362, 176-177. 
Piermarini, S., Micheli, L., Ammida, N. H., Palleschi, G. and Moscone, D. (2007) 
Electrochemical immunosensor array using a 96-well screen-printed microplate for aflatoxin B1 
detection. Biosens. Bioelectron. 22(7), 1434-1440. 
Radoi, A., Dumitru, L., Barthelmebs, L. and Marty, J. L. (2009) Ochratoxin A in some French 
wines: Application of a direct competitive ELISA based on an OTA–HRP conjugate. Anal. 
Lett. 42, 1187-1202. 
Ramesh, V. B., Sashidhar, R. B., Ramakrishna, Y. and Munshi, K. (1989) Outbreak of 
trichothecene mycotoxicosis associated with consumption of mould-damaged wheat products 
in Kashmir Valley, India. The Lancet 333(8628), 35-37. 
 239 
Rangnoi, K., Jaruseranee, N., O'Kennedy, R., Pansri, P. and Yamabhai, M. (2011) One-step 
detection of aflatoxin-B1 using scFv-alkaline phosphatase-fusion selected from human phage 
display antibody library. Mol. Biotechnol. 49(3), 240-249. 
Rejeb, S. B., Cleroux, C., Lawrence, J. F., Geay, P. Y., Wu, S. and Stavinski, S. (2001) 
Development and characterization of immunoaffinity columns for the selective extraction of a 
new developmental pesticide, Thifluzamide, from peanuts. Anal. Chim. Acta 432, 193-200. 
Riazipour, M., Imani Fooladi, A. A. and Razzaghi-Abyaneh, M. (2009) Natural occurrence of 
T-2 toxin in domestic and imported rice. Iranian J. of Public Health 38(4), 111-116. 
Richard, J. L. (2007) Some major mycotoxins and their mycotoxicosis-An overview. Int. J. 
Food Microbiol. 119(1-2), 3-10. 
Rieger, M., Cervino, C., Sauceda, J. C., Niessner, R. and Knopp, D. (2009) Efficient 
hybridoma screening technique using capture antibody-based microarrays. Anal. Chem. 81(6), 
2373-2377. 
Robens, J. and Cardwell, K. (2003) The costs of mycotoxin management to the USA: 
management of aflatoxins in the United States. J. Toxicol. 22(2-3), 139-152. 
Sanvicens, N., Moore, E. J., Guilbault, G. G. and Marco, M. P. (2006) Determination of 
haloanisols in white wine by immunosorbent solid-phase extraction followed by enzyme-linked 
immunosorbent assay. J. Agric. Food Chem. 54(24), 9176-9183. 
Sblattero, D. and Bradbury, A. (2000) Exploiting recombination in single bacteria to make 
large phage antibody libraries. Nature Biotechnol. 18, 75-80. 
Schade, R. and Hinak, A. (1996) Egg yolk antibodies, state of the art and future prospects. 
ALTEX 13(1), 5-9. 
Schneider, L., Pichler, H. and Krska, R. (2000) An enzyme linked immunoassay for the 
determination of deoxynivalenol in wheat based on chicken egg yolk antibodies. Fresenius J. 
Anal. Chem. 367(1), 98-100. 
 240 
Scholler, J., Perdersen, H. and Brix, L. (2010) MHC peptide complexes and uses thereof in 
infectious diseases, U.S. Patent 8268964, Sep. 18, 2012. 
Schothorst, R. C. and Jekel, A. A. (2003) Determination of trichothecenes in beer by capillary 
gas chromatography with flame ionisation detection. Food chem. 82(3), 475-479. 
Schwarzkopf, C., Staak, C., Behn, I. and Erhard, M. (2000) Immunization, In: Chicken egg 
yolk antibodies, production and application: IgY technology, Springer lab manuals, 25-64 pp, 
1st edition, Springer-Verlag, Germany.  
Shan, G., Lipton, C., Gee, S. J. and Hammock, B. D. (2002) Immunoassay, biosensors and 
other nonchromatographic methods, In: Handbook of Residue Analytical Methods for 
Agrochemicals, 623-679 pp, Volume 1, 1st  edition, Philip W. Lee (ed.)., John Wiley & Sons 
Ltd, Chichester, U.K.  
Shier, W. T., Shier, A. C., Xie, W. and Mirocha, C. J. (2001) Structure-activity relationships 
for human estrogenic activity in zearalenone mycotoxins. Toxicon 39(9), 1435-1438. 
Sittampalam, G. S., Smith, W. C., Miyakawa, T. W., Smith, D. R. and McMorris, C. (1996) 
Application of experimental design techniques to optimize a competitive ELISA. J. Immunol. 
Methods 190(2), 151-161. 
Smith, G. P. (1985) Filamentous fusion phage: novel expression vectors that display cloned 
antigens on the virion surface. Science 228(4705), 1315-1317. 
Sokolovic, M., Garaj-Vrhovac, V. and Simpraga, B. (2008) T-2 toxin: incidence and toxicity in 
poultry. Arh. Hig. Rada Toksikol. 59(1), 43-52. 
Sokolović, M. and Simpraga, B. (2006) Survey of trichothecene mycotoxins in grains and 
animal feed in Croatia by thin layer chromatography. Food Control 17(9), 733-740. 
Soleimany, F., Jinap, S., Rahmani, A. and Khatib, A. (2011) Simultaneous detection of 12 
mycotoxins in cereals using RP-HPLC-PDA-FLD with PHRED and a post-column 
derivatization system. Food Addit. Contam. 28(4), 494-501. 
 241 
Song, L. Y., Shan, L. Z., Yu, Z., Ying, L. S., Zhe, W. and Bing, L. X. (2009) Development of 
an indirect competitive enzyme-linked immunosorbent assay (ic-ELISA) of fumonisin B2. 
Chinese J. Vet. Sci. 29(9), 1204-1207. 
Spanjer, M. C., Rensen, P. M. and Scholten, J. M. (2008) LC-MS/MS multi-method for 
mycotoxins after single extraction, with validation data for peanut, pistachio, wheat, maize, 
cornflakes, raisins and figs. Food Addit. Contam. Part A Chem. Anal. Control Expo Risk Assess 
25(4), 472-489. 
Srinivasan, A., Uppuluri, P., Lopez-Ribot, J. and Ramasubramanian, A. K. (2011) 
Development of a high-throughput Candida albicans biofilm chip. PLoS One 6(4), 1-9. 
Stapleton, S. (2007) Novel antibody-based assays for disease and food contaminant detection. 
School of Biotechnology, Dublin City University, Dublin. Ph.D. 
Strachan, G., McElhiney, J., Drever, M. R., McIntosh, F., Lawton, L. A. and Porter, A. J. 
(2002) Rapid selection of anti-hapten antibodies isolated from synthetic and semi-synthetic 
antibody phage display libraries expressed in Escherichia coli. FEMS Microbiol. Lett. 210(2), 
257-261. 
Stroka, J., Spanjer, M., Buechler, S., Barel, S., Kos, G. and Anklam, E. (2004) Novel sampling 
methods for the analysis of mycotoxins and the combination with spectroscopic methods for 
the rapid evaluation of deoxynivalenol contamination. Toxicol. Lett. 153(1), 99-107. 
Sulyok, M., Berthiller, F., Krska, R. and Schuhmacher, R. (2006) Development and validation 
of a liquid chromatography/tandem mass spectrometric method for the determination of 39 
mycotoxins in wheat and maize. Rapid Commun. Mass Spectrom. 20(18), 2649-2659. 
Sun, S., Mo, W., Ji, Y. and Liu, S. (2001) Preparation and mass spectrometric study of egg 
yolk antibody (IgY) against rabies virus. Rapid Commun. Mass Spectrom. 15(9), 708-712. 
Sunwoo, H. H., Wang, W. W. and Sim, J. S. (2006) Detection of Escherichia coli O157:H7 
using chicken immunoglobulin Y. Immunol. Lett. 106(2), 191-193. 
 242 
Takumi, Y., Hiroaki, K., Kazuyuki, I., Tatsuya, S., Hiroaki, Y., Kazuki, M., Osamu, K. and 
Yoshinori, K. (2004) A practical method for measuring deoxynivalenol, nivalenol and T-2+HT-
2 toxin in foods by an enzyme-linked immunosorbent assay using monoclonal antibodies. 
Biosci. Biotechnol. Biochem. 68(10), 2076-2085. 
Tanaka, T., Yoneda, A., Inoue, S., Sugiura, Y. and Ueno, Y. (2000) Simultaneous 
determination of trichothecene mycotoxins and zearalenone in cereals by gas chromatography-
mass spectrometry. J. Chromatogr. A 882(1-2), 23-28. 
Tang, D., Sauceda, J. C., Lin, Z., Ott, S., Basova, E., Goryacheva, I., Biselli, S., Lin, J., 
Niessner, R. and Knopp, D. (2009) Magnetic nanogold microsphere-based lateral-flow 
immunodipstick for rapid detection of aflatoxin B2 in food. Biosens. Bioelectron. 25(2), 514-
518. 
Teshima, R., Hirai, K., Sato, M., Ikebuchi, H., Ichinoe, M. and Terao, T. (1990) 
Radioimmunoassay of nivalenol in barley. Appl. Environ. Microbiol. 56(3), 764-768. 
Teshima, R., Kawase, M., Tanaka, T., Hirai, K., Sato, M., Sawada, J., Ikebuchi, H., Ichinoe, 
M. and Terao, T. (1990) Production and characterization of a specific monoclonal antibody 
against mycotoxin zearalenone. J. Agric. Food chem. 38, 1618-1622. 
Thongrussamee, T., Kuzmina, N. S., Shim, W. B., Jiratpong, T., Eremin, S. A., Intrasook, J. 
and Chung, D. H. (2008) Monoclonal-based enzyme-linked immunosorbent assay for the 
detection of zearalenone in cereals. Food Addit. Contam. Part A Chem. Anal. Control Expo. 
Risk Assess 25(8), 997-1006. 
Tomita, M. and Tsumoto, K. (2010) Recent advances in antigen-based generation of 
monoclonal antibodies. Curr. Immunol. Rev. 6(1), 56-61. 
Tudos, A. J., Lucas-van den Bos, E. R. and Stigter, E. C. (2003) Rapid surface plasmon 
resonance-based inhibition assay of deoxynivalenol. J Agric Food Chem 51(20), 5843-5848. 
Turner, N. W., Subrahmanyam, S. and Piletsky, S. A. (2009) Analytical methods for 
determination of mycotoxins: a review. Anal. Chim. Acta 632(2), 168-180. 
 243 
Uchigashima, M., Saigusa, M., Yamashita, H., Miyake, S., Fujita, K., Nakajima, M. and 
Nishijima, M. (2009) Development of a novel immuno-affinity column for aflatoxin analysis 
using an organic solvent-tolerant monoclonal antibody. J. Agric. Food Chem. 57(19), 8728-
8734. 
Uchigashima, M., Yamaguchi Murakami, Y., Narita, H., Nakajima, M. and Miyake, S. (2012) 
Development of an immuno-affinity column for ochratoxin analysis using an organic solvent-
tolerant monoclonal antibody. Methods 56(2), 180-185. 
Ueda, K. and Akiwa, M. (2007) Production monoclonal antibodies against T-2 toxin. Tech. 
bullet. Faculty of Agriculture, Kagawa University 59, 99-102.  
Urraca, J. L., Benito-Pena, E., Perez-Conde, C., Moreno-Bondi, M. C. and Pestka, J. J. (2005) 
Analysis of zearalenone in cereal and swine feed samples using an automated flow-through 
immunosensor. J. Agric. Food Chem. 53(9), 3338-3344. 
Van der Gaag, B., Spath, S., Dietrich, H., Stigter, E., Boonzaaijer, G., van Osenbruggen, T. 
and Koopal, K. (2003) Biosensors and multiple mycotoxin analysis. Food control 14, 251-254. 
Vaughan, T. J., Williams, A. J., Pritchard, K., Osbourn, J. K., Pope, A. R. and Earnshaw, J. C. 
(1996) Human antibodies with sub-nanomolar affinities isolated from a large non-immunized 
phage display library. Nature Biotechnol. 14, 309-314. 
Vidal, J. C., Duato, P., Bonel, L. and Castillo, J. R. (2009) Use of polyclonal antibodies to 
ochratoxin A with a quartz-crystal microbalance for developing real-time mycotoxin 
piezoelectric immunosensors. Anal. Bioanal. Chem. 394(2), 575-582. 
Wang, J., Duan, S., Zhang, Y. and Wang, S. (2010) Enzyme-linked immunosorbent assay for 
the determination of T-2 toxin in cereals and feedstuff. Microchim. Acta 169, 137-144. 
Wang, J., Zhou, Y., Liu, W., Zhu, X., Du, L. and Wang, Q. (2008) Fumonisin level in corn-
based food and feed from Linxian county, a high-risk area for esophageal cancer in China. 
Food Chem. 106(1), 241-246. 
 244 
Wannemacher, R. W. and Wiener, S. L. (1997) Trichothecene mycotoxins, In: Textbook Of 
Military Medicine, 655-676 pp, Zajtchuk, R. (eds.)., Walter Reed Army Medical Center, 
U.S.A. 
Wannemacher, R. W. J., Bunner, D. L. and Dinterman, R. E. (1989). Inactivation of low 
molecular weight agents of biological origin, In: Symposium on agents of biological origin, 
115-122 pp, US Army Chemical Research, Development and Engineering Center, Aberdeen 
Proving Grounds, Maryland, U.S.A.  
 
Weidenborner, M. (2001) Encyclopedia of food mycotoxins, 1st edition, Springer-Verlag, 
Germany.  
Whitaker, T. B., Slate, A. B., Jacobs, M., Hurley, J. M., Adams, J. G. and Giesbrecht, F. G. 
(2006) Sampling almonds for aflatoxin, part I: estimation of uncertainty associated with 
sampling, sample preparation, and analysis. J. AOAC Int. 89(4), 1027-1034. 
Wilkes, J. G. and Sutherland, J. B. (1998) Sample preparation and high-resolution separation 
of mycotoxins possessing carboxyl groups. J. Chromatogr. B 717, 135-156. 
Willats, W. G. (2002) Phage display: practicalities and prospects. Plant Mol. Biol. 50(6), 837-
854. 
Willner, I. and Katz, E. (2000) Integration of layered redox proteins and conductive supports 
for bioelectronic applications. Angew. Chem. Int. Edt. 39(7), 1180-1218. 
Winter, G. and Milstein, C. (1991) Man-made antibodies. Nature (Lond.)  349(6307), 293-
299. 
Won-Bo Shim, Anna Yu, K., Kim, Y.J., Yang, Z.Y., Park, S.J., Sergei, A.E.,  Lee, I.S. and 
Chung, D.H. (2004) Fluorescence polarization immunoassay based on a monoclonal antibody 
for the detection of ochratoxin A. Int. J. Food Science and Technol. 39, 829-837. 
Wortberg, M., Goodrow, M. H., Gee, S. J. and Hammock, B. D. (1996) Immunoassays for 
simazine and atrazine with low cross-reactivity for propazine. J. Agric. Food Chem. 44, 2210-
2219. 
 245 
Wu, A. H. (2006) A selected history and future of immunoassay development and applications 
in clinical chemistry. Clin. Chim. Acta 369(2), 119-124. 
Xiao, H., Clarke, J. R., Marquardt, R. R. and Frohlicht, A. A. (1995) Improved methods for 
conjugating selected mycotoxins to carrier proteins and dextran for immunoassays. J. Agric. 
Food Chem. 43, 2092-2097. 
Yan, Z. and Huang, J. (2000) Chromatographic behavior of mouse serum immunoglobulin G 
in protein G perfusion affinity chromatography. J. Chromatogr. B Biomed. Sci. Appl. 738(1), 
149-154. 
Yau, K. Y., Lee, H. and Hall, J. C. (2003) Emerging trends in the synthesis and improvement 
of hapten-specific recombinant antibodies. Biotechnol. Adv. 21(7), 599-637. 
Yu, F. Y. and Chu, F. S. (1996) Production and characterization of antibodies against 
Fumonisin B1. J. Food Prot. 59(9), 992-997. 
Yuan, Q., Clarke, J. R., Zhou, H. R., Linz, J. E., Pestka, J. J. and Hart, P. L. (1997) Molecular 
cloning, expression and characterization of a functional single-chain antibody to the mycotoxin 
zearalenone. Appl. Environ. Microbiol. 63(1), 263-269. 
Zeng, H., Li, Y., Jin, J. and Sun, H. (2003) Determination of zearalenone and its metabolites in 
grains by capillary electrophoresis. J. Sichuan University 34 (2), 333-336. 
Zinedine, A., Soriano, J. M., Molto, J. C. and Manes, J. (2007) Review on the toxicity, 
occurrence, metabolism, detoxification, regulations and intake of zearalenone: An oestrogenic 
mycotoxin. Food Chem. Toxicol. 45, 1-18. 
 
 
 
 
 
 
 
 
 246 
 
 
 
 
 
 
 
 
 
 
 
               APPENDIX 
 
 
 
 
 
 
 
 
 
 
 
 
 247 
Appendix I 
Validation of immunoassay 
The various parameters that need to be considered in order to fully assess the performance of an 
immunoassay are: accuracy, precision, sensitivity, specificity, suitability and robustness 
(DeSilva et al., 2003).  
Accuracy: Accuracy is measure of percentage bias and is calculated using the formula  
Pecentage (%) Bias = (measured value – true value/ true value) X 100 
The accuracy value can be obtained from a comparison of the measured value with a known 
reference standard value is made.  
Precision: Precision is a statistical measure of variations between repeated measurements of 
the same sample. It is a measure of random errors which are determined based on the % CV 
value (coefficient of variance) or RSD (Relative standard deviation) of replicate measurements. 
The statistical values can be determined through the performance of either inter- or intra-day 
assays.  
Sensitivity: Sensitivity defines the smallest amount of analyte that can be detected in an assay. 
To assure the suitability of the assay for intended purpose the sensivity of the assay is 
considered. At this point the affinity and purity of antibodies plays a major role. During assay 
optimization the various factors that might effect the affinity of the antibody like the washings, 
buffer constituents, incubation time etc., need to be considered.  
Specificity: The specificity of any immunoassay is the measure of cross reactivity. The 
specificity of ligands e.g. antibodies plays a crucial role in ligand binding assays (LBA’s) in the 
determination of sensitivity and robustness of the assays.  
Robustness: The robustness of an assay is the efficiency of the assay to withstand minor 
variation in the experimental conditions. This is generally a follow-up method after assay 
optimization. The validation process also involves the application of various statistical analysis 
methods.  
 248 
Limit of Blank (LOB) or Blank value: It is a measure of replicates of blank samples, without 
the analyte.  
Limit of detection (LOD): Limit of detection is the lowest value of an analyte that could be 
distinguished from the blank value or limit of blank (LOB).  
Limit of qantification (LOQ): It is the lowest analyte concentration that can be detected 
quantitatively with a certain precision. In general the LOQ is higher than LOD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 249 
                                                         Appendix II 
MALDI-TOF analysis of mycotoxin-BSA conjugates 
(b)
(a)
(c)
(d)
67840.44
mass/charge (m/z)
In
te
n
s
. 
[a
.u
.]
0
200
400
600
67840.44
4,000 8,000 12,0000
mass/charge (m/z)
In
te
n
s
. 
[a
.u
.]
0
200
400
600
800
66,458.98
4,000 8,000 12,0000
mass/charge (m/z)
In
te
n
s
. 
[a
.u
.]
0
50
100
150
76,793.40
4,000 8,000 12,0000
mass/charge (m/z)
In
te
n
s
. 
[a
.u
.]
500
1000
1500
75,530.31
4,000 8,000 12,0000
67, .
 
Figure 1: MALDI-TOF analysis of mycotoxin-BSA conjugates. Molecular mass of (a) BSA (66,458.98 
Da), (b) AFB2-BSA (75,530.31 Da), (c) ZEN-BSA (76,793.40 Da) and (d) T-2-BSA (67,840.44 Da) were 
shown. 
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Appendix III 
 
Mycotoxin conjugate characterization using fluorescence assay and hapten density 
determination by MALDI-TOF and TNBS assays 
 
Table 1: Mycotoxin conjugate confirmation (fluorescence assay), hapten density determination 
(MALDI-TOF & TNBS assays) 
 
            Hapten density Mycotoxin conjuagte Fluorescence 
Estimation    MALDI-TOF TNBS 
 
AFB2-BSA 
 
 
 
 
 
 
 
 
 
AFB2-KLH 
 
 
863 (Conj) 
48 (BSA) 
45 (PBS) 
Ex/Em:360/420nm 
 
906 (Conj) 
53 (BSA) 
46 (PBS) 
Ex/Em:360/440nm 
 
135 (Conj) 
46 (KLH) 
45 (PBS) 
Ex/Em:360/420nm 
 
163 (Conj) 
49 (KLH) 
46 (PBS) 
Ex/Em:360/440nm 
 
   
    29 
 
 
 
 
        N/A 
  
  26 
 
 
 
 
   120 
 
ZEN-BSA 
 
 
 
 
ZEN-KLH 
525 (Conj) 
11 (BSA) 
8 (PBS) 
Ex/Em:236/418nm 
 
923 (Conj) 
8 (KLH) 
6 (PBS) 
Ex/Em:236/440nm 
 
        32 
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   35 
 
 
 
   94 
T-2-BSA 
 
T-2-KLH 
N/A       
        
N/A 
        20 
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Appendix IV 
Murine immune responses to mycotoxin BSA and KLH conjugates  
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Figure 2: Murine immune response to six different mycotoxin conjugates. Each of the mycotoxin BSA 
and KLH conjugates were used for immunizing three Balb/c mice. The antibody response was measured 
after the third boost by indirect ELISA. The results indicate that the mycotoxin-KLH conjugates are 
efficient in producing a better immune response than the mycotoxin-BSA conjugates. 
